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===================

###### Praziquantel 40 mg/kg versus placebo for treating urinary schistosomiasis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ----------------------------------
  **Praziquantel 40 mg/kg versus placebo for treating urinary schistosomiasis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Patient or population:** People with urinary schistosomiasis  **Settings:** Endemic areas in sub‐Saharan Africa  **Intervention:** Praziquantel 40 mg/kg (single dose) versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**                                                                  **Relative effect  (95% CI)**                                                                           **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                                                                           

  **Placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Praziquantel 40 mg/kg**                                                                                                                                                                                                                                                                        

  **Parasitological failure**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **91 per 100**                                                                                                 **38 per 100**   (26 to 54)                                                                             **RR 0.42**   (0.29 to 0.59)       864  (7 trials)                        ⊕⊕⊕⊕  **high**^1,2,3,4^
  At 1 to 2 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Percentage egg reduction**   At 1 to 2 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Mean change in egg excretion in the control groups ranged from a **53.2%** reduction to a **138%** increase.   Mean egg excretion in the intervention groups was reduced by **\> 98%** in all trials                   Not pooled                         678\                                   ⊕⊕⊕⊕  **high**^1,2,3,5^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (6 trials)                             

  **Microhaematuria**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **53 per 100**                                                                                                 **28 per 100**   (17 to 45)                                                                             **RR 0.53**   (0.33 to 0.84)       119  (1 trial)                         ⊕⊕⊝⊝  **low**^6,7,8^
  At 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Haemoglobin**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          The mean haemoglobin ranged across control groups from  **11.3 to 11.9 G/dL**                                  The mean haemoglobin in the intervention groups was **0.08 G/dL lower**   (0.24 lower to 0.09 higher)   ―                                  727  (2 trials)                        ⊕⊕⊕⊝  **moderate**^3,\ 9,10\ 11^
  At 6 to 8 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Adverse events**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ―                                                                                                              ―                                                                                                       ―                                  1591  (9 trials)                       ⊕⊕⊝⊝  **low**^12^

  The basis for the **assumed risk** is the mean risk in the control groups across trials. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ----------------------------------

^1^ No serious risk of bias: Several trials were at unclear or low risk of selection bias. However, a sensitivity analysis excluding these trials still found a strong effect.  ^2^ No serious inconsistency: Six of the seven trials found large consistent effects. The seventh trial found no difference, this may be explained by the different diagnostic criteria used in this trial.  ^3^ No serious indirectness: These seven trials are all conducted in children in endemic areas of sub‐Saharan Africa.  ^4^ No serious imprecision: The result is statistically significant and the 95% CI is narrow around a clinically important effect.  ^5^ No serious imprecision: The trials are small and most did not report tests of statistical significance, however the differences are large.  ^6^ No serious risk of bias: This trial was well conducted.  ^7^ Downgraded by 1 for serious indirectness: Only a single trial reports this outcome. Further trials from different settings would be needed to be confident in this effect.  ^8^ Downgraded by 1 for serious imprecision: This trial is underpowered.  ^9^ Downgraded by 1 for serious risk of bias: both trials had inadequate sequence generation and allocation concealment.  ^10^ No serious inconsistency: Low statistical heterogeneity.  ^11^ No serious imprecision: only two trials reported this outcome. CIs are narrow. The effect is not statistically significant and does not appear to be clinically important, when compared to the baseline data.  ^12^ Downgraded by 2 for serious risk of bias: Three trials do not comment on adverse events. Six trials made comments that praziquantel was generally well tolerated and no statistically significant differences were noted. However, adverse events were poorly reported in all six trials such that meta‐analysis, and assessment of other quality criteria was not possible.

###### Praziquantel 40 mg/kg single dose versus 30 mg/kg single dose

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ------------------------------
  **Praziquantel 40 mg/kg compared to praziquantel 30 mg/kg for treating urinary schistosomiasis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Patient or population:** people with urinary schistosomiasis  **Settings:** endemic areas in Sub‐Saharan Africa  **Intervention:** praziquantel 40 mg/kg (single dose)  **Comparison:** praziquantel 30 mg/kg (single dose)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**                                                   **Relative effect  (95% CI)**                                                                              **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                                                               

  **Praziquantel 30 mg/kg single dose**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **Praziquantel 40 mg/kg single dose**                                                                                                                                                                                                                                                

  **Parasitological failure**   At 1 month                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **32 per 100**                                                                                  **24 per 100**   (19 to 32)                                                                                **RR 0.76**   (0.59 to 0.99)       401  (4 trials)                        ⊕⊕⊝⊝  **low**^1,2,3,4^

  **Mean percent egg reduction**   At 1 month                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               The mean reduction in control groups ranged from an **85%** reduction to a **99%** reduction.   The mean reduction in the intervention groups was **\> 95%** in all trials                                 Not pooled                         362\                                   ⊕⊕⊝⊝  **low**^1,3,5,6^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (4 trials)                             

  **Parasitological failure**   At 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **29 per 100**                                                                                  **28 per 100**\                                                                                            **RR 0.97**\                       669\                                   ⊕⊕⊕⊝\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (22 to 36)                                                                                                 (0.76 to 1.23)                     (6 trials)                             **moderate**\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ^1,3,7,8^

  **Mean percent egg reduction**   At 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              The mean reduction in control groups ranged from an **97%** reduction to a **99%** reduction.   The mean reduction in the intervention groups ranged from a **46%** reduction^15^ to a **99%** reduction   Not pooled                         362\                                   ⊕⊕⊝⊝  **low**^1,3,9,10^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (4 trials)                             

  **Haematuria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **26 per 100**                                                                                  **23 per 1000**   (12 to 44)                                                                               **RR 0.89**   (0.47 to 1.67)       117  (1 trial)                         ⊕⊝⊝⊝  **very low**^11,12,13^

  **Proteinuria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **15 per 100**                                                                                  **13 per 100**   (5 to 31)                                                                                 **RR 0.85**   (0.34 to 2.12)       117  (1 trial)                         ⊕⊝⊝⊝  **very low**^11,12,13^

  **Adverse events**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ―                                                                                               ―                                                                                                          Not estimable                      992  (8 trials)                        ⊕⊕⊝⊝  **low**^14^

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ------------------------------

^1^ Downgraded by 1 for serious risk of bias: None of the trials described a method of allocations concealment or blinding outcome assessors.  ^2^ No serious inconsistency: No statistical heterogeneity in the relative effect of the two praziquantel doses. However, treatment failure with praziquantel 40 mg/kg ranged from 0% to than more than 50%.  ^3^ No serious indirectness: All trials were conducted in sub‐Saharan Africa, in patients aged from seven to 20 years.  ^4^ Downgraded by 1 for serious imprecision: None of the individual studies found statistical significant differences, and overall, the meta‐analysis remains underpowered to confidently detect an effect.  ^5^ No serious inconsistency: Three of the four trials report the difference was not statistically significant. The fourth trial did not report significance but effects were similar.  ^6^ Downgraded by 1 for serious imprecision: We were unable to pool the data, and as such cannot exclude a small difference in effect between the two doses in a pooled analysis.  ^7^ No serious inconsistency. Low statistical heterogeneity.  ^8^ No serious imprecision. The effect is of no clinically important difference between the two doses, and the 95% CIs are narrow.  ^9^ Downgraded by 1 for serious inconsistency: In one trial praziquantel 40 mg/kg had a very low percent egg reduction of 46%. The reasons for this are unclear.  ^10^ Unable to assess precision as the data were not pooled.  ^11^ Downgraded by 1 for serious risk of bias: This trial did not adequately describe allocation concealment. Participants and clinicians were not blinded.  ^12^ Downgraded by 1 for serious indirectness: Only one trial from one setting.  ^13^ Downgraded by 1 for serious imprecision. This trial is underpowered to detect an effect. The 95% CI is wide and includes clinically important benefits and no effect.  ^14^ Downgraded by 2 for serious risk of bias. Six out of ten trials comparing praziquantel 40 mg/kg to lower doses did not comment on adverse events, and of the remaining only two used prospective active surveillance to monitor adverse events. Only two trials out of ten described blinding for clinicians or participants.

###### Praziquantel 40 mg/kg multiple doses versus single dose

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ----------------------------- ---
  **Praziquantel 40 mg/kg multiple doses compared to single dose for treating urinary schistosomiasis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **Patient or population:** patients with treating urinary schistosomiasis  **Settings:** endemic settings  **Intervention:** Praziquantel 40 mg/kg multiple doses (every three months for two years)  **Comparison:** Praziquantel 40 mg/kg single dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**                               **Relative effect  (95% CI)**                                                **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   **Comments**                  

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                                           

  **Praziquantel 40 mg/kg single dose**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **Praziquantel 40 mg/kg multiple doses**                                                                                                                                                                                                                         

  **Parasitological failure**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **90 per 100**                                                              **244 per 100**   (132 to 450)                                               **RR 2.71**   (1.47 to 5.00)       62  (1 trial)                          ⊕⊝⊝⊝  **very low**^1,2,3,4^    
  At 2 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Mean percent egg reduction**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           This study reports a**81%** reduction after a single dose of praziquantel   This study reports a**96%** reduction after multiple doses of praziquantel   ―                                  62\                                    ⊕⊝⊝⊝  **very low**^1,2,3,4^    
  At 2 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            (1 trial)                                                            

  **Parasitological failure**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **63 per 100**                                                              **56 per 100**   (37 to 89)                                                  **RR 0.92**   (0.59 to 1.42)       43  (1 trial)                          ⊕⊝⊝⊝  **very low**^1,2,3,4^    
  At 3 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Haematuria**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **48 per 100**                                                              **34 per 100**   (20 to 56)                                                  **RR 0.7**   (0.42 to 1.17)        43  (1 trial)                          ⊕⊝⊝⊝  **very low**^1,2,3,4^    
  At 3 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  **Adverse events**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ―                                                                           This study reports a**96%** reduction after multiple doses of praziquantel   ―                                  43\                                    ⊕⊝⊝⊝  **very low**^5^          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (1 trial)                                                            

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio;                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ----------------------------- ---

^1^ Downgraded by 2 for serious risk of bias. The one trial reporting the outcome did not report adequately on sequence generation and blinding. Allocation was not concealed, and loss to follow up was very high.  ^2^ No serious inconsistency: only one trial.  ^3^ No serious indirectness: only one trial.  ^4^ Downgraded by 1 for serious imprecision: This single trial is small and underpowered to reliably detect an effect.  ^5^ This trial did not report on adverse events.

###### Metrifonate 3 x 7.5 mg/kg given two weeks apart versus placebo

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------- ---------------------------------- -------------------------------------- -----------------------------
  **Metrifonate compared to placebo for treating urinary schistosomiasis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Patient or population:** patients with treating urinary schistosomiasis  **Settings:** endemic settings  **Intervention:** metrifonate 3 x 7.5 mg/kg given two weeks apart  **Comparison:** placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**                        **Relative effect  (95% CI)**                     **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                           

  **Placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Metrifonate 3 x 7.5 mg/kg given two weeks apart**                                                                                                                                              

  **Parasitological failure**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **40 per 100**                                                       **16 per 100**\                                   **RR 0.41**\                       93\                                    ⊕⊕⊝⊝\
  At 2 to 2.5 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             (12 to 22)                                        (0.3 to 0.56)                      (1 trial)                              **low**^1,2,3,4^

  **Mean percent egg reduction**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Egg excretion increased by 131% in the placebo group in this study   Egg excretion was reduced by 100% in this trial   ‐                                  93\                                    ⊕⊕⊝⊝\
  At 2 to 2.5 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (1 trial)                              **low**^1,2,3,4^

  **Parasitological failure**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **96 per 100**                                                       **29 per 100**\                                   **RR 0.3**\                        400  (1 trial)                         ⊕⊕⊕⊝  **moderate**^2,3,5,6^
  At 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (23 to 36)                                        (0.24 to 0.37)                                                            

  **Mean percent egg reduction**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **13%** increase                                                     **94%** reduction                                 ―                                  400\                                   ⊕⊕⊕⊝\
  At 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         (1 trial)                              **moderate**^2,3,5,7^

  **Adverse events**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ―                                                                    ―                                                 ―                                  493\                                   ^8^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (2 trials)                             

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                            

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------- ---------------------------------- -------------------------------------- -----------------------------

^1^ Downgraded by 1 for serious risk of bias; the single trial reporting this outcome did not adequately describe sequence generation, allocation concealment and blinding of participants, clinicians or outcome assessors.  ^2^ No serious inconsistency. Only one trial.

^3^ No serious indirectness. This single trial was conducted in children in rural sub‐Saharan Africa.  ^4^ Downgraded by 1 for serious imprecision. The trial was underpowered.

^5^ Downgraded by 1 for serious risk of bias. The trial did not report on sequence generation and allocation concealment. The study described blinding of participants, clinicians and outcome assessors.

^6^ No serious imprecision. CIs are narrow and both CI limits have clinically important effects. The trial is adequately powered for this outcome.

^7^ No serious imprecision. The difference in effect between metrifonate and placebo group is large.

^8^ None of the trials reported on adverse events.

###### Artesunate versus placebo

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------- -------------------------------------- -----------------------------
  **Artesunate compared to placebo for treating urinary schistosomiasis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Patient or population:** patients with treating urinary schistosomiasis  **Settings:** endemic settings  **Intervention:** artesunate 4 mg/kg for three days  **Comparison:** placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**                                                     **Relative effect  (95% CI)**                                     **No of participants  (studies)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                         

  **Placebo**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Artesunate**                                                                                                                                                                                                                                 

  **Parasitological failure**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **87 per 100**                                                                                    **46 per 100**   (14 to 148)                                      **RR 0.53**   (0.16 to 1.71)        251  (2 trials)                        ⊕⊕⊝⊝  **very low**^1,2,3,4^
  At 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Mean percent egg reduction**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Mean change in egg excretion ranged from range from **47.1%** reduction to **111.5%** increase.   Reduction in egg excretion ranged from **52.1%** to a **69.3%**   ―                                   276\                                   ⊕⊝⊝⊝  **low**^1,3,5,6^
  At 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        (2 trials)                             

  **Microhaematuria**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **53 per 100**                                                                                    **65 per 100**   (45 to 94)                                       **RR 1.22**   (0.85 to 1.76)        119  (1 trial)                         ⊕⊕⊝⊝  **low**^7,8,9,10^
  At 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Adverse events**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ―                                                                                                 ―                                                                 ―                                   276\                                   ⊕⊕⊝⊝\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (2 trials)                             **low**^11,12^

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                          

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------- -------------------------------------- -----------------------------

^1^ Downgraded by 1 for serious risk of bias. One trial described sequence generation, allocation concealment and blinding adequately, whereas the second study did not.

^2^ Downgraded by 1 for serious inconsistency. One of the trials (at high risk of bias) reported a large effect, while the other trial (at low risk of bias) detected no effect.

^3^ No serious indirectness. The trials were conducted in Gabon and Nigeria in patients of a similar age range.

^4^ Downgraded by 1 for serious imprecision. The CI is very wide and reaches from no benefit to a significant benefit after treatment.

^5^ No for serious inconsistency. Percent egg reductions the studies reported were similar.

^6^ Downgraded by 1 for serious imprecision. The meta analysis is underpowered.

7 No serious risk of bias. The one trial reporting the outcome reported adequately on sequence generation, allocation concealment and blinding.

^8^ No serious inconsistency: only one trial.

^9^ No serious indirectness: This trial was conducted in school children in Gabon.

^10^ Downgraded by 2 for very serious imprecision: only one trial reporting 74 events in 119 participants evaluated this outcome.

^11^Downgraded by 1 for serious risk of bias: only one trial was blinded. Both trials reported on adverse events, but the methods are unclear.

^12^ Downgraded by 1 for imprecision. One study reported on clinically diagnosed outcomes per treatment group, but was underpowered to confidently detect a difference.

###### Praziquantel and artesunate versus praziquantel

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- -----------------------------
  **Praziquantel plus artesunate compared to praziquantel alone for treating urinary schistosomiasis**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Patient or population:** patients with urinary schistosomiasis  **Settings:** Countries endemic for urinary schistosomiasis  **Intervention:** Praziquantel plus artesunate  **Comparison:** Praziquantel alone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **Illustrative comparative risks\* (95% CI)**                                                     **Relative effect  (95% CI)**                                                         **No of participants  (trials)**   **Quality of the evidence  (GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Corresponding risk**                                                                                                                                                                                                                                            

  **Praziquantel 40 mg/kg single dose alone**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **Praziquantel 40 mg/kg single dose plus artesunate 4 mg/kg/d for 3 days**                                                                                                                                                                                        

  **Parasitological failure at 8 weeks**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    **27 per 100**                                                                                    **17 per 100**\                                                                       **RR 0.62** (0.38 to 0.99)         265  (2 trials)                        ⊕⊕⊝⊝  **low**^1,2,3,4^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (10 to 27)                                                                                                                                                      

  **Percent egg reduction**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Egg reduction in the Praziquantel groups ranged from 52.1% reduction to a 97.11**%** reduction.   Egg reduction in the Praziquantel and ARS groups ranged from 93.5**%** to 98.8**%**   ―                                  265\                                   ⊕⊝⊝⊝  **very low**^1,2,5,6^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       (2 trials)                             

  **Microhaematuria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **28 per 100**                                                                                    **19 per 100**\                                                                       **RR 0.69**   (0.4 to 1.18)        177  (1 trial)                         ⊕⊕⊝⊝  **low**^7,8^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (11 to 33)                                                                                                                                                      

  **Adverse events**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ―                                                                                                 ―                                                                                     ―                                  156\                                   ⊕⊝⊝⊝\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       (1 trial)                              **very low**^9,10^

  \*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  GRADE Working Group grades of evidence  **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.  **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- -----------------------------

^1^ Downgraded by 1 for serious risk of bias: only one out of two studies did report adequate random sequence generation, allocation concealment and blinding or participants and clinicians, while the other study did not provide enough information to allow a judgement.  ^2^ No serious inconsistency. Both studies favour the combination of Praziquantel and ARS over Praziquantel alone.  ^3^ No serious indirectness. The trials were conducted in rural communities in Gabon and Nigeria, in children (6 to 15 years) and young adults (4 to 20 years)  ^4^ Downgraded by 1 for serious imprecision: Only two studies were included in this comparison. The effect size, described by the 95% CI ranged from a very small, clinically non‐important effect to a clinically important effect.  ^5^ Downgraded by 1 for serious inconsistency: egg reduction varied widely between the two trials.  ^6^ Downgraded by 1 for serious imprecision: Only two studies reported this outcome.  ^7^ No serious risk of bias. The one study that reporting this outcome described adequate random sequence generation, allocation concealment and blinding.  ^8^ Downgraded by 2 for serious imprecision: only one small study reported this outcome, the outcome is not statistically significant with wide 95% CI.  ^9^ Downgraded by 2 for serious risk of bias. This study did not provide enough information to allow a judgement regarding sequence generation, allocation concealment and blinding.  ^10^Downgraded by 1 for serious imprecision. Only one study reported on adverse events. The study was underpowered, and no difference in adverse events was detected between treatment groups.

Background {#CD000053-sec1-0002}
==========

Urinary schistosomiasis, also called bilharzia or snail fever, is an intravascular infection caused by parasitic *Schistosoma haematobium* worms. It is endemic in sub‐Saharan Africa, the Arabian peninsula and the Middle East. According to the World Health Organization (WHO), at least 243 million people required treatment for schistosomiasis in 2011 ([WHO 2013](#CD000053-bbs2-0116){ref-type="ref-list"}), and more than 700 million people live in endemic areas ([WHO 2014](#CD000053-bbs2-0117){ref-type="ref-list"}).

The WHO currently recommends regular chemoprophylaxis with praziquantel for populations at risk to prevent the long term consequences of infection. These programmes usually target school children ([Table 25](#CD000053-tbl-0025){ref-type="table"}), but may be extended to the whole community in high risk settings ([King 2011](#CD000053-bbs2-0102){ref-type="ref-list"}).

###### Population based treatment according to prevalence among schoolchildren (WHO)

  ------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  ** **\                    **Prevalence among school‐aged children**                                                  **Action to be taken**                                                          ** Comment**
  **Category**                                                                                                                                                                                         

  High‐risk community       50% by parasitological methods (intestinal or urinary schistosomiasis;\                    Treat all school‐age children (enrolled and not enrolled) once a year           Also treat adults considered to be at risk (from special groups to entire communities living in endemic areas)\
                            or\                                                                                                                                                                         
                            30% by questionnaire for visible haematuria\                                                                                                                               
                            (urinary schistosomiasis)                                                                                                                                                  

  Moderate‐risk community   \> 10 to \< 50% by parasitological methods (intestinal and urinary schistosomiasis); or\   Treat all school‐age children (enrolled or not enrolled) once every two years   Also treat adults considered to be at risk (special groups only)
                            30% by questionnaire for visible haematuria (urinary schistosomiasis)                                                                                                      

  Low--risk community       \< 10% by parasitological methods (intestinal and urinary schistosomiasis)                 Treat all school‐age children\                                                  Praziquantel should be available in dispensaries and clinics for treatment of suspected cases.
                                                                                                                       (enrolled and not enrolled) twice during their primary schooling age\           
                                                                                                                       (for example, once on of suspected cases\                                       
                                                                                                                       entry and once on exit)                                                         
  ------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------

Description of the condition {#CD000053-sec2-0001}
----------------------------

Human infection with *S. haematobium* is acquired through contact with water bodies containing cercariae, the larval form of the parasite. The cercariae are able to penetrate human skin and migrate via blood vessels to the liver, where they mature into male and female forms for reproduction. Typically, they then migrate further to the venous plexus of the urinary bladder, and begin to produce eggs which the infected person excretes in their urine ([Gryseels 2006](#CD000053-bbs2-0099){ref-type="ref-list"}). If these eggs reach water, they hatch into miracidia, infect specific freshwater snails which act as intermediate hosts, before emerging as cercariae that can infect humans ([Gray 2011](#CD000053-bbs2-0098){ref-type="ref-list"}; [Ross 2002](#CD000053-bbs2-0108){ref-type="ref-list"}).

Any illness associated with acute infection is typically mild, but chronic schistosomiasis can cause considerable morbidity with chronic pain, anaemia, fatigue, under nutrition and reduced exercise tolerance ([King 2005](#CD000053-bbs2-0101){ref-type="ref-list"}). A review of 124 observational studies and 11 randomized controlled trials (RCTs) in 2005 estimated that up to 15% of people infected with any form of schistosomiasis suffer disabling long‐term complications ([King 2005](#CD000053-bbs2-0101){ref-type="ref-list"}). The main pathological process occurs when schistosome eggs become trapped in the tissue around the bladder and ureters causing chronic inflammation, which may obstruct the ureters, damage the kidneys, and lead to bladder cancer. Occasionally, eggs can become trapped in other tissues such as the brain and spinal cord ([WHO 1985](#CD000053-bbs2-0111){ref-type="ref-list"}).

Two‐thirds of all infected persons are schoolchildren (aged five to 14 years), and the intensity of infection with *S. haematobium* is highest in children aged ten to 14 years ([WHO 1985](#CD000053-bbs2-0111){ref-type="ref-list"}).

The standard test for urinary schistosomiasis is urine filtration and microscopic examination of the urine sample ([WHO 1991](#CD000053-bbs2-0112){ref-type="ref-list"}). The urine sample is passed through a filter paper and the eggs retained on the filter are counted either with or without staining. Sedimentation and centrifugation is less commonly used for urine concentration ([Cook 2003](#CD000053-bbs2-0094){ref-type="ref-list"}). High urine egg counts are related to high infection intensity.

Parasitologists define cure when eggs can no longer be detected in one or more urine samples using standard methods. Besides parasitological cure, researchers also record the relative reduction in egg output after treatment compared to pre‐treatment levels. This outcome, expressed as % egg reduction, is an indirect estimate of a reduction of the worm burden ([Cook 2003](#CD000053-bbs2-0094){ref-type="ref-list"}).

Blood and protein excretion in the urine is usually elevated in urinary schistosomiasis and decreases when the infection resolves. The most commonly used test is a dipstick test. Ultrasound can demonstrate organ involvement of the urinary tract as well as its resolution.  

Description of the intervention {#CD000053-sec2-0002}
-------------------------------

Praziquantel is the current treatment for urinary schistosomiasis recommended by the WHO ([WHO 2006](#CD000053-bbs2-0115){ref-type="ref-list"}). Historically, metrifonate was also used but this fell out of favour due to the need for multiple doses ([Feldmeier 1999](#CD000053-bbs2-0096){ref-type="ref-list"}; [WHO 1998](#CD000053-bbs2-0113){ref-type="ref-list"}). More recently, there has been interest in the antischistosomal properties of artemisinin derivates and mefloquine, more commonly used for treating malaria ([Utzinger 2004](#CD000053-bbs2-0110){ref-type="ref-list"}).

Praziquantel is an pyrazinoisoquinoline derivative with activity against adult worms of all schistosome species (*S. mansoni*, *S. intercalatum* and *S. japonicum*), but not against maturing worms. Praziquantel has a rapid onset of action. It is well‐tolerated, can be given as a single dose ([Utzinger 2004](#CD000053-bbs2-0110){ref-type="ref-list"}) and paediatric formulations are available ([Stothard 2013](#CD000053-bbs2-0109){ref-type="ref-list"}).

Metrifonate, an organophosphorous cholinesterase inhibitor, is active against *S. haematobium* but not against other schistosome species ([Utzinger 2004](#CD000053-bbs2-0110){ref-type="ref-list"}).

Artemisinin, extensively used as potent antimalarial, has highest activity against immature schistosomes. Artemsinins are safe and well‐tolerated ([Utzinger 2004](#CD000053-bbs2-0110){ref-type="ref-list"}).

How the intervention might work {#CD000053-sec2-0003}
-------------------------------

After treatment with praziquantel, the worms appear to die quickly but egg excretion continues for several weeks. There are several possible reasons for this:

Firstly, some worms might not have been mature at the time of praziquantel treatment and therefore not killed by praziquantel ([Cioli 2003](#CD000053-bbs2-0093){ref-type="ref-list"}). Maturation of the worms after infection takes four to six weeks, and after two months eggs can be detected in the urine.Secondly, the patient might have been re‐infected ([Cioli 2003](#CD000053-bbs2-0093){ref-type="ref-list"}).Thirdly, dead eggs still wander out of the tissue into the urine several weeks after clearing adult worms ([Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}). Therefore, a follow‐up four to six weeks after treatment is useful ([Renganathan 1998](#CD000053-bbs2-0106){ref-type="ref-list"}). There is also considerable variation in daily urinary egg output ([Cook 2003](#CD000053-bbs2-0094){ref-type="ref-list"}).

Although there is concern that *S. haematobium* might develop resistance against praziquantel ([Fenwick 2006](#CD000053-bbs2-0097){ref-type="ref-list"}), there is no clinically relevant evidence for resistance up to now ([Doenhoff 2008](#CD000053-bbs2-0095){ref-type="ref-list"}).

In endemic settings, reinfection with *S. haematobium* is likely, and cure (often defined as complete cessation of egg excretion) is not a sustainable long term goal. However, reduction of infection intensity results in clinical improvement, low morbidity and prevention of long term complications. Therefore, WHO promotes morbidity control rather than cure as an objective for schistosomiasis control programmes ([WHO 2002](#CD000053-bbs2-0114){ref-type="ref-list"}).

Why it is important to do this review {#CD000053-sec2-0004}
-------------------------------------

At present, praziquantel as the only drug in use that is exposed to resistance development. It is therefore important to monitor its performance and to assess the effects of other drugs against urinary schistosomiasis.  

Dosing regimens for subgroups such as highly infected patient groups, incremental benefits of drug combinations, double dosing and optimal interval between doses have to be determined to inform control programmes for urinary schistosomiasis.

Paediatric schistosomiasis has gained attention as a public health problem, and evaluation of existing treatment studies is indicated.

Objectives {#CD000053-sec1-0003}
==========

To evaluate the efficacy and safety of drugs for treating urinary schistosomiasis.

Methods {#CD000053-sec1-0004}
=======

Criteria for considering studies for this review {#CD000053-sec2-0005}
------------------------------------------------

### Types of studies {#CD000053-sec3-0001}

Randomized controlled trials.

### Types of participants {#CD000053-sec3-0002}

Patients diagnosed with urinary schistosomiasis by: 

detection of macro or microhaematuria;identification of schistosome eggs by urine microscopy;detection of parasite antigens in blood or urine.

### Types of interventions {#CD000053-sec3-0003}

#### Intervention {#CD000053-sec4-0001}

Drugs used to treat urinary schistosomiasis.  Drugs considered as obsolete (such as ambilhar, oltipraz and niridazole) were not included. Metrifonate was included.

#### Control {#CD000053-sec4-0002}

Placebo, no intervention, an alternative regimen of the same drug, or an alternative drug used to treat urinary schistosomiasis.

### Types of outcome measures {#CD000053-sec3-0004}

#### Primary outcomes {#CD000053-sec4-0003}

Parasitological failure at one month post‐treatment (as defined by the trial authors);Percent egg reduction at one month.

#### Secondary outcomes {#CD000053-sec4-0004}

Parasitological failure at time‐points \> one month;Percent egg reduction from baseline at \> one month;Clinical outcomes: resolutions of signs and symptoms (for example, haematuria and proteinuria);Anaemia (decrease of the number of red blood cells or the quantity of haemoglobin in the blood);Growth outcomes (gain in body weight, body length).

##### Adverse events {#CD000053-sec5-0001}

Serious adverse events;Other adverse events

Search methods for identification of studies {#CD000053-sec2-0006}
--------------------------------------------

We attempted to identify all relevant trials regardless of language and publication status (published, unpublished, in press, under review and in progress).

### Electronic searches {#CD000053-sec3-0005}

We searched the following databases using the search terms outlined in [Appendix 1](#CD000053-sec2-0016){ref-type="app"}: The Cochrane Infectious Diseases Group Specialized Register (23 May 2014); Cochrane Central Register of Controlled Trials (CENTRAL), published in *The Cochrane Library* (2014, Issue 4); MEDLINE (1966 to 23 May 2014); EMBASE (1974 to 23 May 2014); and LILACS (1982 to 23 May 2014). We also searched the metaRegister of Controlled Trials (mRCT) using \'Schistosoma haematobium\' as the search term (23 May 2014).

### Searching other resources {#CD000053-sec3-0006}

We checked the reference lists of all studies identified by the above methods for additional studies relevant to this review.

Data collection and analysis {#CD000053-sec2-0007}
----------------------------

### Selection of studies {#CD000053-sec3-0007}

Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG) Information Retrieval Specialist, searched the literature and retrieved trial titles and abstracts.

VK and FZ independently screened the results of the search and retrieved full trial reports of all potentially relevant trials. Then, VK and FZ independently assessed each trial for inclusion using an eligibility form based on the inclusion criteria. We resolved any discrepancies by discussion with PG.

### Data extraction and management {#CD000053-sec3-0008}

VK and FZ independently extracted data using pre‐tested standardized forms. We resolved any differences through discussion with PG. For each trial we extracted details of the trial methods, participants, interventions and outcomes.

VK and FZ extracted the number of participants randomized and number of participants followed up in each treatment arm. For dichotomous outcomes, we extracted the number of participants experiencing the event in each group. For continuous outcomes summarized as geometric means, we extracted means and their standard error, if reported. If the data were presented as arithmetic means, we extracted arithmetic means and their standard deviations (SD), if reported, for each treatment group. Where continuous data were summarized as medians and ranges, these were extracted and entered into tables.  

VK and FZ double‐entered the data and cross‐checked to minimise errors. VK tried to contact trial authors for clarification or insufficient of missing data when necessary and summarised data reported in multiple publications as one single data set.

### Assessment of risk of bias in included studies {#CD000053-sec3-0009}

VK and FZ independently assessed the risk of bias of each trial using an assessment form based on the Cochrane Collaboration\'s \'Risk of bias\' tool ([Higgins 2008](#CD000053-bbs2-0100){ref-type="ref-list"}). DS verified the assessment results.

We assessed the risk of bias for six domains: sequence generation; allocation concealment; blinding (of participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other sources of bias. We categorized these judgments as low, high or unclear risk of bias.

For sequence generation, allocation concealment and blinding, we quoted the method as described in the trial in the [Characteristics of included studies](#CD000053-sec2-0024){ref-type="sec"} tables. For blinding, we stated the blinding method and who was blinded separately for different outcomes. For incomplete outcome data, we assigned a judgement for different outcomes (for example, loss to follow‐up at different time points).

We resolved disagreements by discussion or consultation. Where risk of bias was unclear, we attempted to contact the trial authors for clarification.

### Measures of treatment effect {#CD000053-sec3-0010}

We presented dichotomous outcomes as risk ratios (RR), and continuous outcomes as mean differences or geometric mean ratios. All results are shown with a 95% confidence interval (CI).

### Unit of analysis issues {#CD000053-sec3-0011}

For trials including more than two comparison groups, we split and analysed as individual pair‐wise comparisons. When conducting meta‐analysis we ensured that participants and cases in the placebo group were not counted more than once, by dividing the placebo cases and participants evenly between the intervention groups.

### Dealing with missing data {#CD000053-sec3-0012}

The primary analysis is a complete case analysis where the number of evaluable participants at each time point is used as the denominator.

### Assessment of heterogeneity {#CD000053-sec3-0013}

We assessed heterogeneity by inspecting forest plots for overlapping CIs and outlying data. We applied the Chi^2^ test with a P value \< 0.10 to indicate statistically significant heterogeneity, and the I^2^ statistic with a value of greater than 50% to indicate moderate heterogeneity. 

### Assessment of reporting biases {#CD000053-sec3-0014}

We planned to evaluate the possibility of publication bias by constructing funnel plots, but there were too few trials within each comparison to make this meaningful.

### Data synthesis {#CD000053-sec3-0015}

We analysed the data in pair‐wise comparisons using [Review Manager (RevMan)](#CD000053-bbs2-0107){ref-type="ref-list"}. We stratified the primary analysis by drug dose and the time point after treatment. Data were combined in meta‐analyses using a fixed‐effect model. If we detected moderate heterogeneity but still considered combination of the trials to be appropriate we used a random‐effects model. We presented data which could not be presented in forest plots in tables (medians, means without measure of variance, ranges).

We assessed quality of evidence using the GRADE approach, and displayed the results in \'Summary of Findings\' tables. The GRADE approach defines quality as a measure of \'our confidence in the effect estimates\' and defines four levels of quality; high, moderate, low and very low. The evidence from RCTs is rated as \'high quality\' but can be downgraded where there are major concerns about: 1) the risk of bias of the trials; 2) inconsistency between the trial results; 3) a mismatch between the question being asked and the trial setting, population, intervention or control; 4) the trial being underpowered; or 5) evidence of publication bias.

### Subgroup analysis and investigation of heterogeneity {#CD000053-sec3-0016}

We planned to conduct the following subgroup analyses to explore the potential causes of heterogeneity. However, there were too few trials within each comparison to make this meaningful: patient age (children versus adults), intensity of infection, endemicity.

### Sensitivity analysis {#CD000053-sec3-0017}

Data were insufficient to assess the robustness of results by sensitivity analyses to evaluate risk of bias components and the effects of missing data.

Results {#CD000053-sec1-0005}
=======

Description of studies {#CD000053-sec2-0008}
----------------------

### Results of the search {#CD000053-sec3-0018}

Following database searches, we identified 116 individual citations, and a further 40 potential studies after we checked trial abstracts. Following abstract screening, we assessed 71 full text articles for inclusion. [Figure 1](#CD000053-fig-0001){ref-type="fig"} shows the flow diagram of these trials.

![Study flow diagram](nCD000053-AFig-FIG01){#CD000053-fig-0001}

### Included studies {#CD000053-sec3-0019}

We included 30 RCTs, enrolling 8965 participants, and reported in 39 publications. Twenty trials were over 20 years old, and only eight were published since the year 2000.

#### Settings {#CD000053-sec4-0005}

All but one trial were conducted in sub Saharan Africa; 13 trials from East Africa: Somalia (one) Sudan (three), Tanzania (two), Kenya (six), Malawi (one); 13 trials from West Africa: Cameroon (two), Gabon (three), Niger (two), Mali (one), Nigeria (two), Cote d\' Ivoire (one), Ghana (one), Gambia (one); and three trials from southern Africa: Zimbabwe (two), and Zambia (one). Most trials were based in rural settings, but two were conducted in peri‐urban or semi‐rural settings, three were from urban settings, and in one trial the setting was not described. The remaining trial was conducted in an urban setting in Saudi Arabia.

Twenty trials were based in schools and one in a college, seven in villages, farms or settlements, one in antenatal clinics and two in referral hospitals.

#### Participants {#CD000053-sec4-0006}

Twenty‐four trials enrolled school‐age children and young adults, although the exact age‐range varied; age six to 20 years (16 trials), age five to 18 years (three trials), age two to 23 years (five trials). Two trials enrolled adults only, and four trials didn\'t clearly state the age range.

All trials diagnosed *S. haematobium* infection by detection of eggs or miracidia on urine microscopy. Sixteen trials reported egg counts as geometric mean egg counts, four trials as arithmetic mean egg counts, three trials reported both. One study reported geometric mean miracidial counts. Six trials used ranges or medians.

#### Interventions {#CD000053-sec4-0007}

Eight trials compared praziquantel with placebo, and 14 trials published between 1981 and 2009 compared different doses or regimens of praziquantel.

Five trials compared metrifonate with placebo, and seven trials published between 1983 and 1990 directly compared the efficacy of praziquantel and metrifonate.

More recently, three trials published between 2001 and 2009 evaluated artesunate as single agent or in combination with praziquantel, and two trials published in 2009 and 2011 evaluated mefloquine.

### Excluded studies {#CD000053-sec3-0020}

We excluded 65 studies for the reasons given in the \'[Characteristics of excluded studies](#CD000053-sec2-0025){ref-type="sec"}\' table.

Risk of bias in included studies {#CD000053-sec2-0009}
--------------------------------

Many trials lacked adequate descriptions of methods to allow judgements on risk of bias, and so have been classified as unclear (see [Figure 2](#CD000053-fig-0002){ref-type="fig"}).

![Risk of bias summary: review authors\' judgements about each risk of bias item for each included trial.](nCD000053-AFig-FIG02){#CD000053-fig-0002}

### Allocation {#CD000053-sec3-0021}

Fourteen trials adequately described a random method of sequence generation, but only six described a method of allocation concealment and could be considered at low risk of selection bias ([Abden Abdi 1989 SOM](#CD000053-bbs2-0001){ref-type="ref-list"}; [Basra 2012 GAB](#CD000053-bbs2-0003){ref-type="ref-list"}; [Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}; [Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}; [Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}; [Sacko 2009 MLI](#CD000053-bbs2-0024){ref-type="ref-list"}).

### Blinding {#CD000053-sec3-0022}

Ten trials reported adequate attempts to blind participants and trial staff to treatment allocation, six trials were unblinded and blinding was unclear in the remaining trials. Seven trials reported adequate blinding of outcome assessors.

### Incomplete outcome data {#CD000053-sec3-0023}

Many trials had high levels of attrition, particularly at later time points. When trials presented cure or failure rates as percentages, we were unable to assess attrition. We considered the risk of attrition bias to be unclear in 13 trials and high in nine trials.

### Selective reporting {#CD000053-sec3-0024}

We found evidence of reporting bias in one trial, as trial authors did not present pre‐specified outcomes. In three trials, selective reporting was at unclear risk of bias.

### Other potential sources of bias {#CD000053-sec3-0025}

Trial authors reported baseline imbalances in two trials, which we identified as sources of other bias.

The trials were mostly funded by funds, trusts or international agencies (see [Characteristics of included studies](#CD000053-sec2-0024){ref-type="sec"} tables). Eight trials did not declare funding, four received drug donations and only two trials declared funding by pharmaceutical companies (both Dafra Pharma).

Effects of interventions {#CD000053-sec2-0010}
------------------------

See: [Table 1](#CD000053-tbl-0001){ref-type="table"}; [Table 2](#CD000053-tbl-0002){ref-type="table"}; [Table 3](#CD000053-tbl-0003){ref-type="table"}; [Table 4](#CD000053-tbl-0004){ref-type="table"}; [Table 5](#CD000053-tbl-0005){ref-type="table"}; [Table 6](#CD000053-tbl-0006){ref-type="table"}

### Section A: Praziquantel {#CD000053-sec3-0026}

#### Praziquantel 40 mg/kg single dose versus placebo (comparison 1) {#CD000053-sec4-0008}

*On average, a single 40 mg/kg dose of praziquantel reduces the proportion of people still excreting eggs at one to two months after treatment by around 60% compared to placebo, and reduces the mean number of eggs excreted by over 95%.*

Eight trials compared a single 40 mg/kg dose of praziquantel with placebo or no treatment in schoolchildren in sub‐Saharan Africa. We have listed the definitions of parasitological failure in [Table 26](#CD000053-tbl-0026){ref-type="table"}.

###### Definion of cure, reporting and calculation of egg counts

  ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study ID**                                                           **Definition cure**                                                                                                                                                                                **Reporting of egg counts/10 mL urine**       **Methods to calculate egg counts**                                                                                                                                                                                                                                                                                                                                                         **Comment**

  [Abden Abdi 1989 SOM](#CD000053-bbs2-0001){ref-type="ref-list"}        Patients without schistosome eggs in their urine after treatment                                                                                                                                   Mean (SD), % ER                               Not reported                                                                                                                                                                                                                                                                                                                                                                                No hatching test employed, cured might be underestimated because of dead eggs

  [Al Aska 1990 SAU](#CD000053-bbs2-0002){ref-type="ref-list"}           Clinical improvement\                                                                                                                                                                              Mean, range                                   Not reported                                                                                                                                                                                                                                                                                                                                                                                ―
                                                                         Disappearance of ova from the urine on three successive examinations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [Basra 2012 GAB](#CD000053-bbs2-0003){ref-type="ref-list"}             Three consecutive urine samples without presence of eggs                                                                                                                                           Median, interquartile range                   Not reported                                                                                                                                                                                                                                                                                                                                                                                ―

  [Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}     Cure not reported                                                                                                                                                                                  GMEC                                          Not reported                                                                                                                                                                                                                                                                                                                                                                                Hb and weight as outcomes

  [Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}          Two negative egg counts on two consecutive days                                                                                                                                                    GMEC                                          Arithmetric mean of two egg counts per participant before and after treatment including 0 egg counts (cured patients). Geometric means of these arithmetic means.                                                                                                                                                                                                                           We received the data file from the study author\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Day to day variation in egg counts explains 10% cure rate with placebo.

  [Davis 1981 ZMB](#CD000053-bbs2-0006){ref-type="ref-list"}             Defined as three negative urine defined as the absence of hatched miracidia, although recently dead or black eggs might be present.                                                                Geometric mean miracidial count               At follow‐up: If the first urine specimen contained hatched miracidia, then random 10 mL samples were taken from further bladder collections, the miracidial count was recorded, and the geometric mean of the counts was compared directly with the geometric mean of the pretreatment counts.                                                                                             Quantitaive hatching test.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      if the first sedimented urine specimen was negative, then two further urine specimens taken on consecutive days were sedimented and examined.

  [de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}          No definition of cure given, presumably absence of urinary egg excretion                                                                                                                           Minimum and maximum value, median, 90%value   Not reported                                                                                                                                                                                                                                                                                                                                                                                Excretion of eggs following treatment

  [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}       No definition of cure given, cure rates and egg reduction rates as end points                                                                                                                      Mean ± SD                                     \"Treatment‐related changes  in egg counts were investigated using paired Student's t  test.\"                                                                                                                                                                                                                                                                                              ―

  [Jewsbury 1976 ZWE](#CD000053-bbs2-0009){ref-type="ref-list"}          No definition of cure given                                                                                                                                                                        \"median urine egg count\"                    Not reported                                                                                                                                                                                                                                                                                                                                                                                ―

  [Kardaman 1985 SDN](#CD000053-bbs2-0010){ref-type="ref-list"}          No definition of cure given, \"negative\"                                                                                                                                                          GMEC                                          Not reported                                                                                                                                                                                                                                                                                                                                                                                \"It would appear that the cure rate determined in any trial is dependent on the pretreatment egg count and on the \...urine examination techniques used.\"

  [Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}            Absence of urinary egg excretion\                                                                                                                                                                  GMEC                                          *S. haematobium* egg counts before and after treatment were averaged for every child (arithmetic mean) and the GM egg count for each treatment group was calculated. Because egg counts are over dispersed, they were logarithmically transformed log \[count+1\], and the GM was expressed as the antilogarithm of the mean.\                                                              (ERR; defined as reduction of geometric mean egg count  among *S. haematobium*--positive children after treatment, compared  with the respective geometric mean pretreatment)
                                                                         Cure rate (CR, defined as the percentage of children excreting no *S. haematobium* eggs 26 days after treatment among children with confirmed parasites at baseline)                                                                             Egg reduction rate (ERR) defined as reduction of geometric mean (GM) egg count among *S. haematobium* positive children after treatment, compared with the respective GM pretreatment.\                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                          The ERR was calculated as (1 ‐ \[GM egg count after treatment/GM egg counts at enrolment\] x 100                                                                                                                                                                                                                                                                                            

  [King 1989 KEN](#CD000053-bbs2-0012){ref-type="ref-list"}              No definition of cure given                                                                                                                                                                        AMEC\                                         Not reported                                                                                                                                                                                                                                                                                                                                                                                Infection was identified and quantified by Nucleopore filtration
                                                                                                                                                                                                                                                                            GMEC                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [King 1990 KEN](#CD000053-bbs2-0013){ref-type="ref-list"}              No definition of cure given                                                                                                                                                                        AMEC\                                         Not reported                                                                                                                                                                                                                                                                                                                                                                                Infection was identified and quantified by Nucleopore filtration
                                                                                                                                                                                                                                                                            GMEC                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}              Cure defined as egg‐negative                                                                                                                                                                       GMEC                                          Not reported                                                                                                                                                                                                                                                                                                                                                                                ―

  [McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}           Probable cure rate: excretion of no or only non viable eggs in the urine                                                                                                                           GMEC, 95%confidence limit of the mean         Not reported                                                                                                                                                                                                                                                                                                                                                                                ―

  [McMahon 1983 TZA](#CD000053-bbs2-0016){ref-type="ref-list"}           People were considered cured when no eggs or non‐viable eggs were excreted in the urine                                                                                                            Screening: GMEC of miracidia/10 mL urine\     \"In non cured cases the reduction of egg excretion was calculated.\"                                                                                                                                                                                                                                                                                                                       ―
                                                                                                                                                                                                                                                                            reduction in egg excretion                                                                                                                                                                                                                                                                                                                                                                                                                

  [Mott 1985 GHA](#CD000053-bbs2-0017){ref-type="ref-list"}              Absence of *S. haematobium* eggs in two random 5 mL samples of urine from the same specimen                                                                                                        GMEC 5 mL urine samples\                      Not reported                                                                                                                                                                                                                                                                                                                                                                                ―
                                                                                                                                                                                                                                                                            reduction in GMEC                                                                                                                                                                                                                                                                                                                                                                                                                         

  [Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}              No definition given                                                                                                                                                                                GMEC                                          \"Egg counts are geometric means in subjects who remained  infected. Reduction in egg no. after treatment in infected children was significant in all infections at 45 days.\"                                                                                                                                                                                                              ―

  [Omer 1981 SDN](#CD000053-bbs2-0019){ref-type="ref-list"}              100% reduction of egg excretion (absence of egg excretion in the urine)\                                                                                                                           GMEC                                          Not reported                                                                                                                                                                                                                                                                                                                                                                                Only children with GMEC \> 60/10 mL (in three egg counts) included
                                                                         or 98% egg reduction and neg miracidial hatching test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  [Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}          No definition of cure given                                                                                                                                                                        GMEC mean ± SD                                Not reported                                                                                                                                                                                                                                                                                                                                                                                Only children with GMEC \> 60/10 mL (in three egg counts) included

  [Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}              No definition of cure given                                                                                                                                                                        AMEC\                                         Percentage reduction in egg output was determined by comparing the arithmetic and geometric means of pooled egg counts before and after treatment. The geometric mean was obtained by recording the logarithm of egg counts and using the n +1 transformation for a series of counts after treatment that included zeros.                                                                   We did not use a hatching test to determine the viability of excreted ova since percentage reduction in egg output rather than parasitological cure was our main criterion of efficacy.
                                                                                                                                                                                                                                                                            % egg count reduction                                                                                                                                                                                                                                                                                                                                                                                                                     

  [Rey 1983 NER](#CD000053-bbs2-0022){ref-type="ref-list"}               No definition of cure given                                                                                                                                                                        AMEC\                                         Not reported                                                                                                                                                                                                                                                                                                                                                                                If possible, a hatching test was that at the last control (6 months)
                                                                                                                                                                                                                                                                            \"nombre moyenne\"\                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                            average number                                                                                                                                                                                                                                                                                                                                                                                                                            

  [Rey 1984 NER](#CD000053-bbs2-0023){ref-type="ref-list"}               No definition of cure given, \"negativation\"                                                                                                                                                      AMEC\                                         Not reported                                                                                                                                                                                                                                                                                                                                                                                ―
                                                                                                                                                                                                                                                                            moyenne des nombres d\'oeufs/10 mL urine\                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                            Number average                                                                                                                                                                                                                                                                                                                                                                                                                            

  [Sacko 2009 MLI](#CD000053-bbs2-0024){ref-type="ref-list"}             The  cure rate was calculated as the proportion of infected individuals who became parasitologically negative (0 egg/10 mL urine based on three urine samples) at three months post treatment      GMEC                                          Individual egg counts were  calculated as the mean number of eggs per 10 mL of urine in the three urine samples. To compare the effect of the treatment on the intensity of the infection at 3,  6 and 18 months geometric mean egg/10 mL for all urine samples examined for *S. haematobium* eggs were calculated as log10(x+1) to allow egg count of  0 to be included in the analysis.   ―

  [Stephenson 1985 KEN](#CD000053-bbs2-0025){ref-type="ref-list"}        no definition of cure given                                                                                                                                                                        AMEC                                          Not reported                                                                                                                                                                                                                                                                                                                                                                                ―

  [Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}        ―                                                                                                                                                                                                  AMEC\                                         Not reported                                                                                                                                                                                                                                                                                                                                                                                ―
                                                                                                                                                                                                                                                                            GMEC                                                                                                                                                                                                                                                                                                                                                                                                                                      

  [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}            Cure defined as negative egg counts\                                                                                                                                                               GMEC                                          Not reported                                                                                                                                                                                                                                                                                                                                                                                \"in cases were only one egg was found in three (urine) examinations the egg count was always taken as positive.\"
                                                                         \"infections as were cured by a negative GMEC at 1,3 and 6 months\"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  [Tchuente 2004 CMR](#CD000053-bbs2-0028){ref-type="ref-list"}          The parasitologic cure rates were calculated as the proportion  of children excreting eggs at the first survey before treatment  and who were not excreting eggs in their urine after treatment.   GMEC                                          Geometric mean (GM) values of all  individuals were used to assess average egg counts of each group. The GM was calculated as the antilogarithm of the  mean of all log transformed egg counts + 1.\                                                                                                                                                                                        The parasitological cure rates were calculated as the proportion of children excreting eggs at the first survey before treatment and who were not excreting eggs in their urine after treatment.
                                                                                                                                                                                                                                                                                                                          The intensity reduction rate was calculated as \[1 − (GM egg counts per 10  mL of urine after treatment/GM egg counts per 10 mL before treatment)\] × 100                                                                                                                                                                                                                                   

  [van den Biggelaar 02 GAB](#CD000053-bbs2-0029){ref-type="ref-list"}   Negative for both eggs and circulating antigen\                                                                                                                                                    GMEC interquartile range                      Not reported                                                                                                                                                                                                                                                                                                                                                                                ―
                                                                         failure: pos. for eggs or circulating antigen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"}           No definition of cure given                                                                                                                                                                        GMEC                                          When appropriate a log~10~ transformation was used in statistical analysis to make their skewed distribution approximate to normal. This was reversed for the presentation of results to give a geometric mean which included zero values.                                                                                                                                                  ―
  ---------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

##### Parasitological failure {#CD000053-sec5-0002}

Praziquantel 40 mg/kg as a single dose reduced parasitological treatment failure by around 60% at one to two months compared to placebo (RR 0.42, 95% CI 0.29 to 0.59; 864 participants, seven trials, [Analysis 1.1](#CD000053-fig-00101){ref-type="fig"}). The absolute level of treatment failure with praziquantel ranged from 16.6% ([McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}) to 77.5% ([de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}). Treatment failure with placebo was greater than 80% in all seven trials and over 90% in four trials.

Four trials reported follow‐up beyond two months ([Analysis 1.1](#CD000053-fig-00101){ref-type="fig"}). Failure rate increased over time in two trials, as might be expected in areas of schistosomiasis transmission as people become re‐infected ([McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}; [Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}). However, treatment outcomes improved in [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"} over time, with moderate reductions in treatment failure at one month and three months and a 70% reduction at six months. The trial authors stated that this improvement might have been due to excretion of remaining eggs from the urinary tract over time.

The fourth trial, [de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}, found no difference in treatment failure between praziquantel and placebo at any time point. The trial authors used a more sensitive diagnostic method (three urine samples, filtration of the whole volume up to 350 mL when the 10 mL urine sample contained fewer than 10 eggs) and a strict definition of cure (no excretion of eggs, no viability testing of eggs). This may explain the high failure rates observed despite high percent egg reductions comparable to other trials.

[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} reported treatment failure at eight months, its only time point. A single dose of praziquantel reduced treatment failure by 86% compared to placebo (RR 0.14, 95% CI 0.08 to 0.22; 209 participants, one trial, [Analysis 1.1](#CD000053-fig-00101){ref-type="fig"}).

Six trials reported parasitological failure stratified by intensity of infection; the categorisation of strata varied between trials (642 participants, see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}). At the first follow‐up at four to six weeks, three out of four trials had a tendency to higher failure in participants with higher infection intensity. The pattern attenuated at later time points.

##### Percent egg reduction {#CD000053-sec5-0003}

Seven trials reported mean urine egg counts per 10 mL urine at baseline, and at one to two months after a single dose of praziquantel 40 mg/kg or placebo (867 participants, seven trials, see [Table 27](#CD000053-tbl-0027){ref-type="table"}), although we were only able to reliably interpret this data for six trials (678 participants).

###### Praziquantel 40 mg/kg single dose versus placebo: % egg reduction at one and two months

  --------------------------------------------------------------------- --------------------- ---------------------------- ---------------------------- --------------------------------------- ----------------------- --------------------------------------- ------------------- ------------------ --------------------------- -----------------
  **Study ID**                                                          **Subgroup**          **Timepoint**                **Measure**                  **Praziquantel 40 mg/kg single dose**   **Placebo**             **P value difference between groups**                                                                      

  **Egg count/10 mL**\                                                  **% egg reduction**   **Egg count/10 mL**\         **% egg reduction**                                                                                                                                                                                     
  **(Range/95% CI)**\                                                                         **(Range/95% CI)**\                                                                                                                                                                                                                  
  **N**                                                                                       **N**                                                                                                                                                                                                                                

  **Baseline**                                                          **Follow‐up**         **Baseline**                 **Follow‐up**                                                                                                                                                                                           

  [de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}         ―                     1 month                      Median                       66\                                     1\                      98.5                                    124\                58\                53.2                        P = 0.29\
                                                                                                                                                        N = 48                                  N = 40                                                          N = 21              N = 18                                         not significant

  [McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}          ―                     1 month                      Miracidial count\            288.4 (33.2 to 2508.9)\                 1.1 (0 to 8.3) N = 30   99.6                                    324.9\              187.5\             42.3                        Not reported
                                                                                                                           (95% CI)                     N = 32                                                                                                  (22.1 to 4783.3)\   (6.3 to 5601.3)\                               
                                                                                                                                                                                                                                                                N = 37              N = 29                                         

  [Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}             ―                     1 month                      GMEC\                        385.5\                                  1.8/\                   99.5\                                   136.8\              119.9\             12.35 (GMEC)\               Not reported
                                                                                                                           AMEC                         780.9\                                  1.8                     99.7                                    188.8\              437.2              ‐ 131.5 (AMEC) (increase)   
                                                                                                                                                        N = 97                                                                                                  N = 52                                                             

  [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}           light infections\     1 month                      GMEC\                        15.1\                                   0.4                     99.7                                    15.7\               37.5               ‐138\                       Not reported
                                                                        \< 50/10 mL                                        N = (both light and heavy)   N = 77\                                                                                                 N = 90\                                (increase)                  
                                                                                                                                                        (both groups)                                                                                           (both groups)                                                      

  heavy infections\                                                     1 month               GMEC\                        204.7\                       4.0                                     98.1                    191.9\                                  147.0               23.39              Not reported                
  \< 100/10 mL                                                                                N = (both light and heavy)   N = 77\                                                                                      N = 90\                                                                                                    
                                                                                                                           (both groups)                                                                                (both groups)                                                                                              

  [Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}             ―                     45 days                      GMEC                         Not reported\                           1.4                     ―                                       N = 94              29.8               ―                           Not reported
                                                                                                                                                        N = 95                                                                                                                                                                     

  [Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}         ―                     8 weeks                      GMEC\                        38.51\                                  1.11\                   97.11                                   21.57\              11.41\             47.1                        Significant
                                                                                                                           (range)                      (1 to 3313)\                            N = 89                                                          (1 to 778)\         N = 30                                         
                                                                                                                                                        N = 90                                                                                                  N = 30                                                             

  [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}^2^   without placebo       8 weeks                      ―                            42.0 ± 1.7\                             9.8 ± 0.5\              76.7                                    34.1 ± 0.8\         72.0 ± 2.3\        ‐ 111.5\                    P \< 0.001^2^
                                                                                                                                                        N = 52                                  N = 42                                                          N = 52              N = 44             (increase)                  
  --------------------------------------------------------------------- --------------------- ---------------------------- ---------------------------- --------------------------------------- ----------------------- --------------------------------------- ------------------- ------------------ --------------------------- -----------------

^1^P for therapeutic efficacy (not defined) Praziquantel versus placebo

^2^ Treatment group: Praziquantel 40 mg/kg without placebo. [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"} also reports a second treatment group (Praziquantel 40 mg/kg with placebo), data not shown.

The mean egg count was reduced by more than 95% at one to two months following praziquantel in five trials, and by 75% in one trial. In the placebo groups the change in mean egg count ranged from a 53% decrease to a 115% increase.

Percent egg reduction in the praziquantel group remained high (\> 95%) in all three trials reporting at three months, and in all four trials at six months. Percent egg reduction was variable in the placebo group, ranging from 26% increase to 54% reduction at three months and from 5% to 64% reduction at six months (see [Table 28](#CD000053-tbl-0028){ref-type="table"}). One additional trial, [Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}, reported percent egg reduction at eight months as its only time point (209 participants, see [Table 28](#CD000053-tbl-0028){ref-type="table"}). Percent egg reduction after praziquantel was 99% compared to 5% with placebo.

###### Praziquantel 40 mg/kg single dose versus placebo: % egg reduction at later time points

  -------------------------------------------------------------------- --------------------- --------------------------- --------------------- --------------------------------------- ----------------- ------------------------------------------- ------------------- ------------------------ -------------- -----------------
  **Study ID**                                                         **Subgroup**          **Time point**              **Measure**           **Praziquantel 40 mg/kg single dose**   **Placebo**       **P value for difference between groups**                                                               

  **Egg count /10 mL urine**                                           **% egg reduction**   **Egg count/10 mL urine**   **% egg reduction**                                                                                                                                                                     

  **Baseline**                                                         **Follow‐up**         **Baseline**                **Follow‐up**                                                                                                                                                                           

  [McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}         ―                     3 months                    miracidial count\     288.4 (33.2 to 2508.9)\                 1.1 (0 to 16.3)   99.6                                        324.9\              149.4\                   54             Not reported
                                                                                                                         (95% CI)              N = 32                                                                                                (22.1 to 4783.3)\   (6.3 to 3556.6)                         
                                                                                                                                                                                                                                                     N = 37                                                      

  [Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}            ―                     3 months                    GMEC\                 385.5\                                  1.9\              99.5 (GMEC)\                                136.8\              85.9\                    37.2 (GMEC)\   Not reported
                                                                                                                         AMEC                  780.9\                                  1.9               99.75(AMEC)                                 188.8\              270.3                    43.16\         
                                                                                                                                               N = 97                                                                                                N = 52                                       (AMEC)         

  [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}          light infections\     3 months                    GMEC                  15.1\                                   0.4               97.35                                       15.7\               19.8                     ‐26.11\        Not reported
                                                                       \< 50/10 mL                                                             N = 77\                                                                                               N = 90                                       (increase)     
                                                                                                                                               (for both groups)                                                                                                                                                 

  heavy infections\                                                    GMEC                  204.7\                      2.0                   99.02                                   191.9\            94.7                                        50.65               Not reported                            
  \< 100/10 mL                                                                               N = 77\                                                                                   N = 90                                                                                                                    
                                                                                             (for both groups)                                                                                                                                                                                                   

  [de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}        ―                     5 months                    median                66\                                     0                 100                                         124\                95                       23.38          P = 0.27\
                                                                                                                                               N = 48                                                                                                N = 21                                                      not significant

  [McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}         ―                     6 months                    miracidial count\     288.4 (33.2 to 2508.9)\                 1.1\              99.6                                        324.9\              188.6 (13.9 to 2563.5)   41.95          Not reported
                                                                                                                         (95% CI)              N = 32                                  (0‐20.3)                                                      (22.1 to 4783.3)\                                           
                                                                                                                                                                                                                                                     N = 37                                                      

  [Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}            ―                     6 months                    GMEC\                 385.5\                                  2.4\              99.3 (GMEC)\                                136.8\              69.7\                    49.0\          Not reported
                                                                                                                         AMEC                  780.9\                                  20.1              97.4\                                       188.8\              261.8                    GMEC\          
                                                                                                                                               N = 97                                                    (AMEC)                                      N = 52                                       ‐38.7\         
                                                                                                                                                                                                                                                                                                  (increase)\    
                                                                                                                                                                                                                                                                                                  AMEC           

  [Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}   ―                     6 months                    GMEC                  41/10 mL\                               2/10 mL           95.1                                        39/10 mL\           14/10 mL                 64.1            
                                                                                                                                               N = 238                                                                                               N = 198                                                     

  [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}          light infections\     6 months                    GMEC                  15.1\                                   0.2               98.67                                       15.7\               11.7                     25.5           Not reported
                                                                       \< 50/10 mL                                                             N = 77\                                                                                               N = 90                                                      
                                                                                                                                               (for both groups)                                                                                                                                                 

  heavy infections\                                                    204.7\                0.6                         99.7                  191.9\                                  75.5              60                                          Not reported                                                
  \< 100/10 mL                                                         N = 77\                                                                 N = 90                                                                                                                                                            
                                                                       (for both groups)                                                                                                                                                                                                                         

  [Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}      ―                     8 months                    GMEC\                 57/\                                    0.2/\             99.64 (GMEC)\                               38/\                36/\                     5.26\          Not reported^1^
                                                                                                                         AMEC                  112\                                    1                 99.1 (AMEC)                                 85\                 102                      (GMEC)\        
                                                                                                                                               N = 105                                                                                               N = 104                                      ‐20\           
                                                                                                                                                                                                                                                                                                  (increase)\    
                                                                                                                                                                                                                                                                                                  (AMEC)         
  -------------------------------------------------------------------- --------------------- --------------------------- --------------------- --------------------------------------- ----------------- ------------------------------------------- ------------------- ------------------------ -------------- -----------------

^1^Praziquantel 40 mg/kg single dose: significant egg reduction in praziquantel group (before, after treatment) P \< 0.0002. no significant reduction in the placebo group (before, after treatment).

Five trials reported percent egg reduction stratified by intensity of infection (764 participants, [Appendix 2](#CD000053-sec2-0017){ref-type="app"}). At four to six weeks, all trials reported percent egg reductions over 90% across the strata. Percent egg reduction as a relative measure was at least as high in heavy infections as in mild infections, but post‐treatment egg counts as an absolute measure tended to be higher in people with high intensity infections. This pattern persisted at later time points.

##### Clinical resolution {#CD000053-sec5-0004}

At eight weeks the proportion of patients with persistent haematuria (defined as \> 5 erythrocytes/mL) was lower in those given praziquantel than placebo in one small trial which reported this (RR 0.53, 95% CI 0.33 to 0.84; 119 participants, one trial, [Analysis 1.2](#CD000053-fig-00102){ref-type="fig"}). There were substantial reductions in the mean number of erythrocytes in the urine in three trials at one to two months, but we could not combine these data in a meta‐analysis (357 participants, three trials, see [Appendix 3](#CD000053-sec2-0018){ref-type="app"}).

Proteinuria was reduced by 65% to 84% at one to two months after praziquantel compared to increases in the placebo groups (238 participants, two trials, see [Appendix 3](#CD000053-sec2-0018){ref-type="app"}).

Two trials reported mean haemoglobin at baseline and at six to eight months after treatment with no difference between groups (mean difference ‐0.08, 95% CI ‐0.24 to 0.09; 727 participants, two trials, [Analysis 1.3](#CD000053-fig-00103){ref-type="fig"}).

Three trials measured a variety of growth parameters ([Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}; [Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}; [Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}). Two trials reported little or no effect on the outcomes measured ([Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}; [Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}). The third trial ([Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}) reports 14 measures, some of which are reported as statistically significant, but all appear to be of no or only borderline clinical importance (see [Appendix 4](#CD000053-sec2-0019){ref-type="app"}). Most notably, there is a reported increase in children\'s physical fitness as measured by the Harvard Step test. The difference in mean improvement between groups was 6.8% at five weeks (mean end scores 81.2% praziquantel versus 75.5% placebo). Scores between 68% and 82% are considered average. Children that took praziquantel also gained 1.2 kg more weight than those in the control group, however baseline differences between groups were of a similar magnitude to this effect.

##### Adverse events {#CD000053-sec5-0005}

Of nine trials, six (with 1286 participants) commented on adverse events. Only four described the methods used for data collection, but rarely reported them in detail (see [Appendix 5](#CD000053-sec2-0020){ref-type="app"}). Adverse events were usually monitored in the first days after medication. Only two trials actually reported numbers of adverse events, and only abdominal pain was reported by both trials. The absolute number of adverse events was low and none were more common with praziquantel than placebo (see [Analysis 1.4](#CD000053-fig-00104){ref-type="fig"}). The other trials summarized narratively with comments such as \"both treatments were well tolerated\" (see [Appendix 5](#CD000053-sec2-0020){ref-type="app"}).

#### Praziquantel 40 mg/kg versus lower doses (comparison 2) {#CD000053-sec4-0009}

*Praziquantel doses of 20 to 40 mg/kg result in similar reductions in mean egg excretion, but 40 mg/kg is marginally superior at achieving cure.*

Ten trials compared praziquantel 40 mg/kg with lower doses: 30 mg/kg (seven trials), 20 mg/kg (three trials), and 10 mg/kg (three trials). All trials were conducted in sub‐Saharan Africa in schoolchildren, apart from one trial, which recruited college students and army recruits.

Treatment with praziquantel 40 mg/kg had fewer treatment failures than lower doses when measured at four to six weeks after treatment (versus 30 mg/kg; RR 0.76, 95% CI 0.59 to 0.99; 401 participants, four trials, [Analysis 2.1](#CD000053-fig-00201){ref-type="fig"}, versus 20 mg/kg; RR 0.74, 95% CI 0.59 to 0.93; 338 participants, two trials, [Analysis 2.1](#CD000053-fig-00201){ref-type="fig"}). However, there was no difference between 40 mg/kg and 30 mg/kg at two to three months (517 participants, five trials, [Analysis 2.2](#CD000053-fig-00202){ref-type="fig"}), or six months after treatment (699 participants, six trials, [Analysis 2.3](#CD000053-fig-00203){ref-type="fig"}).

In the five trials comparing praziquantel 40 mg/kg and 30 mg/kg, the mean number of eggs excreted was reduced by greater than 90% with both doses and without significant differences between groups (495 participants, five trials, see [Table 29](#CD000053-tbl-0029){ref-type="table"}).

###### Praziquantel 40 mg/kg single dose versus 30 mg/kg single dose: % egg reduction

  ------------------------------------------------------------------ ------------------------------- --------------------------- --------------------------------- -------------------------------- -------------------------------- --------------------------------------- ------------------------- ------------------ ----------------------- ----------------------
  **Study ID**                                                       **Subgroup**                    **Time point**              **Measure**                       **Praziquantel 40 mg/kg (SD)**   **Praziquantel 30 mg/kg (SD)**   **P value difference between groups**                                                                        

  **Egg count/10 mL urine**                                          **% reduction**                 **Egg count/10 mL urine**   **% reduction**                                                                                                                                                                                                  

  **Baseline**                                                       **Follow‐up**                   **Baseline**                **Follow‐up**                                                                                                                                                                                                    

  [McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}       ―                               1 month                     GMEC\                             288.4 (33.2 to 2508.9)\          1.1 (0‐8.3)\                     99.61                                   308.5 (31.2 to 3034.7)\   1.2 (0 to 15.4)\   99.6                    Not significant\
                                                                                                                                 (95 Confidence limits of mean)\   N = 33                           N = 30                                                                   N = 32                    N = 31                                     P value not reported
                                                                                                                                 N                                                                                                                                                                                                                

  [Rey 1983 NER](#CD000053-bbs2-0022){ref-type="ref-list"}^1^        ―                               1 month                     AMEC\                             7.5 ± 1.7\                       0.24\                            96.8                                    7.5 ± 1.7\                0.74\              90.13                   Not significant
                                                                                                                                 N                                 N = 57                           N = 54                                                                   N = 46                    N = 39                                     

  [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}^2^     heavy infection\                1 month                     GMEC\                             204.7\                           4.0                              98.04                                   185.4\                    3.1                98.32                   Not reported
                                                                     \< 100/10 mL                                                N                                 N = 77 for both groups                                                                                    N = 72 for both groups                                               

  light infection\                                                   1 month                         GMEC                        15.1                              0.4                              97.35                            15.9                                    0.6                       96.23                                      
  \> 50/10 mL                                                                                                                                                                                                                                                                                                                                     

  [Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}^3^   ―                               1 month                     GMEC\                             Stratum 1\                       N = 21                           97.69 ± 0.98                            Stratum 1:\               N = 19             85.65 ± 13.08           Not significant\
                                                                                                                                 mean ± SE,\                       87.4 ± 23.46\                                                                                             111.67 ± 47.14\                                                      Not reported
                                                                                                                                 N =                               N = 15\                                                                                                   N = 15\                                                              
                                                                                                                                                                   Stratum 2\                                                                                                Stratum 2:\                                                          
                                                                                                                                                                   339.4 ± 32.61\                                                                                            306.83 ± 54.29\                                                      
                                                                                                                                                                   N = 5\                                                                                                    (N = 6)\                                                             
                                                                                                                                                                   Stratum 3\                                                                                                Stratum 3:\                                                          
                                                                                                                                                                   518.00 ± 0.71\                                                                                            1507.00 ± 1400.07\                                                   
                                                                                                                                                                   N = 2\                                                                                                    N = 2\                                                               
                                                                                                                                                                   N = 22                                                                                                    N = 23                                                               

  [King 1989 KEN](#CD000053-bbs2-0012){ref-type="ref-list"}                                          2‐3 months                  AMEC (± SD)\                      377\                             31 (± 21)\                       91.7\                                   327\                      22 ± 17\           93.27\                  Not significant\
                                                                                                                                 GMEC\                             255\                             2\                               (AMEC)\                                 204\                      2\                 (AMEC)\                 Not reported
                                                                                                                                 N =                               N = 64                           N = 54                           99.2\                                   N = 69                    N = 60             99\                     
                                                                                                                                                                                                                                     (GMEC)                                                                               (GMEC)                  

  [McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}                                       3 months                    GMEC\                             288.4 (33.2 to 2508.9)\          1.1 (0‐16.3)\                    99.61                                   308.5 (31.2 to 3034.7)\   0.9 (0 to 13.4)\   97.08                   Not significant\
                                                                                                                                 (95 Confidence limits of mean)\   N = 33                           N = 29                                                                   N = 31                    N = 31                                     Not reported
                                                                                                                                 N                                                                                                                                                                                                                

  [Rey 1983 NER](#CD000053-bbs2-0022){ref-type="ref-list"}                                           3 months                    AMEC\                             7.5 ± 1.7\                       0.42\                            94.4                                    7.5 ± 1.7\                1.21\              83.86                   Not reported
                                                                                                                                 N =                               N = 57                           N = 52                                                                   N = 46                    N = 42                                     

  [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}^3^     heavy infections \< 100/10 mL   3 months                    GMEC\                             204.7\                           2.0                              99.02                                   185.4\                    1.1                99.4                    Not reported
                                                                                                                                 N =                               N = 77 for both groups                                                                                    N = 72 for both groups                                               

  light infections \> 50/10 mL                                       3 months                        GMEC                        15.1                              0.4                              97.35                            15.9                                    0.4                       97.48                                      

  [Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}^3^   ―                               3 months                    GMEC\                             Stratum 1\                                                        97.55 ± 0.85 (N = 18)                   Stratum 1\                                   99.01 ± 0.47 (N = 19)   Not significant\
                                                                                                                                 mean ± SE,\                       87.4 ± 23.46\                                                                                             111.67 ± 47.14\                                                      Not reported
                                                                                                                                 N =                               N = 15\                                                                                                   N = 15\                                                              
                                                                                                                                                                   Stratum 2\                                                                                                Stratum 2\                                                           
                                                                                                                                                                   339.4 ± 32.61\                                                                                            306.83 ± 54.29\                                                      
                                                                                                                                                                   N = 5\                                                                                                    N = 6\                                                               
                                                                                                                                                                   Stratum 3\                                                                                                Stratum 3\                                                           
                                                                                                                                                                   518.00 ± 0.71\                                                                                            1507.00 ± 1400.07\                                                   
                                                                                                                                                                   N = 2\                                                                                                    N = 2\                                                               
                                                                                                                                                                   N = 22                                                                                                    N = 23                                                               

  [McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}       ―                               6 months                    GMEC\                             288.4 (33.2 to 2508.9)\          1.1 (0 to 20.3)\                 99.6                                    308.5 (31.2 to 3034.7)\   1.4 (0 to 39.5)\   99.46                   Not significant\
                                                                                                                                 (95 Confidence limits of mean)    N = 33                           N = 28                                                                   N = 32                    N = 28                                     Not reported

  [Rey 1983 NER](#CD000053-bbs2-0022){ref-type="ref-list"}           ―                               6 months                    AMEC                              7.5 ± 1.7\                       4\                               46.6                                    7.5 ± 1.7\                0.18\              97.6                    Not reported
                                                                                                                                                                   N = 57                           N = 34                                                                   N = 46^2^                 N = 28                                     

  [Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}^3^     heavy infections \< 100/10 mL   6 months                    GMEC\                             204.7 (N = 77)                   0.6                              99.7                                    185.4 (N = 72)            0.7                99.62                   Not significant\
                                                                                                                                 N =                                                                                                                                                                                                              Not reported

  light infections \> 50/10 mL                                       6 months                        GMEC N =                    15.1 (N = 77)                     0.2                              98.67                            15.9 (N = 72)                           0.1                       99.37                                      

  [Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}^4^   ―                               6 months                    GMEC\                             Stratum 1\                       (N = 15)                         93.09 ± 0.12                            Stratum 1\                (N = 17)           98.72 ± 0.28            Not significant\
                                                                                                                                 mean ± SE,\                       87.4 ± 23.46\                                                                                             111.67 ± 47.14\                                                      Not reported
                                                                                                                                 (N =)                             (N = 15)\                                                                                                 (N = 15)\                                                            
                                                                                                                                                                   Stratum 2\                                                                                                Stratum 2\                                                           
                                                                                                                                                                   339.4 ± 32.61\                                                                                            306.83 ± 54.29\                                                      
                                                                                                                                                                   (N = 5)\                                                                                                  (N = 6)\                                                             
                                                                                                                                                                   Stratum 3\                                                                                                Stratum 3\                                                           
                                                                                                                                                                   518.00 ± 0.71\                                                                                            1507.00 ± 1400.07\                                                   
                                                                                                                                                                   (N = 2)\                                                                                                  (N = 2)\                                                             
                                                                                                                                                                   (N = 22)                                                                                                  (N = 23)                                                             

  ―                                                                  9 months                        (N = 6)                     92.4 ± 5.92                       (N = 8)                          96.49 ± 1.59                                                                                                                                  

  ―                                                                  12 months                       (N = 3)                     99.3 ± 0.26                       (N = 4)                          99.28 ± 0.46                                                                                                                                  
  ------------------------------------------------------------------ ------------------------------- --------------------------- --------------------------------- -------------------------------- -------------------------------- --------------------------------------- ------------------------- ------------------ ----------------------- ----------------------

^1^Baseline data not reported separately per group.

^2^A reduction as low as 46% after praziquantel 40 mg/kg was not observed by any other study that reported this outcome. At six months, five other studies reported % egg reduction above 90% (see [Table 28](#CD000053-tbl-0028){ref-type="table"} and [Table 29](#CD000053-tbl-0029){ref-type="table"})

^3^Heavy and light infections together; N = 77 for Praziquantel 40 mg/kg and N = 72 for Praziquantel 30 mg/kg.

^4^ GMEC/10 mL urine, stratum 1: 60 to 250, stratum 2: 251 to 500, stratum 3 \> 500.

In trials comparing 40 mg/kg and 20 mg/kg, again the mean number of eggs excreted was reduced by more than 95% for both doses and differences in percent egg reduction appeared small (636 participants, four trials, see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}). Treatment with praziquantel 40 mg/kg appeared to result in greater percent egg reductions than 10 mg/kg (357 participants, three trials, see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}).

One small trial from Kenya ([King 1989 KEN](#CD000053-bbs2-0012){ref-type="ref-list"}) reported similar numbers of participants with persistent haematuria or proteinuria at three months with praziquantel 40 mg/kg, 30 mg/kg and 20 mg/kg, but 40 mg/kg was superior to 10 mg/kg (haematuria at three months: RR 0.35, 95% CI 0.21 to 0.58, 119 participants, one trial, [Analysis 2.4](#CD000053-fig-00204){ref-type="fig"}; proteinuria at three months: RR 0.25, 95% CI 0.12 to 0.51; 119 participants, one trial, [Analysis 2.5](#CD000053-fig-00205){ref-type="fig"}). A larger trial by the same authors comparing 40 mg/kg and 20 mg/kg ([King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}) detected fewer participants with haematuria at six weeks following praziquantel 40 mg/kg (RR 0.63, 95% CI 0.47 to 0.86; 245 participants, one trial, [Analysis 2.6](#CD000053-fig-00206){ref-type="fig"}), and fewer participants with proteinuria (RR 0.66, 95% CI 0.46 to 0.96; 245 participants, one trial, [Analysis 2.7](#CD000053-fig-00207){ref-type="fig"}). These differences were still observed at nine months (haematuria: RR 0.59, 95% CI 0.44 to 0.78; 215 participants, one trial, [Analysis 2.8](#CD000053-fig-00208){ref-type="fig"}; proteinuria RR 0.67, 95% CI 0.5 to 0.9; 214 participants, one trial, [Analysis 2.9](#CD000053-fig-00209){ref-type="fig"}). [King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"} also reported ultrasound findings (bladder thickening, bladder irregularity and hydronephrosis) before and after treatment with praziquantel 40 mg/kg and 20 mg/kg respectively, but the results were inconclusive (264 participants, see [Appendix 6](#CD000053-sec2-0021){ref-type="app"}).

Six of these trials did not comment on adverse events. Four trials described the methods of data collection, but often in insufficient detail; two out of four trials used active, prospective surveillance for adverse events ([Appendix 5](#CD000053-sec2-0020){ref-type="app"}). Two trials stated for all treatment arms collectively that adverse events after praziquantel treatment were mild and transient. Two trials reported numbers of adverse events with no differences between groups (163 participants, [Analysis 3.2](#CD000053-fig-00302){ref-type="fig"}).

#### Praziquantel 40 mg/kg single dose versus split dose (comparison 3) {#CD000053-sec4-0010}

*Splitting the dose of praziquantel 40 mg/kg into two 20 mg/kg doses over 24 hours has not been shown to improve tolerability and may actually cause more vomiting and dizziness.*

Three trials compared the single 40 mg/kg dose with a split dose regimen giving two doses of 20 mg/kg over 24 hours. There was no statistically significant difference in treatment failure at one month (RR 0.75, 95% CI 0.51 to 1.11; 374 participants, three trials), three months (RR 0.74, 95% CI 0.45 to 1.2; 361 participants, three trials), or six months (RR 0.83, 95% CI 0.51 to 1.35; 234 participants, three trials, [Analysis 3.1](#CD000053-fig-00301){ref-type="fig"}). Similarly percent egg reduction was over 90% for both groups (332 participants, three trials, see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}).

These trials enrolled 191 participants for a single dose of praziquantel 40 mg/kg and 195 participants for a split dose of 2 x 20 mg/kg. All trials used active surveillance for adverse events (see [Appendix 5](#CD000053-sec2-0020){ref-type="app"}). Adverse events were generally reported to be mild and transient. However one trial reports significantly more vomiting and dizziness with the split dose compared to the single dose (vomiting: RR 0.5, 95% CI 0.29 to 0.86; dizziness: RR 0.39, 95% CI 0.16 to 0.94; 373 participants, three trials, [Analysis 3.2](#CD000053-fig-00302){ref-type="fig"}).

#### Praziquantel 40 mg/kg single dose versus multiple doses (comparison 4 and 5) {#CD000053-sec4-0011}

*There are too few trials to determine the optimal frequency and timing of repeated praziquantel dosing.*

Two trials compared the standard single dose of praziquantel (40 mg/kg) with two or three doses given at two or three week intervals, and found no statistically significant differences in parasitological failure ([Analysis 4.1](#CD000053-fig-00401){ref-type="fig"}, [Analysis 4.2](#CD000053-fig-00402){ref-type="fig"}), percentage egg reduction ([Appendix 2](#CD000053-sec2-0017){ref-type="app"}), or clinical resolution ([Appendix 3](#CD000053-sec2-0018){ref-type="app"}; [Analysis 4.3](#CD000053-fig-00403){ref-type="fig"}).

One additional very small trial from a high transmission setting in Gabon ([van den Biggelaar 02 GAB](#CD000053-bbs2-0029){ref-type="ref-list"}), compared praziquantel 40 mg/kg every three months for two years to a single dose of praziquantel 40 mg/kg given at the beginning of the trial. At two years, patients who received only one dose of praziquantel had almost three times the risk of treatment failure compared to multiple doses (RR 2.71, 95% CI 1.47 to 5.00; 62 participants, one trial, [Analysis 5.1](#CD000053-fig-00501){ref-type="fig"}). Percent egg reduction was 96% after multiple doses and 80% after a single dose of praziquantel at two years (90 participants, see [Table 30](#CD000053-tbl-0030){ref-type="table"}). These effects were no longer apparent one year after the last praziquantel dose.

###### Praziquantel 40 mg/kg multiple doses versus single dose: % egg reduction

  ------------------------------------------------------------------------- --------------------- -------------- --------------------------------------- --------------------- ------------------------------------------ --------------------- -------------- ------- --------------
  **Study ID**                                                              **Time point**        **Measure**    **Praziquantel 40 mg/kg single dose**   **% egg reduction**   **Praziquantel 40 mg/kg multiple doses**   **% egg reduction**   **Comments**           

  **Egg count/10 mL**                                                       **Egg count/10 mL**                                                                                                                                                                        

  **Baseline**                                                              **Follow‐up**         **Baseline**   **Follow‐up**                                                                                                                                         

  [van den Biggelaar 02 GAB](#CD000053-bbs2-0029){ref-type="ref-list"}^1^   2 years               GMEC\          47\                                     9 (2‐45)              80.85                                      47\                   2 (1‐3)        95.74   Significant\
                                                                                                  (IQR)          N = 45                                                                                                   N = 45                                       P = 0.002
  ------------------------------------------------------------------------- --------------------- -------------- --------------------------------------- --------------------- ------------------------------------------ --------------------- -------------- ------- --------------

^1^Baseline egg counts not reported separately per treatment group; no difference at baseline stated. Praziquantel 40 mg/kg given every 3 months over 2 years. Location: Gabon, endemic area.

These trials did not report on adverse events.

### Section B: Metrifonate {#CD000053-sec3-0027}

#### Metrifonate single dose versus placebo (comparison 6) {#CD000053-sec4-0012}

*A single dose of metrifonate 10 mg/kg probably reduces egg excretion but is only marginally better than placebo at achieving cure.*

Two trials compared a single dose of metrifonate to placebo, although one trial only reported outcomes at a single time point eight months after treatment ([Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}).

In the first trial ([Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}), 80% of those treated with metrifonate continued to excrete eggs one month after treatment which was only marginally better than placebo (RR 0.83, 95% CI 0.74 to 0.94; 142 participants, one trial, [Analysis 6.1](#CD000053-fig-00601){ref-type="fig"}), and no difference was seen at six months (RR 0.94, 95% CI 0.87 to 1.02; 102 participants, one trial, [Analysis 6.1](#CD000053-fig-00601){ref-type="fig"}).

In the second trial ([Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}), 61% of those treated with metrifonate continued to excrete eggs eight months after treatment compared with almost 100% who received placebo (RR 0.63, 95% CI 0.54 to 0.73, 210 participants, one trial, [Analysis 6.1](#CD000053-fig-00601){ref-type="fig"}). Egg excretion was also reduced by more than 90% eight months after treatment compared to just 5% with placebo (210 participants, see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}).

The second trial also reported mean haemoglobin at baseline and eight months (with no difference between groups, [Analysis 6.2](#CD000053-fig-00602){ref-type="fig"}), and various measures of nutrition and growth (see [Appendix 4](#CD000053-sec2-0019){ref-type="app"}). However, this trial had three arms and the nutritional measures are reported for the metrifonate and praziquantel groups combined. Consequently, we were unable to evaluate the effect of metrifonate. Trial authors did not report adverse events.

#### Metrifonate multiple doses versus placebo (comparison 7) {#CD000053-sec4-0013}

*Subsequently trials evaluated multiple doses of metrifonate given two weeks apart, which improved the proportion of patients being cured.*

Two trials evaluated three doses of metrifonate 7.5 mg/kg given two weeks apart ([Jewsbury 1976 ZWE](#CD000053-bbs2-0009){ref-type="ref-list"}; [Stephenson 1985 KEN](#CD000053-bbs2-0025){ref-type="ref-list"}), and reported much reduced treatment failures compared to placebo at 11 weeks (RR 0.41, 95% CI 0.30 to 0.56; 93 participants, one trial, [Analysis 7.1](#CD000053-fig-00701){ref-type="fig"}) and six months respectively (RR 0.30, 95% CI 0.24 to 0.37; 400 participants, one trial, [Analysis 7.1](#CD000053-fig-00701){ref-type="fig"}).

A third small trial ([de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}) comparing two 10 mg/kg doses given two weeks apart with placebo found very low levels of cure and no difference compared to placebo at one month or five months (51 participants, one trial, [Analysis 7.1](#CD000053-fig-00701){ref-type="fig"}). However, this is the same trial that found very high levels of treatment failure with praziquantel, which may be a result of the highly sensitive method used for detecting low level egg excretion and the strict definition of cure.

All three trials found substantial reductions in the number of eggs being excreted at their various time points (\> 90% reductions in all three trials, see [Table 31](#CD000053-tbl-0031){ref-type="table"}).

###### Metrifonate 20 mg/kg given as divided dose versus placebo: % egg reduction

  -------------------------------------------------------------------- --------------------- ------------------------------------- --------------------------------------------------------- ----------------------------- --------------------------------------- --------- -------- ------------ ------------------
  **Study ID**                                                         **Time point**        **Measure**                           **Metrifonate 21.5 mg, 20 mg/kg given as divided dose**   **Placebo or no treatment**   **P value difference between groups**                                   

  **Egg count/10 mL urine**                                            **% egg reduction**   **Egg count/10 mL urine**             **% egg reduction**                                                                                                                                             

  **Baseline**                                                         **Follow‐up**         **Baseline**                          **Follow‐up**                                                                                                                                                   

  [de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}^1^     1 month               median\                               95\                                                       1\                            98.94                                   124\      58\      53.22        Not significant\
                                                                                             N =\                                  N = 38                                                    N = 32                                                                N = 21    N = 18                P = 0.29
                                                                                             (reports min, max, 90th percentile\                                                                                                                                                                   
                                                                                             and median\                                                                                                                                                                                           
                                                                                             of egg counts/10 mL)                                                                                                                                                                                  

  [Jewsbury 1976 ZWE](#CD000053-bbs2-0009){ref-type="ref-list"}^2^     11 weeks              median\                               101\                                                      0                             100                                     26\       60       ‐130.77\     Not reported
                                                                                             N =                                   N = 32                                                                                                                          N = 38             (increase)   

  11 weeks                                                             median\               40\                                   0                                                         100                                                                                                   
                                                                       N =                   N = 23                                                                                                                                                                                                

  [de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}^1^     5 months              median\                               124\                                                      1\                            99.19                                   124\      95\      23.38        Not significant\
                                                                                             N =\                                  N = 38                                                    N = 32                                                                N = 21    N = 19                P = 0.27
                                                                                             (reports min, max, 90th percentile\                                                                                                                                                                   
                                                                                             and median\                                                                                                                                                                                           
                                                                                             of egg counts/10 mL)                                                                                                                                                                                  

  [Stephenson 1985 KEN](#CD000053-bbs2-0025){ref-type="ref-list"}^3^   6 months              AMEC\                                 109\                                                      7                             94                                      110\      124      ‐12.7\       Not reported
                                                                                             N =                                   N = 202                                                                                                                         N = 198            (increase)   
  -------------------------------------------------------------------- --------------------- ------------------------------------- --------------------------------------------------------- ----------------------------- --------------------------------------- --------- -------- ------------ ------------------

^1^Metrifonate 2 x 10 mg/kg, dose interval two weeks. Placebo: multivitamins.

^2^Reports two groups with metrifonate 7.5 mg x 3, dose interval two weeks. Control group: nil.

^3^ Metrifonate 3 x 7.5 mg/kg, dose interval one to two weeks.

[Stephenson 1985 KEN](#CD000053-bbs2-0025){ref-type="ref-list"} also reported mean haemoglobin, with slightly higher values at six months after metrifonate compared to placebo (mean difference 0.3 G/dL, 95% CI 0.14 to 0.46; 400 participants, one trial, [Analysis 7.2](#CD000053-fig-00702){ref-type="fig"}). The authors noted that hookworm endemicity was high, and metrifonate also has an effect on hookworm which could account for this finding.

None of the trials reported on adverse events.

#### Direct comparisons of different metrifonate regimens (comparisons 8 and 9) {#CD000053-sec4-0014}

*In one trial, multiple doses of 10 mg/kg were superior to a single dose.*

One three‐arm trial directly compared a single dose of 10 mg/kg with two or three doses given two weeks apart. Parasitological failure at one month was 53% with a single dose, 40% with two doses, and 19% with three doses. The difference was statistically significant for three doses versus one dose (RR 0.36, 95% CI 0.17 to 0.77; 93 participants, one trial, [Analysis 8.1](#CD000053-fig-00801){ref-type="fig"}), but not two doses versus one dose (RR 0.75, 95% CI 0.5 to 1.13; 112 participants, one trial, [Analysis 8.1](#CD000053-fig-00801){ref-type="fig"}). Results were similar at four months ([Analysis 8.2](#CD000053-fig-00802){ref-type="fig"}).

The percent egg reduction was also improved from 37% after a single dose to 88% after three doses, although this was not maintained at the four months\' follow‐up (see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}). This trial did not report on adverse events.

One additional trial ([Abden Abdi 1989 SOM](#CD000053-bbs2-0001){ref-type="ref-list"}) compared three doses of 7.5 mg/kg given two weeks apart with three doses of 5 mg/kg given in one day. The trial detected no difference for parasitological failure at one month, three months or six months (201 participants, one trial, [Analysis 9.1](#CD000053-fig-00901){ref-type="fig"}). Egg reduction at one month was above 90% after both metrifonate doses and was sustained (\> 90%) at two, three and six months (201 participants, see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}). This trial recorded adverse events by active surveillance ([Appendix 5](#CD000053-sec2-0020){ref-type="app"}). It did not detect a significant difference for any of the symptoms between treatment groups (201 participants, one trial, [Analysis 9.2](#CD000053-fig-00902){ref-type="fig"}) The adverse events were mild and transient.Headache and abdominal pain were most common.

### Section C: Praziquantel versus metrifonate {#CD000053-sec3-0028}

#### Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose (comparison 10) {#CD000053-sec4-0015}

*Single dose praziquantel 40 mg/kg was more effective than single dose metrifonate 10 mg/kg in curing patients and reducing egg excretion.*

Three trials compared the standard dose of praziquantel 40 mg/kg with a single dose of metrifonate 10 mg/kg, although one trial only reported outcomes at eight months after treatment ([Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}).

In the first trial ([Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}), parasitological failure at one month was halved with praziquantel 40 mg/kg compared to metrifonate 10 mg/kg (RR 0.46, 95% CI 0.34 to 0.61; 183 participants, one trial, [Analysis 10.1](#CD000053-fig-01001){ref-type="fig"}). Treatment failure increased in both groups over the following five months which the authors suspect was due to egg excretion by maturing worms, as transmission and re‐infection were low in the trial setting ([Analysis 10.1](#CD000053-fig-01001){ref-type="fig"}). The second trial ([Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"}), also found praziquantel to be superior to metrifonate at two to three months as its only time point (RR 0.45, 95% CI 0.27 to 0.75; 72 participants, one trial, [Analysis 10.1](#CD000053-fig-01001){ref-type="fig"}).

The third trial ([Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}), found substantial reductions in both treatment failure (RR 0.21, 95% CI 0.13 to 0.36; 208 participants, one trial, [Analysis 10.1](#CD000053-fig-01001){ref-type="fig"}) and egg excretion (see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}), with praziquantel compared to metrifonate. Haemoglobin levels measured in this trial were higher in the praziquantel treatment arm both at baseline and at follow‐up (208 participants, one trial, [Analysis 10.2](#CD000053-fig-01002){ref-type="fig"}). The trial did not detect a difference in growth parameters between groups but does not report them separately (see [Appendix 4](#CD000053-sec2-0019){ref-type="app"}).

None of the trials reported on adverse events.

#### Praziquantel 40 mg/kg single dose versus multiple doses of metrifonate 10 mg/kg {#CD000053-sec4-0016}

*Two small trials found no difference in parasitological treatment failure or egg excretion between single dose praziquantel 40 mg/kg and two or three doses of metrifonate 10 mg/kg*.

Two small trials compared praziquantel 40 mg/kg single dose to two and three doses of metrifonate 10 mg/kg given two weeks apart. The trials detected no difference in parasitological treatment failure at different time points and with different metrifonate regimens. However, in one trial both drugs performed poorly ([de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}), and in one trial both performed well ([Al Aska 1990 SAU](#CD000053-bbs2-0002){ref-type="ref-list"}) (see [Analysis 10.3](#CD000053-fig-01003){ref-type="fig"}). The trial where both drugs performed poorly for parasitological failure has been discussed above and this is likely to be due to the very sensitive method for detecting eggs. In this trial, both drugs reduced mean egg excretion by over 98% at one month and five months (see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}), and a decrease in haematuria by over 90% at one month. Reduction in proteinuria was almost 80% in both groups (see [Appendix 3](#CD000053-sec2-0018){ref-type="app"}).

Only [Al Aska 1990 SAU](#CD000053-bbs2-0002){ref-type="ref-list"} reported adverse events; dizziness was more common after praziquantel (RR 2.9, 95% CI 1.59 to 5.3; 100 participants, one trial, [Analysis 10.4](#CD000053-fig-01004){ref-type="fig"}). Dizziness (20% in the praziquantel group and 10% in the metrifonate group) and abdominal pain (12% both in the praziquantel and metrifonate group) were the most common side effects ([Appendix 5](#CD000053-sec2-0020){ref-type="app"}).

#### Additional comparisons of praziquantel and metrifonate {#CD000053-sec4-0017}

One small trial compared a single dose of praziquantel 30 mg/kg to three doses of metrifonate 10 mg/kg given two weeks apart and found no difference in parasitological failure at two months, but a statistically significant difference in favour of praziquantel at four months (RR 0.24, 95% CI 0.07 to 0.8; 52 participants, one trial, [Analysis 10.5](#CD000053-fig-01005){ref-type="fig"}). Egg reduction at four months was above 98% in both treatment groups ([Appendix 2](#CD000053-sec2-0017){ref-type="app"}). In this trial, abdominal pain was more common in the metrifonate group (RR 0.33, 95% CI 0.12 to 0.92; 60 participants, one trial, [Analysis 10.6](#CD000053-fig-01006){ref-type="fig"}), while no difference was detected for the eight other clinically diagnosed symptoms reported.

One large population‐based trial from Kenya compared praziquantel 40 mg/kg given once a year to metrifonate 10 mg/kg given three times a year. After one year, this trial detected no difference in treatment failure, haematuria or proteinuria (1400 participants, one trial, [Analysis 10.7](#CD000053-fig-01007){ref-type="fig"}), but mean egg excretion was reduced by over 80% in both groups at one year ([Appendix 2](#CD000053-sec2-0017){ref-type="app"}). There continued to be no difference in parasitological failure at two years, but praziquantel was superior in the third year (RR 0.62, 95% CI 0.42 to 0.93; 827 participants one trial, [Analysis 10.8](#CD000053-fig-01008){ref-type="fig"}). Ultrasound findings, recorded in a sub‐sample of children, were inconclusive (373 participants, [Appendix 6](#CD000053-sec2-0021){ref-type="app"}).

One further small trial compared a single dose of praziquantel 40 mg/kg with a combination of praziquantel 10 mg/kg and metrifonate 10 mg/kg. At two to three months there was no difference in treatment failure (72 participants, one trial, [Analysis 10.9](#CD000053-fig-01009){ref-type="fig"}). Percent egg reduction was 99.4% after praziquantel alone and 92.9% after the combination treatment (see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}).

### Section D: Artesunate {#CD000053-sec3-0029}

#### Artesunate versus placebo (comparison 11) {#CD000053-sec4-0018}

*The two placebo controlled trials of artesunate had inconsistent results, and the single trial at low risk of bias found only a modest effect on egg excretion compared to placebo.*

Two trials compared artesunate 4 mg/kg once daily for three days with placebo. The two trials had inconsistent results on parasitological failure, with one trial finding no difference between artesunate and placebo, and one finding lower treatment failures with artesunate at eight weeks (251 participants, two trials, [Analysis 11.1](#CD000053-fig-01101){ref-type="fig"}). The trial finding an effect was at unclear risk of both selection and detection bias due to an inadequate description of trial methods ([Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}).

Both trials found that artesunate reduced egg excretion compared to placebo ([Table 32](#CD000053-tbl-0032){ref-type="table"}), but the percent reduction was low compared to that seen in placebo controlled trials of praziquantel (percent egg reductions of between 52% and 69%).

###### Artesunate versus placebo: % egg reduction

  --------------------------------------------------------------------- ---------------- ---------------------- ------------------------------------- ------------- --------------------------------------- ------------- ------------- ------------ -----------------------------------------
  **Study ID**                                                          **Time point**   **Measure**            **Artesunate 4 mg/kg/d for 3 days**   **Placebo**   **P value difference between groups**                                            

  **Egg count/10 mL urine**                                             **% egg**\       **Egg count/10 mL**    **% egg**\                                                                                                                           
                                                                        **reduction**                           **reduction**                                                                                                                        

  **Baseline**                                                          **Follow‐up**    **Baseline**           **Follow‐up**                                                                                                                        

  [Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}         8 weeks          GMEC (range)\          35.22 (1‐4360)\                       10.8\         69.34                                   21.56\        11.41\        47.1         Not significant
                                                                                         95% CI N =             N = 90                                N = 89                                                (1‐778)\      N = 30                     
                                                                                                                                                                                                            N = 30                                   

  [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}^1^   8 weeks          Mean ova count ± SD\   39.8 ± 1.1\                           19.1 ± 1.0\   52.1                                    34.1 ± 0.8\   72.0 ± 2.3\   111.5\       P for \"therapeutic efficacy\" \< 0.001
                                                                                         N =                    N = 52                                N = 44                                                N = 52        N = 44        (increase)   
  --------------------------------------------------------------------- ---------------- ---------------------- ------------------------------------- ------------- --------------------------------------- ------------- ------------- ------------ -----------------------------------------

^1^Treatment group: Praziquantel 40 mg/kg without placebo. [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"} also reports a second treatment group (Praziquantel 40 mg/kg with placebo), data not shown.

The trial at unclear risk of bias also reported improved reductions in haematuria and proteinuria compared to placebo, while the trial at low risk of bias ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}) found no effect on proteinuria (see [Appendix 3](#CD000053-sec2-0018){ref-type="app"}). No differences in adverse events were reported (see [Appendix 5](#CD000053-sec2-0020){ref-type="app"}, [Analysis 11.3](#CD000053-fig-01103){ref-type="fig"}).

#### Praziquantel versus artesunate (comparison 12) {#CD000053-sec4-0019}

*The results of the three trials are inconsistent, with the single trial at low risk of bias finding only a modest reduction in egg excretion with artesunate.*

Three trials ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}; [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}; [Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}) compared artesunate 4 mg/kg/d for three days with praziquantel 40 mg/kg single dose.

The three trials had mixed results. In two trials artesunate performed poorly, with parasitological treatment failures of over 70% at one month and two months respectively ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}; [Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}). In these trials praziquantel was clearly superior ([Analysis 12.1](#CD000053-fig-01201){ref-type="fig"}). In the third trial ([Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}), at unclear risk of bias due to inadequate description of trial methods, artesunate performed similarly to praziquantel with 28% treatment failures at two months ([Analysis 12.1](#CD000053-fig-01201){ref-type="fig"}).

The percent egg reduction with artesunate varied across the three trials from 52% to 85% (see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}). In the single trial where both praziquantel and artesunate performed well at reducing treatment failures, both drugs had fairly modest effects on egg excretion ([Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}).

Only the trial at unclear risk of bias ([Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}) reported substantial effects of artesunate on haematuria and proteinuria (see [Appendix 3](#CD000053-sec2-0018){ref-type="app"}). In the trial at low risk of bias ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}) praziquantel was clearly superior at reducing microhematuria (RR 0.43, 95% CI 0.3 to 0.62; 178 participants, one trial, [Analysis 12.2](#CD000053-fig-01202){ref-type="fig"}).

All trials reported on adverse events with no significant differences noted between groups (see [Appendix 5](#CD000053-sec2-0020){ref-type="app"}, [Analysis 12.3](#CD000053-fig-01203){ref-type="fig"}).

#### Praziquantel versus praziquantel plus artesunate (comparison 13) {#CD000053-sec4-0020}

*The results of the two trials were inconsistent but the trial at low risk of bias found no benefit with adding artesunate to praziquantel.*

Two of the trials comparing artesunate with praziquantel also had a treatment arm where patients received both drugs ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}; [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}). Again, in the trial at low risk of bias ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}) adding artesunate to praziquantel did not substantially reduce treatment failures or percent egg reduction at eight weeks compared to praziquantel alone, whereas in the trial at unclear risk of bias ([Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}), adding artesunate improved outcomes ([Analysis 13.1](#CD000053-fig-01301){ref-type="fig"}; [Table 33](#CD000053-tbl-0033){ref-type="table"}; [Appendix 2](#CD000053-sec2-0017){ref-type="app"}). No differences in adverse events were reported (see [Appendix 5](#CD000053-sec2-0020){ref-type="app"}).

###### Praziquantel and Artesunate versus Praziquantel: % egg reduction

  --------------------------------------------------------------------- --------------------- --------------------- --------------------------------------------------------------------------- --------------------------------------- --------------------------------------- --------------- -------------------- ------- -----------------
  **Study ID**                                                          **Time point**        **Measure**           **Praziquantel 40 mg/kg single dose and artesunate 4 mg/kg/d for 3 days**   **Praziquantel 40 mg/kg single dose**   **P value difference between groups**                                                

  **Egg count/10 mL**                                                   **% egg reduction**   **Egg count/10 mL**   **% egg reduction**                                                                                                                                                                                      

  **Baseline**                                                          **Follow‐up**         **Baseline**          **Follow‐up**                                                                                                                                                                                            

  [Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}         8 weeks               GMEC (range),\        31.5\                                                                       0.36\                                   98.8                                    38.51\          1.11 (0.7 to 1.7)\   97.11   Not significant
                                                                                              (95% CI)\             (1 to 3225)\                                                                N = 88                                                                          (1 to 3313)\    N = 89                       
                                                                                              N =                   N = 90                                                                                                                                                      N = 90                                       

  [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}^1^   8 weeks               mean ± SD\            62.2 ± 2.1\                                                                 4.0 (± 15.2) N = 44                     93.6                                    39.8 (± 1.1)\   19.1 (± 1.0)\        52.1    Not reported
                                                                                              N =                   N = 52                                                                                                                                                      N = 52          N = 44                       
  --------------------------------------------------------------------- --------------------- --------------------- --------------------------------------------------------------------------- --------------------------------------- --------------------------------------- --------------- -------------------- ------- -----------------

^1^Treatment group: Praziquantel 40 mg/kg without placebo. [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"} also reports a second treatment group (Praziquantel 40 mg/kg with placebo), data not shown.

### Section E: Others {#CD000053-sec3-0030}

#### Mefloquine versus sulfadoxine‐pyrimethamine (comparison 14) {#CD000053-sec4-0021}

In a single trial comparing the use of mefloquine and sulfadoxine‐pyrimethamine as intermittent preventive treatment for malaria in pregnancy, a re‐analysis of the small number of mothers infected with *S. haematobium* found more women were cured at one month after mefloquine compared to sulfadoxine‐pyrimethamine (RR 0.57, 95% CI 0.4 to 0.83; 44 participants, one trial, [Analysis 14.1](#CD000053-fig-01401){ref-type="fig"}), and an egg reduction of 80% four weeks after treatment and 98% ten weeks after treatment (see [Appendix 2](#CD000053-sec2-0017){ref-type="app"}).

#### Praziquantel versus mefloquine alone or mefloquine in combination with artesunate (comparison 15 and 16) {#CD000053-sec4-0022}

A single small trial ([Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}) reported lower treatment failures with praziquantel 40 mg/kg alone than with mefloquine 25 mg/kg (RR 0.15, 95% CI 0.05 to 0.43; 45 participants, one trial, [Analysis 15.1](#CD000053-fig-01501){ref-type="fig"}) or with mefloquine in combination with artesunate 4 mg/kg/d for three days (RR 0.23, 95% CI 0.07 to 0.74; 44 participants, one trial, [Analysis 16.1](#CD000053-fig-01601){ref-type="fig"}). At four weeks, this trial reports a percent egg reduction of 74% at four weeks with mefloquine alone (19 participants), 96% with mefloquine and artesunate combined, and 97% with praziquantel ([Appendix 2](#CD000053-sec2-0017){ref-type="app"}).

[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"} recorded adverse events by active, prospective surveillance. Adverse events were mild to moderate and common in all groups. There were no statistically significant differences in any individual adverse event ([Appendix 5](#CD000053-sec2-0020){ref-type="app"}).

#### Praziquantel versus praziquantel and albendazole (comparison 17) {#CD000053-sec4-0023}

One trial ([Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}) compared a single dose of praziquantel 40 mg/kg with a combination of single dose praziquantel 40 mg/kg plus albendazole 400 mg at day 45 (RR 0.9, 95% CI 0.62 to 1.3; 193 participants, one trial, [Analysis 17.1](#CD000053-fig-01701){ref-type="fig"}). The authors concluded that albendazole does not influence the effect of praziquantel.

Adverse events were monitored by active, prospective surveillance and described as mild and transient. Diarrhoea, headache and abdominal pain were observed most frequently, but adverse events were reported for participants treated for *S. haematobium* and *S. mansoni* together ([Appendix 5](#CD000053-sec2-0020){ref-type="app"}).

Discussion {#CD000053-sec1-0006}
==========

For a summary of the main results of the review and GRADE assessment of the quality of evidence see: [Table 1](#CD000053-tbl-0001){ref-type="table"}; Summary of findings table 2; [Table 2](#CD000053-tbl-0002){ref-type="table"}; [Table 3](#CD000053-tbl-0003){ref-type="table"}; [Table 4](#CD000053-tbl-0004){ref-type="table"}; [Table 5](#CD000053-tbl-0005){ref-type="table"}; and [Table 6](#CD000053-tbl-0006){ref-type="table"}.

Summary of main results {#CD000053-sec2-0011}
-----------------------

On average, a single 40 mg/kg dose of praziquantel reduced the proportion of people still excreting *S. haematobium* eggs in their urine by around 60% compared to placebo at one to two months after treatment (*high quality evidence*), and reduced the mean number of schistosome eggs in the urine by over 95% in five out of six trials (*high quality evidence*). Splitting praziquantel 40 mg/kg into two doses over 12 hours probably has no benefits over a single dose.

Two small trials compared a single 40 mg/kg dose of praziquantel with two or three doses of 10 mg/kg metrifonate and found no differences in cure. In one trial both drugs performed badly and in one trial both performed well.

Three trials evaluated the antimalarial artesunate, and two trials evaluated mefloquine, with inconsistent results.

Overall completeness and applicability of evidence {#CD000053-sec2-0012}
--------------------------------------------------

The WHO currently recommend that schistosomiasis is treated with a single dose of praziquantel of at least 40 mg/kg ([WHO 2006](#CD000053-bbs2-0115){ref-type="ref-list"}). In this review we found no trials evaluating doses higher than 40 mg in urinary schistosomiasis, but doses of 40 mg/kg or even 30 mg/kg are effective at reducing egg excretion and achieving cure.

Of all the drugs that have been evaluated for treating urinary schistosomiasis, praziquantel has by far the strongest evidence base. It has been evaluated across a wide range of endemic countries, and most trials were conducted in children who bear the highest burden of disease. However, few trials included children younger than five years of age, and [Stothard 2013](#CD000053-bbs2-0109){ref-type="ref-list"} suggested that higher doses of praziquantel might be required for this group. We would have liked to explore this possibility through an analysis stratified by age, but the data did not allow this and no firm conclusions can be made. In addition, most trials concentrated on parasitological efficacy, and few reported clinical outcomes such as improvement in haematuria or anaemia. Data on resolution of long‐term morbidity after treatment, as nutritional outcomes and sonographic findings are very rare, and follow‐up is limited to less than one year.

The absolute proportion of people cured by praziquantel varied between trials while percent egg reduction was relatively homogenous. This may be explained by low sensitivity and negative predictive value of the diagnostic test, compounded with the fact that egg yield varies during the day and with physical activity. This means that patients with few eggs in their urine may be variably declared as positive or negative in different settings. The proportional reduction in the mean egg counts from before to after treatment is less prone to this error. It also appears that some trials based post‐treatment egg reduction on the whole trial population (including cured patients with zero egg counts), while other trials based the post‐treatment calculations on those patients still excreting eggs. We were unable to combine egg reduction values in meta‐analysis, and assess statistical significance, due to the poor reporting of standard deviations and methods for calculating the mean ([Table 26](#CD000053-tbl-0026){ref-type="table"}).

None of the included trials suggested drug resistance as a possible cause of high parasitological failure, or of recurrent schistosomiasis over prolonged follow‐up. In high transmission areas two mechanisms could explain rising parasitological failure over time: maturation of immature worms (which escape the action of praziquantel) to egg producing adults, and reinfection.

Previously the WHO also recommended metrifonate at 7.5 mg/kg for three doses (given two weeks apart), but this drug is now largely unavailable ([Danso‐Appiah 2008](#CD000053-bbs2-0118){ref-type="ref-list"}). We found some evidence that repeated doses of metrifonate had reasonable antischistosomal effects but we found no trials directly comparing this dose with the standard dose of praziquantel. Combining praziquantel with metrifonate is one possible strategy for improving parasitological cure as they attack *S. haematobium* by different mechanisms ([Utzinger 2004](#CD000053-bbs2-0110){ref-type="ref-list"}). However, we only found one small trial evaluating a combination approach and this used a low dose of praziquantel rather than the standard 40 mg/kg ([Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"}).

Antimalarials (such as artesunate and mefloquine) given alone or in combination with praziquantel are another potential future treatment option, but the current evidence base is limited to a few trials with inconsistent results. As many locations in sub‐Saharan Africa are co‐endemic for schistosomiasis and malaria, there are also concerns about development of *Plasmodium* parasite resistance to artemisinins, especially as they would be used in a single dose and without a companion antimalarial drug ([Utzinger 2004](#CD000053-bbs2-0110){ref-type="ref-list"}). Any change in policy would need to fully consider this potential public health harm.

Quality of the evidence {#CD000053-sec2-0013}
-----------------------

We used the GRADE approach to assess the quality for the evidence.

We consider the evidence for substantial benefits with praziquantel compared to placebo to be of high quality, meaning we have confidence in this result. Many of the included trials are old, but reassuringly the findings of the most recent trial conducted in 2005/2006 are consistent with the older studies.

However, we consider most of the evidence for other comparisons in this review to be of low or even very low quality. Most of the trials evaluating metrifonate are old and precede guidelines on transparent reporting of clinical trials. As such, many trials lacked adequate descriptions of methods to allow judgements on risk of bias, and so risk of bias has been classified as unclear. Trials were also generally small and underpowered to reliably detect or exclude effects.

Of the three trials reporting on the antischistosomal effects of artesunate, only one was at low risk of bias and this trial found little effect with artesunate compared to placebo ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}). Although the metanalysis suggests artesunate may improve cure when added to praziquantel, this evidence was of low quality due to inconsistency between trials, and the single trial showing a large effect being at unclear risk of bias for all domains.

Potential biases in the review process {#CD000053-sec2-0014}
--------------------------------------

Our information specialist followed a detailed, reproducible search strategy, and we searched reference lists of included trials. However, some trials might not be available online, and therefore an electronic search will not identify them.

In many cases, clarification of information with authors was not possible as no contact e‐mail addresses were available as the trials were very old.

Agreements and disagreements with other studies or reviews {#CD000053-sec2-0015}
----------------------------------------------------------

Two recent systematic reviews evaluated the use of artemisinins in treating urinary schistosomiasis ([Liu 2011](#CD000053-bbs2-0104){ref-type="ref-list"}; [Pérez del Villar 2012](#CD000053-bbs2-0105){ref-type="ref-list"}), and both concluded that the combination of artesunate plus praziquantel is superior to praziquantel alone, While we find some evidence to support this we conclude that this evidence is only of low quality and encourage further high quality and adequately powered trials before any change in treatment policy. Of note, the trial at lowest risk of bias ([Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}), found no significant difference in cure between artesunate alone and placebo, or between praziquantel plus artesunate and praziquantel alone.

One further systematic review evaluated single or repeated doses of praziquantel, and found no evidence of benefit with repeated dosing compared to a single dose in people with *S. haematobium* infection ([King 2011](#CD000053-bbs2-0102){ref-type="ref-list"}). We would agree that repeating doses two or three weeks apart does not seem to provide benefit over a single dose based on two trials with 686 participants. However, repeating doses at three monthly intervals over two years did seem to provide some additional benefits in a single small trial and further trials could evaluate this.

Authors\' conclusions {#CD000053-sec1-0007}
=====================

Implications for practicePraziquantel is the most studied drug for treating urinary schistosomiasis and has the strongest evidence base. Although there is some evidence that 30 mg/kg may be sufficient, operationally this would prove difficult as 40 mg/kg is used to treat people with intestinal schistosomiasis, and the two diseases often overlap.

Implications for researchPotential strategies to improve future treatments for schistosomiasis include the combination of praziquantel with metrifonate, or with antimalarials with antischistosomal properties such as artesunate and mefloquine. Evaluation of these combinations requires rigorous. adequately powered trials using standardized outcome measures. It is both important and urgent that these parameters be agreed upon and applied. Trial protocols with standardised diagnostic methods, time points of follow‐up and efficacy outcomes would enable us to combine trials in meta‐analysis and to reduce heterogeneity between trials.

What\'s new {#CD000053-sec1-0013}
===========

**DateEventDescription**7 July 2014New search has been performedThe review has been updated and revised with a new author team.7 July 2014New citation required but conclusions have not changedA new author team was put in place for this review update.

We would like to thank the authors of the previous version of this review Anthony Danso‐Appiah, Jürg Utzinger, and Jianping Liu, who stood down for this update.

We thank the trial authors for their research, which enabled us to conduct a systematic review and particularly trial authors that responded to our requests for further information. We acknowledge Paul Garner for his expertise, experience and encouragement; Anne Marie Stephani, whose ready technical assistance with [Review Manager (RevMan)](#CD000053-bbs2-0107){ref-type="ref-list"} was most helpful; and to Vittoria Lutje for her approachability and support. The editorial base of the Cochrane Infectious Diseases Group is funded by the UK Department for International Development for the benefit of developing countries.

**Search setCIDG SR\*CENTRALMEDLINE\*\*EMBASE\*\*LILACS\*\***1Schistosoma haematobiumSCHISTOSOMIASIS HAEMATOBIASCHISTOSOMA HAEMATOBIASCHISTOSOMA‐HAEMATOBIASchistosoma haematobium2praziquantelurinary schistosomiasisurinary schistosomiasisurinary schistosomiasisurinary schistosomiasis3metrifonate1 OR 21 OR 21 OR 21 or 24albendazolepraziquantelpraziquantelpraziquantelpraziquantel5artesunatemetrifonatemetrifonatemetrifonatemetrifonate6artemetheralbendazolealbendazolealbendazolealbendazole72‐6/ORartesunateartesunateartesunateartesunate81 AND 7artemetherartemetherartemetherartemether9‐‐4‐8/OR4‐8/OR4‐8/OR4‐8/OR10‐‐3 AND 93 AND 93 AND 93 AND 911‐‐‐‐Limit 10 to humanLimit 10 to human‐‐

 \*Cochrane Infectious Diseases Group Specialized Register.

 \*\*Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration ([Lefebvre 2008](#CD000053-bbs2-0103){ref-type="ref-list"}); upper case: MeSH or EMTREE heading; lower case: free text term.

Praziquantel 40 mg/kg single dose versus placebo: parasitological failure stratified by severity of infection {#CD000053-sec3-0031}
=============================================================================================================

**Trial IDTime pointStratificationGMEC or miracidial count/10 mL urinePraziquantel 40 mg/kg single dosePlaceboP value difference between groupsParasitological failureParasitological failure**[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}1 monthlight\< 100\
N = 77 for all strata37.7%100%Not reportedheavy\> 10091.7%100%[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}1 monthlight60 to 250\
N = 101 for all strata13.6%――moderate251 to 50012.1%―heavy≥ 50034.5%―[King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}6 weekslight0 to 99\
N = 486/48\
12%――moderate100 to 399\
N = 2713/27\
50%―heavy≥ 400\
N = 2615/26\
59%―[McMahon 1983 TZA](#CD000053-bbs2-0016){ref-type="ref-list"}2 monthslight250 to 500 miracidia\
N = 101/10――moderate501 to 1000 miracidia\
N = 102/10―heavy\> 1000 miracidia\
N = 101/10―[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}3 monthslight60 to 250\
N = 101 for all strata15.9%――moderate251 to 5008.1%―heavy≥ 50046.4%―[King 1989 KEN](#CD000053-bbs2-0012){ref-type="ref-list"}3 monthslight1 to 99\
N = 90%――moderate100 to 399\
N = 2910%―heavy≥ 400\
N = 1833%―[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}3 monthslight\< 100\
N = 77 for all strata43.1%\
N = 90 for all strata98.3%Not reportedheavy\> 10079.2%95.5%[McMahon 1983 TZA](#CD000053-bbs2-0016){ref-type="ref-list"}4 monthslight250 to 500 miracidia\
N = 101/10――moderate501 to 1000 miracidia\
N = 101/10―heavy\> 1000 miracidia\
N = 101/10―[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}6 monthslight60 to 250\
N = 101 for all strata18.6%――moderate251 to 50026.3%―heavy≥ 50028%―[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}6 monthslight\< 100\
N = 77 for all strata25%96.1%Not reportedheavy\> 10036.8%100%[Omer 1981 SDN](#CD000053-bbs2-0019){ref-type="ref-list"}6 monthslight60 to 249\
N = 111/11――moderate250 to 499\
N = 113/11―heavy\> 500\
N = 142/14―

Praziquantel 40 mg/kg single dose versus placebo: % egg reduction stratified by severity of infection {#CD000053-sec3-0032}
=====================================================================================================

**Trial IDTime pointStratumBy GMEC/10 mL/urine or by \"egg count\"Praziquantel 40 mg/kg single dosePlaceboP value difference between groupsGMEC/10 mL urine% egg reductionGMEC/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}1 monthlight20 to 12451.7\
N = 212.195.9352.7\
N = 2035.632.45Not reportedmoderate125 to 499234.7\
N = 301.599.36248.0\
N = 32256.2‐ 3.2 % (increase)heavy500 to 1999907.6\
N = 381.799.86―――very heavy\> 20003433.3\
N = 82.899.9―――[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}^1^1 monthlight\< 5015.1\
N = n.r.0.497.3515.737.5138.85 (increase)―heavy\> 100204.7\
N = n.r.4.098191.9147.023.4―[King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}6 weekslight0 to 99N = 482.0793――――moderate100 to 399N = 272.6799――――heavy≥ 400N = 263.4999.6――――[Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}^2^3 monthslight20 to 12451.7\
N = 211.996.3252.7\
N = 2036.830.17Not reportedmoderate125 to 499234.7\
N = 301.999.19248.0\
N = 32145.741.25heavy500 to 1999907.6\
N = 381.899.8―――very heavy\> 20003433.3\
N = 82.299.93―――[Tchuente 2004 CMR](#CD000053-bbs2-0028){ref-type="ref-list"}3 monthslight\< 508.22\
N = 1830.8689.53%――――heavy\> 50115.59\
N = 634.1196.4%――――[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}3 monthslight\< 5015.1\
N = n.r.0.497.3515.719.826.1 increase―heavy\> 100204.7\
N = n.r.2.099191.994.750.65―[Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}6 monthslight20 to 12451.7\
N = 212.395.5――――moderate125 to 499234.7\
N = 302.099.14――――heavy500 to 1999907.6\
N = 382.699.7――――very heavy\> 20003433.3\
N = 82.899.9――――[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}6 monthslight\< 5015.1\
N = n.r.0.298.6715.711.725.5―heavy\> 100204.7\
N = n.r.0.699.7191.975.560.6―

^1^Stratum I: light infections \< 50 eggs/10 mL, praziquantel (N = 77), placebo (N = 90). \"Pretreatment light infections exhibited better cure rates for *S. haematobium* than pretreatment heavy infections\". Praziquantel (N = 77), placebo (N = 90).

^2^Baseline imbalance in terms of intensity of infection \"In accordance with local ethical guidelines the placebo group consisted only of children with light (20 to 124 ova/10 mL or moderate (125 to 4999 ova/10 mL) infections before treatment.\"

Praziquantel 40 mg/kg single dose versus 20 mg/kg single dose: % egg reduction {#CD000053-sec3-0033}
==============================================================================

**Trial IDSubgroupTime pointMeasurePraziquantel 40 mg/kg single dosePraziquantel 20 mg/kg single doseP value difference between groupsEgg count/10 mL urine% egg**\
**reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}light infections\
\< 50/10 mL1 monthGMEC15.1\
N = 77\
(in both groups)0.497.3515.5\
N = 610.596.77Not reportedheavy infections\
\> 100/10 mL1 monthGMEC204.7\
N = 77\
(in both groups)4.098.04177.3\
N = 613.498.08[King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}―6 weeksGMEC (± CI)\
N =Not reported2.54\
(1.84 to 3.5)\
N = 14598Not reported4.42 (3.1 to 6.3)\
N = 14695Not reported[Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"}―2 to 3 monthsGMEC\
median\
AMEC\
N =54/63/298\
N = 330.3/0/199.4\
100\
99.653/87/313/\
N = 350.8/0.3/798.4\
99.7\
97.60.31[King 1989 KEN](#CD000053-bbs2-0012){ref-type="ref-list"}―3 monthsGMEC\
AMEC ± SD\
GMEC\
N =255\
377/\
N = 642\
31(± 21)\
N = 5699.2 (GMEC)\
91.7 (AMEC)210\
327/\
N = 752\
13 ± 9/\
N = 6899.04 (GMEC)\
96\
(AMEC)Not significant[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}light infections\
\< 50/10 mL3 monthsGMEC15.1\
N = 77\
(in both groups)0.497.3515.5\
N = 610.696.12Not reportedheavy infections\
\> 100/10 mL3 monthsGMEC204.7\
N = 77\
(in both groups)2.099.02177.3\
N = 613.697.97[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}light infections\
\< 50/10 mL6 monthsGMEC15.1\
N = 77\
(in both groups)0.298.6715.5\
N = 610.298.7Not significantheavy infections\
\> 100/10 mL6 monthsGMEC204.7\
N = 77\
(in both groups)0.699.7177.3\
N = 612.798.5

Praziquantel 40 mg/kg single dose versus 10 mg/kg single dose: % egg reduction {#CD000053-sec3-0034}
==============================================================================

**Trial IDSubgroupTime pointMeasurePraziquantel 40 mg/kg single dosePraziquantel 10 mg/kg single doseP value difference between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}light infections\
\< 50/10 mL1 monthGMEC15.1\
N = 770.497.3514.8\
N = 732.384.46Not reportedheavy infections\
\> 100/10 mL1 monthGMEC204.7\
N = 774.098.04197.5\
N = 7334.782.43Not reported[King 1989 KEN](#CD000053-bbs2-0012){ref-type="ref-list"} 2 to 3 monthsGMEC\
AMEC ± SE\
N =245\
378\
N = 642/\
31 ± 21\
N = 5699.183 (GMEC)\
91.79 (AMEC)255\
377\
N = 7220/\
102 ± 22\
N = 6292.156\
(GMEC)\
72.94 (AMEC)0.001[Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"} 2 to 3 monthsGMEC\
median\
AMEC\
N =54\
63\
298\
N = 330.3/\
0/\
1/99.4\
(GMEC)\
100\
(median)\
99.6\
(AMEC)61/82/297N = 387.9/\
5.9/\
33/87.0\
(GMEC)\
92.8\
(median)\
88.8\
(AMEC)Not reported[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}light infections\
\< 50/10 mL3 monthsGMEC15.10.497.3514.82.285.14Not reportedheavy infections\
\> 100/10 mL3 monthsGMEC204.72.099.02197.527.686.02Not reported[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}light infections\
\< 50/10 mL6 monthsGMEC15.10.298.6714.81.291.89Not reportedheavy infections\
\> 100/10 mL6 monthsGMEC204.70.697.07197.514.492.7Not reported

Praziquantel 40 mg/kg single dose versus split dose: % egg reduction {#CD000053-sec3-0035}
====================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single dosePraziquantel 40 mg/kg split dose (2 x 20 mg/kg in one day)P value difference between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Kardaman 1985 SDN](#CD000053-bbs2-0010){ref-type="ref-list"}5 weeksGMEC\
N =Not reported\
N = 11428―Not reported\
N = 10626―No significant difference,\
P value not reported[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}1 monthGMEC+ 95\
range288.4 (33.2 to 2508.9)\
N = 331.1 (0 to 8.3)99.61352.8 (37.0 to 3361.8)\
N =360.8 (0 to 62)99.7P value not reported[Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}^1^1 monthGMEC\
mean + SD\
(N = )Stratum 1\
87.4 ± 23.46\
(N = 15)\
Stratum 2\
339.4 ± 32.61\
(N = 5)\
Stratum 3\
518.00 ± 0.71\
(N = 2)\
N = 22―97.69 ± 0.98\
(N = 21)Stratum 1\
84.93 ± 34.71 (N = 15)\
Stratum 2\
296.00 ± 26.19\
(N = 5)\
Stratum 3\
526.00\
(N = 1)\
N = 21 98.69 ± 0.39\
(N = 19)No significant difference,\
P value not reported[Kardaman 1985 SDN](#CD000053-bbs2-0010){ref-type="ref-list"}3 monthsGMEC‐\
N = 11415―‐\
N =1069―No significant difference,\
P value not reported[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}3 monthsGMEC+ 95% CIs288.4 (33.2 to 2508.9)\
N = 331.1 (0‐16.3)99.61352.8 (37.0 to 3361.8)\
N = 360.5 (0 to 3.9)99.85P value not reported[Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}^1^3 monthsGMEC\
mean + SD\
(N = )Stratum 1\
87.4 ± 23.46\
(N = 15)\
Stratum 2\
339.4 ± 32.61\
(N = 5)\
Stratum 3\
518.00 ± 0.71\
(N = 2)\
N = 22―97.55 ± 0.85 (N = 18)Stratum 1\
84.93 ± 34.71 (N = 15)\
Stratum 2\
296.00 ± 26.19\
(N = 5)\
Stratum 3\
526.00\
(N = 1)\
N = 21―99.48 ± 0.3\
(N = 16)N\
o significant difference,\
P value not reported[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}6 monthsGMEC+ 95 % CIs288.4 (33.2 to 2508.9)\
N =331.1 (0 to 20.3)99.61352.8 (37.0 to 3361.8)\
N =360.6 (0 to 11.3)99.82P value not reported[Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}^1^6 monthsGMEC\
mean + SD\
(N = )Stratum 1\
87.4 ± 23.46\
(N = 15)\
Stratum 2\
339.4 ± 32.61\
(N = 5)\
Stratum 3\
518.00 ± 0.71\
(N = 2)\
N = 22―93.09 ± 0.12 (N = 15)Stratum 1\
84.93 ± 34.71 (N = 15)\
Stratum 2\
296.00 ± 26.19\
(N = 5)\
Stratum 3\
526.00\
(N = 1)\
N = 21―99.52 ± 0.21\
(N = 13)No significant difference in egg counts between treatment groups,\
P value not reported.9 months―92.4 ± 5.92 (N = 6)―98.12 ± 1.13\
(N = 6)12 months―99.3 ± 0.26 (N = 3)―98.68 ± 0.51\
(N = 5)

^1^GMEC/10 mL urine, Stratum 1: 60 to 250 GMEC/10 mL urine; Stratum 2: 251 to 500 GMEC/10 mL; Stratum 3 \> 500 GMEC/10 mL.

Praziquantel 40 mg/kg single dose versus praziquantel 2 x 40 mg/kg or praziquantel 3 x 40 mg/kg given three weeks apart: % egg reduction {#CD000053-sec3-0036}
========================================================================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg (single dose)Praziquantel 2 x 40 mg/kgP value for differences between groupsEgg count /10 mL urineEgg count/10 mL urineBaselineFollow‐up% egg reductionBaselineFollow‐up% egg reduction**[Tchuente 2004 CMR](#CD000053-bbs2-0028){ref-type="ref-list"}6 weeksGMECAll classes 15.83\
Light infection 8.22\
Heavy infection 115.59\
N = 1350.29/\
0.2/\
0.6498.18/\
97.63/\
99.44All classes\
19.00/\
Light infection\
9.5/\
Heavy infection\
129.05\
N = 2460.25/\
0.19/\
0.43/98.69/\
97.99/\
99.67Follow‐up at 6 weeks, 6 weeks after a single dose (cohort 3)\
Follow‐up at 6 weeks, 3 weeks after the second dose (cohort 1)6 weeksGMECAll classes 15.83\
Light infection 8.22\
Heavy infection 115.59\
N = 1350.29/\
0.2/\
0.64/98.18/\
97.63/\
99.44/All classes 16.96\
Light infection 7.3\
Heavy infection 173.02\
N = 1340.27/\
0.17/\
0.64/98.39/\
97.7/\
99.63F\
ollow‐up at 6 weeks, 6 weeks after a single dose (cohort 3)\
P \> 0.066\
Follow‐up at 6 weeks, 3 weeks after the second dose (cohort 2)9 weeksGMECAll classes 15.83\
Light infection 8.22\
Heavy infection 115.59\
N = 1350.17/\
0.15/\
0.23\
N = 7099.06/\
98.29/\
99.80All classes\
16.96\
Light infection\
7.3\
Heavy infection 173.02\
N = 1340.43/\
0.2/\
1.23\
N = 6097.88/\
97.59/\
99.29Follow‐up at 9 weeks, 9 weeks after a single dose (cohort 3)\
Follow‐up at 9 weeks, 6 weeks after the second dose (cohort 2)  **Praziquantel 40 mg/kg (single dose)Praziquantel 3 x 40 mg/kgComments**9 weeksGMECAll classes 15.83\
Light infection 8.22\
Heavy infection 115.59\
N = 1350.17/\
0.15/\
0.23\
N = 7099.06/\
98.29/\
99.80All classes\
0.19\
Light infection\
0.06\
Heavy infection\
0.51\
N = 246―99.18/\
99.61/\
99.36Follow‐up at 9 weeks, 9 weeks after a single dose (cohort 3)\
Follow‐up at 9 weeks: 3 weeks after the last (third) dose (cohort 1)

Praziquantel 40 mg/kg single dose x 2, interval three weeks: one arm received praziquantel single at baseline, one arm received a second dose at three weeks, one arm received the second dose at three weeks and a third dose at six weeks. Follow‐up for all groups at six weeks and nine weeks.

Strata: light infection \< 50/10 mL, heavy infection \> 50/10 mL.

Metrifonate 10 mg/kg single dose versus placebo: % egg reduction {#CD000053-sec3-0037}
================================================================

**Trial IDTime pointMeasureMetrifonate 10 mg/kg single dosePlaceboEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}8 monthsGMEC\
AMEC\
N =47/\
94\
N = 1054/\
23\
N = 10391.48/\
7638/\
85/\
N = 10536/\
102\
N = 1045.26/\
‐20 (increase)

Metrifonate 2 x 10 and 3 x 10 mg/kg given two weeks apart versus 10 mg/kg single dose: % egg reduction {#CD000053-sec3-0038}
======================================================================================================

**Trial IDTime pointMeasureMetrifonate 2 x 10 mg/kgMetrifonate 10 mg/kg single doseEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Rey 1984 NER](#CD000053-bbs2-0023){ref-type="ref-list"}1 monthAMEC\
N =93.2\
N = 9916.9\
N = 4981.9\
N = 5030.4\
N = 12519.1\
N = 6237.24 monthsAMEC\
N =93.2\
N = 9958.4\
N = 3537.3430.4\
N = 12522.8\
N = 6925**Trial IDTime pointMeasureMetrifonate 3 x 10 mg/kgMetrifonate 10 mg/kg single doseEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Rey 1984 NER](#CD000053-bbs2-0023){ref-type="ref-list"}1 monthAMEC\
N =17.8\
N = 622.0\
N = 3188.730.4\
N = 12519.1\
N = 6237.24 monthsAMEC\
N =17.8\
N = 6210.8\
N = 4239.3230.4\
N = 12522.8\
N = 6925

Metrifonate 3 doses two weeks apart: 7.5 mg/kg versus 5 mg/kg: % egg reduction {#CD000053-sec3-0039}
==============================================================================

**Trial IDTime pointMeasureMetrifonate 7.5 mg/kg x 3Metrifonate 5 mg/kg x 3P value difference between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Abden Abdi 1989 SOM](#CD000053-bbs2-0001){ref-type="ref-list"}1 monthEgg count/10 mL urine mean\
(SD)\
% egg reduction mean (SD)1010 (1550)―97 (5)997 (1700)―96 (6)P \> 0.7\
(difference in egg counts at 1 and 6 months)2 months1010 (1550)―97 (6)997 (1700)―96 (7)3 months1010 (1550)―95 (8)997 (1700)―94 (8)6 months1010 (1550)―93 (11)997 (1700)―92 (11)

^1^N = 101 for both groups together

Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose: % egg reduction {#CD000053-sec3-0040}
==========================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single doseMetrifonate 10 mg/kg single doseP value differences between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}8 monthsAMEC\
GMEC112/\
57\
N = 1051/\
0.29994/\
47\
N = 10323/\
476Significant\
P \< 0.0001

Praziquantel 40 mg/kg single dose versus metrifonate 2 x 10 mg/kg given two weeks apart: % egg reduction {#CD000053-sec3-0041}
========================================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single doseMetrifonate 2 x 10 mg/kgP value differences between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}1 monthmedian\
N =66\
N = 481\
N = 4098.4895\
N = 381\
N = 3298.94Not reported5 monthsmedian\
N =66\
N = 480\
N = 3510095\
N = 381\
N = 3298.94

Praziquantel 30 mg/kg single dose versus metrifonate 3 x 10 mg/kg given two weeks apart: % egg reduction {#CD000053-sec3-0042}
========================================================================================================

**Trial IDTime pointMeasurePraziquantel 30 mg/kg single doseMetrifonate 3 x 10 mgP value difference between groupsN% egg reductionN% egg reduction**[McMahon 1983 TZA](#CD000053-bbs2-0016){ref-type="ref-list"}4 monthsGMEC of miracidia/10 mL urine30993098Not reported

Praziquantel 40 mg/kg 1x/year versus metrifonate 10 mg/kg 3x/year: % egg reduction {#CD000053-sec3-0043}
==================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg 1x/yearMetrifonate 10 mg/kg 3x/yearP value difference between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[King 1990 KEN](#CD000053-bbs2-0013){ref-type="ref-list"}^1^12 monthsAMEC (± SD)\
GMECLight\
33\
196 ± 281.81Light\
33\
194 ± 3\
―87.87Not significantModerate\
193\
863 ± 298.44Moderate\
193\
865 ± 2\
―97.4Heavy\
597\
5818 ± 498.65Heavy\
597\
5819 ± 3\
―89.49

^1^Baseline data reported for both treatment groups together.

Praziquantel 40 mg/kg single dose versus praziquantel 10 mg/kg and metrifonate 10 mg/kg: % egg reduction {#CD000053-sec3-0044}
========================================================================================================

**Trial IDTime pointPraziquantel 40 mg/kg single dosePraziquantel 10 mg/kg and Metrifonate 10 mg/kgP value difference between groupsGMEC/10 mL% egg reductionGMEC/10 mL% egg reductionBaselineFollow‐upBaselineFollow‐up**[Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"}^1^2 to 3 months54\
N = 3370.399.467\
N = 394.892.9Not reported

^1^AMEC and median also reported.

Praziquantel versus artesunate: % egg reduction {#CD000053-sec3-0045}
===============================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single doseArtesunate 4 mg/kg/d for 3 daysP value difference between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}26 daysGMEC (range)\
N =32.0 (1 to 457)\
N = 261.1 (1 to 5)9740.2 (2 to 562)\
N = 206.2 (1 to 267)85Significant\
P \< 0.001[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}8 weeksGMEC (range)38.51\
(1 to 3313)\
N = 901.11\
N = 8997.1135.22\
(1 to 4360)\
N = 9010.8\
N = 8969.34Significant, P value not reported[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}18 weeksmean ± SD\
N =42.0 ± 1.7\
N = 529.8 ± 0.5\
N = 4276.739.8 ± 1.1\
N = 5219.1 ± 1.0\
N = 4452.1Not reported

^1^Treatment group: Praziquantel 40 mg/kg without placebo. [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"} also reports a second treatment group (Praziquantel 40 mg/kg with placebo), data not shown.

Mefloquine versus placebo: % egg reduction {#CD000053-sec3-0046}
==========================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single doseMefloquine 25 mg/kg single doseP value difference between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}28 daysGMEC\
range\
N =32.0 (1 to 457)\
N = 261.1 (1 to 5)\
N = 269730.1\
(1 to 2039)\
N = 191.7 (1 to 73)\
N = 1974Significant\
P \< 0.001

Praziquantel versus mefloquine: % egg reduction {#CD000053-sec3-0047}
===============================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single doseMefloquine 25 mg/kg single doseP value difference between groupsEgg count/10 mL urine% egg reductionEgg count/10 mL urine% egg reductionBaselineFollow‐upBaselineFollow‐up**[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}28 daysGMEC\
range\
N =32.0 (1 to 457)\
N = 261.1 (1 to 5)\
N = 269730.1\
(1 to 2039)\
N = 191.7 (1 to 73)\
N = 1974Significant\
P \< 0.001

Praziquantel versus mefloquine and artesunate: % egg reduction {#CD000053-sec3-0048}
==============================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single doseArtesunate 100 mg plus Mefloquine 250 mg fixed dose combination (FDC) x 3 in one dayP value difference between groupsEgg count/10 mL urinepercent egg reductionEgg count/10 mL urinePercent egg reductionBaselineFollow‐upBaselineFollow‐up**[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}28 daysGMEC\
range\
N =32.0 (1 to 457)\
N = 261.1 (1 to 5)\
N = 269742.0\
(1 to 688)\
N = 181.7 (1 to 73)\
N = 1896%Not significant\
P = 0.13

Praziquantel 40 mg/kg single dose versus placebo: haematuria and proteinuria {#CD000053-sec3-0049}
============================================================================

**OutcomeTrial IDTime pointMeasurePraziquantel 40 mg/kg single dosePlaceboP value difference between groupsBaselineFollow‐upMean % changeBaselineFollow‐upMean % changeHaematuria**[de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}1 monthmedian erythrocytes/mykrol (95% CI)159 (34 to 627) N = 561(0 to 2)\
N = 56‐99.37290 (54 to 1224)\
N = 26323 (51 to 864)+11.37Not reported[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}^1^8 weekserythrocytes/mL (95% CI)NR\
N = 89‐ 110^1^   (‐137 to ‐84)―NR\
N = 30‐39^1^   (‐86 to ‐8)―Significant\
P \< 0.001[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}8 weeksunits unclear mean (± SD)47.6(± 2.0) N = 527.6(± 0.9)\
N = 42‐84.03338.0 (±1.6)\
N = 5259.6 (± 2.2) N = 44+56.84P \< 0.001**Proteinuria**[de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}1 monthmedian, g/L\
(95% CI)0.42 (0.22 to 0.62) N = 560.09 (0.05 to 0.12)‐780.24 (0.09 to 0.59)\
N = 260.32 (0.14 to 0.35)+33.3Not reported[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}^2^8 weeksmean (± SD)\
units unclear160.2 (± 5.2) N = 5224.8 ± 1.9\
N = 42‐84185.2 ± 5.0\
N = 52213.9 ± 5.3 N = 44+15.49P \< 0.001

Footnotes {#CD000053-sec4-0024}
---------

^1^Mean change from baseline in erythrocytes/mL urine (95% CI).

^2^Data shown here are for the treatment group praziquantel 40 mg/kg without placebo. [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"} also reports a treatment group for praziquantel with placebo, (data not shown).

Praziquantel 40 mg/kg single dose versus Praziquantel 2 x 40 mg/kg: haematuria {#CD000053-sec3-0050}
==============================================================================

**OutcomeTrial IDTime pointMeasurePraziquantel 40 mg/kg single dosePraziquantel 2 x 40 mg (one additional dose)P value difference between groupsBaselineFollow‐up% changeBaselineFollow‐up% changePrevalence of haematuria^1^**[Sacko 2009 MLI](#CD000053-bbs2-0024){ref-type="ref-list"}\
Koulikoro12 weeksN = 31081.3 %\
(N = ?)15.5 %‐80.975.5 %\
(N = ?)12.9 %‐82.90.51[Sacko 2009 MLI](#CD000053-bbs2-0024){ref-type="ref-list"}\
Selingue12 weeksN = 293―41.4 %‐44.475.5%\
(N = ?)35.6 %‐52.80.03[Sacko 2009 MLI](#CD000053-bbs2-0024){ref-type="ref-list"}\
Koulikoro6 monthsN = 30067.7%\
(N = 150)7.6%‐88.871.1%\
(N = 150)2.2 %‐96.90.32[Sacko 2009 MLI](#CD000053-bbs2-0024){ref-type="ref-list"}\
Selingue6 monthsN = 275N = ?19.7%‐70.971.1%\
(N = ?)16.4 %‐76.90.47

^1^Microhaematuria as diagnosed by dipstick (Haemastix)

Praziquantel 40 mg/kg single dose versus Metrifonate 20 mg/kg given as split dose: haematuria and proteinuria {#CD000053-sec3-0051}
=============================================================================================================

**OutcomeTrial IDTime pointMeasurePraziquantel 40 mg/kg single doseMetrifonate 10 mg/kg two dosesP value difference between groupsBaselineFollow‐up% changeBaselineFollow‐up% changeHaematuria**[de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}1 monthmedian (95% CI)\
Erythrocytes/µl159  (34 to 627)\
N = 561  (0 to 2)‐99.37503  (72 to 930)\
N = 4231  (1 to 112)‐93.93Not reported**Proteinuria**[de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}1 monthmedian (95% CI)\
Proteinuria g/L0.42  (0.22 to 0.62)\
N = 560.09  (0.05 to 0.12)‐78.570.44  (0.2 to 0.73)\
N = 420.09  (0.07 to 0.15)‐79.54Not reported

ARS versus placebo: haematuria and proteinuria {#CD000053-sec3-0052}
==============================================

**OutcomeTrial IDTime pointMeasureArtesunate 4mg/kg/day for 3 daysPlaceboP value difference between groupsBaselineFollow‐up% changeBaselineFollow‐up% changeHaematuria**[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}8 weeksmean change from baseline\
Ery/mL\
(95% CI)――‐34\
(‐59 to ‐9)――‐39\
(‐86 to +8)Not reported[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}^1^8 weeksmean haematuria + SD61.8 ± 2.2\
N = 5225.7 ± 1.6\
N = 44‐58.4138.0 ± 1.6\
N = 5259.6\
± 2.2\
N = 44‐36.24Not reported**Proteinuria**[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}^1^8 weeksmean ± SD\
unit unclear (mg/dL)191.1 ± 5.2\
N = 52102.1 ± 4.4\
N = 44‐46.57185.2 ± 5.0\
N = 52213.9 ± 5.3\
N = 44‐13.41Not reported

Footnotes {#CD000053-sec4-0025}
---------

^1^Treatment group: Praziquantel 40 mg/kg without placebo. [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"} also reports a second treatment group (Praziquantel 40 mg/kg with placebo), data not shown.

Praziquantel versus ARS: haematuria and proteinuria {#CD000053-sec3-0053}
===================================================

**OutcomeTrial IDSubgroupTime pointMeasurePraziquantel 40 mg/kg single doseArtesunate 4 mg/kg/day for 3 daysP value difference between groupsBaselineFollow‐up% changeBaselineFollow‐up% changeHaematuria**[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}―8 weeksMean change from baseline\
Ery/mL\
(95% CI)N = 90N = 89‐ 110\
(‐137‐84)N = 90N = 89‐ 34\
(‐59 to ‐9)Significant\
P \< 0.001[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}with placebo8 weeksMean haematuria ± SD55.9 ± 2\
N = 5213.6 ± 1.2\
N = 44‐75.650.9 ± 1.9\
N = 5211.1 ± 0.9\
N = 44‐78.19Not reportedwithout placebo47.6 ± 2\
N = 527.6 ± 0.9\
N = 42‐8461.8 ± 2.2\
N = 5225.7 ± 1.6\
N = 44‐58.41**Proteinuria**[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}with placebo8 weeksMean proteinuria ± SD190.9 ± 5.2\
N = 5265.7 ± 3.3\
N = 44‐65177.3 ± 5.1\
N = 5285.5 ± 3.9\
N = 44‐51.7Not reportedwithout placebo160.2 ± 5.2\
N = 5224.8 ± 1.9\
N = 42‐84.5191.1 ± 5.2\
N = 52102.1 ± 4.4\
N = 44‐46.5Not reported

Praziquantel versus Praziquantel and ARS: haematuria and proteinuria {#CD000053-sec3-0054}
====================================================================

**OutcomeTrial IDTime pointMeasurePraziquantel 40 mg/kg single doseArtesunate 4 mg/kg/d for 3 days**\
**Praziquantel 40 mg/kg single doseP value difference between groupsBaselineFollow‐up% changeBaselineFollow‐up% changeHaematuria**[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}8 weeksMean change from baseline\
Ery/mL\
(95% CI)――‐110\
(‐137 to ‐84)――‐102 (‐128 to ‐77)Not reported[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}^1^8 weeksMean haematuria ± SD55.9 (± 2)\
N = 4413.6 (± 1.2)‐75.6573.0 (± 2.3)\
N = 448.8 (± 8.7)‐87.94Not reported**Proteinuria**[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}8 weeksMean proteinuria ± SD190.9 ± 5.2\
N = 5265.7 ± 3.3\
N = 44‐65.58267.5 ± 5.4\
N = 524.0 ± 15.2\
N = 44‐ 98.5Not reported

^1^Treatment group: Praziquantel 40 mg/kg with placebo. [Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"} also reports a second treatment group (Praziquantel 40 mg/kg without placebo), data not shown.

Praziquantel 40 mg/kg single dose versus placebo: growth outcomes {#CD000053-sec3-0055}
=================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single dosePlaceboP value difference between praziquantel 40 mg/kg and placebo after treatmentBaselineFollow‐upgrowth greater than placeboP value difference before and after treatmentBaselineFollow‐upDifference before and after treatment**[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}^1^5 weeksHarvard step test score\
mean ± SEM76 ± +‐1.4181.2 ± 16.8% pointsP = 0.000277.1 ± +‐1.5175.5 ± 1.95Not significantP \< 0.05\
significantresting heart rate beats/min\
mean ± SEM81.1+‐ ± 1.6677.9 ± 1.14.3 beats/min\
(decrease)P = 0.00485.8+‐ ± 1.786.9 ± 1.96Not significantP = 0.003\
significantappetite\
mean ± SEM709+‐ ± 58841± 65.2139 mLP = 0.014811+‐ ± 93.4803 ± 78Not significantNnot significant[Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}^2^6 monthsheight\
median cm (SD)134.1 (12.3)135.8 (12.5) 1.6132.8 (12.0)134.5 (12.3)1.7Not significantweight\
median kg (SD)29.2 (7.4)31.3 (8.2) 2.128.3 (7.2)30.2 (7.9)1.9Not significantmiddle upper arm circumference (MUAC)\
median cm (SD)18.4 (2.0)19.0 (2.2) 0.618.3 (2.1)18.7 (2.2)0.4Significanttriceps skinfold\
median\
unit not specified\
(SD)6.7 (1.5)7.1 (1.9) 0.46.6 (1.9)6.9 (2.1)0.3Not significantmean muscle mass median\
unit not specified\
(SD)16.3 (1.8)16.8 (2.0) 0.4716.2 (1.9)16.6 (1.9)0.36Not significantht for age (%)93.692.7 ‐0.7294.193.3‐0.75Not significantwt for age (%)81.382.2 0.9282.583.10.65Not significantwt for ht (%)97.49100.78 3.2896.8799.442.57Not significant[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}^3^8 monthsheight (cm)\
mean ± SEM134.8 ± 1.12138.2 ± 1.100.1 cm0.0002135.9 ± 1.23139.3 ± 1.220.0002Not significantweight (kg)\
mean ± SEM27.3 ± 0.7230.4 ± 0.761.2kg0.000228.4 ± 0.7830.3 ± 0.830.0002P = 0.0001\
significanttriceps skinfold thickness\
mean ± SEM7.4 ± 0.218.8 ± 0.251.4 mm0.00028.2 ± 0.278.1 ± 0.27Not significantP = 0.0001\
significantsubscapular skinfold\
thickness\
mean ± SEM5.6 ± 0.166.9 ± 0.21.4 mm0.00026.0 ± 0.25.9 ± 0.2Not significantP = 0.0001\
significantmid upper arm circumference (MUAC)\
mean ± SEM17.5 ± 0.2218.5 ± 0.240.7 cm0.000217.8 ± 0.2118.0 ± 0.220.0002P = 0.0001\
significantht for age (%)\
mean ± SEM93.0 ± 0.4492.8 ± 0.430.1% points0.0292.9 ± 0.4492.6 ± 0.440.001Not significantwt for age (%)\
mean ± SEM72.7 ± 0.9874.9 ± 1.003.3% points0.000273.8 ± 1.0472.5 ± 1.030.0002Not significantwt for ht (%)\
mean ± SEM89.5 ± 0.7793.0 ± 0.843.7% points0.000290.6 ± 0.7290.4 ± 0.74Not significantP = 0.0001\
significantMUAC/age (%)\
mean ± SEM81.6 ± 0.783.1 ± 0.730.7% points0.000282.2 ± 0.780.5 ± 0.690.0002P = 0.0001\
significanttriceps skinfold/age\
mean ± SEM68.5 ± 1.6780.0 ± 1.8213.2% points0.000275.6 ± 1.8973.9 ± 1.880.014P = 0.0001\
significantsubscapular skinfold/age\
mean ± SEM86.8 ± 1.79102.7 ± 2.2421.4% points0.000291.3 ± 1.9685.7 ± 1.780.0002P = 0.0001\
significant[Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}Reports that anthropometric data were measured at baseline and day 45, no significant difference was found before and after treatment with albendazole and praziquantel. Data not shown in the publication.

^1^[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} reports growth greater than placebo. Sixteenparticipants per group are followed up at 5 weeks. Appetite measured by mL of porridge intake. No significant difference between metrifonate and praziquantel groups for the outcomes resting heart rate, Harvard step test and appetite.

^2^[Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"} has 238 participants in the praziquantel group and 198 in the placebogroup. \"MUAC was the only anthropometric measure with a significant difference between Praziquantel and Placebo group.\". Nno significant differences (before and after interventions) between the groups for height, weight, TSS; TSS:triceps skinfold thickness, MUAC: middle upper arm circumference.

^3^[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} At follow up at eight months, there are 105 participants in the praziquantel group and 104 in the placebo group.

Praziquantel 40 mg/kg or metrifonate 10 mg/kg single dose versus placebo: growth outcomes {#CD000053-sec3-0056}
=========================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg or**\
**Metrifonate 10 mg/kg single dosePlaceboP value for difference between treatment and placebo groupBaselineFollow upgrowth greater than placeboP value for difference before and after treatmentbaselinefollow upP value p for difference before and after treatment**[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}^1^5 weeksheight (cm)\
mean ± SEM133.8 ± 2.02134.4 ± 2.050.2cm0.0002135 ± 3.14134.4 ± 3.140.0002P=0.056\
not significantweight (kg)\
mean ± SEM25.9 ± 1.1827 ± 1.220.2kg0.000226.8 ± 1.9927.7 ± 1.980.0002P=0.11\
not significanttriceps skinfold/age (%)\
mean ± SEM70.8 ± 371 ± 3.112.9% pointsNot significant75 ± 6.5972.3 ± 6.470.052P=0.048\
significantwt for ht (%)\
mean ± SEM87 ± 1.38‐89.7 ± 1.320.9% points0.000287.5 ± 1.4789.3 ± 1.170.004P=0.084\
not significant

^1^[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} reports growth greater than placebo for the treatment group (praziquantel 40 mg/kg group (N = 16) and metrifonate 10 mg/kg group (N = 16) together). THe treatment group has 32 participants, the placebo group 16.

Metrifonate 10 mg/kg single dose versus placebo: growth outcomes {#CD000053-sec3-0057}
================================================================

**Trial IDTime pointMeasureMetrifonate 10 mg/kgPlaceboP value difference treatment and placeboBaselineFollow‐upgrowth greater than placeboP value difference between baseline and follow‐upBaselineFollow‐upP value difference between baseline and follow‐up**[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}^1^5 weeksHarvard step test score\
mean ± SEM76.2 ± 1.683.8 ± 1.229.2%points0.000277.1 ± 1.5175.5 ± 1.95Not significantSignificantresting heart rate\
beats/min\
mean ± SEM82 ± 2.4480.2 ± 1.652.9beats/min0.00485.8 ± 1.786.9 ± 1.96Not significantNot significantappetite\
mean ± SEM797 ± 78.2917 ± 68.4128mL0.051811 ± 93.4803 ± 78P = 0.014P = 0.051\
Not significant.[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}8 monthsheight (cm)\
mean ± SEM139.0 ± 1.27142.6 ± 1.250.2cm0.0002135.9 ± 1.23139.3 ± 1.220.0002Not significantweight (kg)\
mean ± SEM30.1 ± 0.8333.4 ± 0.871.4kg0.000228.4 ± 0.7830.3 ± 0.830.0002P \< 0.05\
significanttriceps skinfold thickness\
mean ± SEM8.2 ± 0.289.7 ± 0.321.5mm0.00028.2 ± 0.278.1 ± 0.27Not significantP \< 0.05\
significantsubscapular skinfold\
thickness\
mean ± SEM6.1 ± 0.27.4 ± 0.251.4mm0.00026.0 ± 0.25.9 ± 0.2Not significantP \< 0.05\
significantmiddle upper arm circumference (MUAC)\
mean ± SEM18.3 ± 0.2219.2 ± 0.240.7cm0.000217.8 ± 0.2118.0 ± 0.220.0002P \< 0.05\
significantht for age (%)\
mean ± SEM93.2 ± 0.4393.3 ± 0.430.1% pointsNot significant92.9 ± 0.4492.6 ± 0.440.001Significantwt for age (%)\
mean ± SEM73.8 ± 1.0476.2 ± 1.083.7% points0.000273.8 ± 1.0472.5 ± 1.030.0002Significantwt for ht\
mean ± SEM89.9 ± 0.7893.3 ± 0.783.6% points0.000290.6 ± 0.7290.4 ± 0.74Not significant.SignificantMUAC/age\
mean ± SEM82.5 ± 0.783.9 ± 0.763%points0.000282.2 ± 0.780.5 ± 0.690.0002Significanttriceps skinfold/age\
mean ± SEM74.4 ± 1.8385.7 ± 1.9313.1% points0.000275.6 ± 1.8973.9 ± 1.880.014Significantsubscapular skinfold/age\
mean ± SEM6.1 ± 0.27.4 ± 0.251.4 mm0.000291.3 ± 1.9685.7 ± 1.780.0002Significant

^1^[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} 16 participants both in the Metrifonate 10 mg group is and placebo group

^2^[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} 103 particpants in the Metrifonate 10 mg group, 104 participants in the placebogroup

Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose: growth outcomes {#CD000053-sec3-0058}
==========================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg single doseMetrifonate 10 mg/kg single doseP value (difference between praziquantel and metrifonate)BaselineFollow‐upGrowth greater than placeboP valuesBaselineFollow‐upGrowth greater than placeboP value**[Stephenson](#CD000053-bbs2-0026){ref-type="ref-list"}^1^[1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}5 weeksHST score\
mean ± SEM76 ± 1.4181.2 ± 16.8% points0.000276.2 ± 1.683.8 ± 1.229.2% points0.0002Significantresting heart rate beats/min\
mean ± SEM81.1 ± 1.6677.9 ± 1.1‐ 4.3 beats/min\
(decrease)0.00482 ± 2.4480.2 ± 1.652.9 beats/min0.004Significantappetite\
mean ± SEM709 ± 58841 ± 65.2139 mL0.014797 ± 78.2917 ± 68.4128 mLl0.051Not significant[Stephenson](#CD000053-bbs2-0026){ref-type="ref-list"}^1^[1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}8 monthsheight (cm)\
mean ± SEM134.8 ± 1.12138.2 ± 1.100.1 cm0.0002139.0 ± 1.27142.6 ± 1.250.2 cm0.00020.0002weight (kg)\
mean ± SEM27.3 ± 0.7230.4 ±0.761.2 kg0.000230.1 ± 0.8333.4 ± 0.871.4 kg0.00020.0002triceps skinfold thickness\
mean ±SEM7.4 ± 0.218.8 ± 0.251.4 mm0.00028.2 ± 0.289.7 ± 0.321.5 mm0.00020.0002subscapular skinfold\
thickness\
mean ± SEM5.6 ± 0.166.9 ± 0.21.4 mm0.00026.1 ± 0.27.4 ± 0.251.4 mm0.00020.0002Middle upper arm circumference (MUAC)\
mean ± SEM17.5 ± 0.2218.5 ± 0.240.7 cm0.000218.3 ± 0.2219.2 ± 0.240.7 cm0.00020.0002ht for age (%)\
mean ± SEM93.0 ± 0.4492.8 ± 0.430.1% points0.0293.2 ± 0.4393.3 ± 0.430.1% pointsNot significantNot significantwt for age (%)\
mean ± SEM72.7 ± 0.9874.9 ± 1.003.3% points0.000273.8 ± 1.0476.2 ± 1.083.7% points0.00020.0002wt for ht (%)\
mean ± SEM89.5 ± 0.7793.0 ± 0.843.7% points0.000289.9 ± 0.7893.3 ± 0.783.6% points0.00020.0002MUAC/age (%)\
mean ± SEM81.6 ± 0.783.1 ± 0.730.7% points0.000282.5 ± 0.783.9 ± 0.763% points0.00020.0002triceps skinfold/age\
mean ± SEM68.5 ± 1.6780.0 ± 1.8213.2% points0.000274.4 ± 1.8385.7 ± 1.9313.1% points0.00020.0002subscapular skinfold/age\
mean ± SEM86.8 ± 1.79102.7 ± 2.2421.4% points0.00026.1 ± 0.27.4 ± 0.2519.7% points0.00020.0002

[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} at 5 weeks, there were 16 participants in the praziquantel group and 16 in the metrifonate group. At 8 months, there were 105 participants in the praziquantel group and 103 in the metrifonate group.

Praziquantel 40 mg/kg single dose versus placebo: adverse events {#CD000053-sec3-0059}
================================================================

**Trial IDN (praziquantel treatment arm)Adverse event monitoringBlindingSummary of adverse events findings**[Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}N = 97 (Praziquantel 40 mg/kg)No commentBlinded for participants and clinicians\"Treatment was well tolerated\".[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}N = 300\
90 (Praziquantel 40 mg/kg)\
90 (ARS 4 mg/kg for 3 days)\
90 (Praziquantel 40 mg/kg and\
ARS 4 mg/kg for 3 days)\
30 (placebo)Adverse events recorded on day 1, 3 and 7\
(changes in the participants condition, compared with baseline)Blinded for participants and cliniciansNo difference between treatment groups regarding the number of adverse events, or distribution of particular adverse events.\
All treatment regimens well tolerated.\
Six moderate and 127 mild adverse events reported.\
Most common adverse events:abdominal pain (overall 14%) and headache (12%).[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}N = 312\
104 (Praziquantel; 52 with placebo, 52 without placebo)\
104 (ARS 4 mg/kg for 3 days; 52 with placebo, 52 without placebo\
52 (Praziquantel\
40 mg/kg and\
ARS 4 mg/kg for 3 days)\
52 (placebo)Careful monitoring for adverse events by trial physician, any potential adverse events were noted and monitored for up to 72 hours post treatment. Final assessment on day 56 for 2 consecutive days.UnclearNo difference between treatment groups.\
No severe adverse events reported within one hour of medication, no child required immediate medical care.\
Good tolerance of all treatment regimens.\
97 incidences of adverse events reported.\
33 cases of headache.[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}N = 101\
32 (Praziquantel 40 mg/kg)\
33 (Praziquantel 30 mg/kg)\
36 (Praziquantel 2 x 20 mg/kg)All children examined clinically before and four and 24 hours after treatment.\
Symptoms recorded after both general and specific queries (anorexia, nausea, vomiting, abdominal pain, diarrhoea, giddiness, tiredness, weakness, body pain, headache and fever)UnclearNo difference between treatment groups and placebo group, no side effects related to the drug or to infection intensity\
common side effects equally frequent before and after treatment[Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}N = 193\
98 (Praziquantel and albendazole)\
95 (Praziquantel)Surveillance for 48 hours for specific side effects\
(drug‐related side effect compared with parasite egg counts, symptoms over the past two weeks, physical examination and treatment group).\
Participants asked for overall rating of side effects and limitations of activity\
recording of request for medication for symptoms and hospitalisation.Blinded for clinicians, participants\
not blinded for outcome assessorsData not reported for *S. haematobium* separately.\
Vomiting, abdominal pain, headache, interference with normal activity, diarrhoea, bloody diarrhoea, request for additional medication for symptoms, and total side effects were all higher in children with documented schistosomiasis.[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}N = 283\
77 (Praziquantel 40 mg/kg)\
72 (Praziquantel 30 mg/kg)\
61 (Praziquantel 20 mg/kg)\
73 (Praziquantel 10 mg/kg)No commentBlinded for clinicians, participants\
not blinded for outcome assessors\"Side effects were not monitored but it appeared that those receiving smaller doses received less abdominal discomfort.\"

Footnotes {#CD000053-sec4-0026}
---------

[Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}and [Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"} did not comment on adverse events.

Praziquantel 40 mg/kg single dose versus 30 mg/kg single dose: adverse events {#CD000053-sec3-0060}
=============================================================================

**Trial IDNAdverse event monitoringBlindingSummary of adverse event finding**[Rey 1983 NER](#CD000053-bbs2-0022){ref-type="ref-list"}N = 103\
57 (Praziquantel 40 mg/kg)\
46 (Praziquantel 30 mg/kg)Not describedUnclear6% had mild adverse events, no difference between groups.[Davis 1981 ZMB](#CD000053-bbs2-0006){ref-type="ref-list"}N = 98\
N = 45 (Praziquantel 40 mg/kg),\
N = 53 (Praziquantel 30 mg/kg)Active surveillance of frequency and severity of side effects after treatment by direct questioning.\
Prospective: paired examinations of pre and post treatment measurements and haematological and clinical chemical variables before and after treatmentSingle blind\
no blinding out outcome assessorsVery good tolerance and patient acceptability for praziquantel; low incidence and severity of side effects.[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}N = 65\
N = 32 (Praziquantel 40 mg/kg)\
33 (Praziquantel 30 mg/kg)All children examined clinically before and four and 24 hours after treatment. Symptoms recorded after both general and specific queries.\
Active surveillance, likely to be prospective.UnclearNo difference between groups.\
Common side effects equally frequent before and after treatment and in treated and placebo groups.\
No side effects related to the drug or to infection intensity.[Omer 1981 SDN](#CD000053-bbs2-0019){ref-type="ref-list"}N = 100\
N = 50 (Praziquantel 40 mg/kg),\
N = 50 (Praziquantel 30 mg/kg)Side effects recorded before and after treatment.\
Method of monitoring not described.\
Monitoring of vital signs (pulse rate, respiratory rate, blood pressure) at 24 and 48 hours.Unclear\
for participants, clinicians and outcome assessorsDifference between groups not reported.\
Mild diarrhoea on day one following treatment in 31% of patients.\
All other symptoms mild and transient.[Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}N = 22 Praziquantel 40 mg/kg\
N = 23 (Praziquantel 30 mg/kg)\
N = 21 (Praziquantel 2 x 20 mg/kg)\
N = 24 (placebo)Clinical examination pre‐treatment and 18 to 24 hours post treatment to detect any unwanted side effects of praziquantel (pulse rate, systolic and diastolic blood pressure).\
Haematological and biochemical blood tests before (standard blood count, Hb electrophoresis, Bilirubin, SGPT, SGOT) and 18 to 24 hours after treatment (packed cell volume, total and differential white blood count, Bilirubin, SGOT, SGPT).\
Therapeutic doses of chloroquine (for Malaria) and levo‐tetramisole (ascariasis) given to all subjects.UnclearDifference in clinically diagnosed side effects not reported.\
No difference between groups in post treatment haematological and biochemical findings (within normal limits).\
Very good tolerance of praziquantel, very few side effects (two cases of moderate abdominal pain).[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}^1^283\
77 (Praziquantel 40 mg/kg),\
72 (Praziquantel 30 mg/kg)No commentBlinded for clinicians, participants.\
Not blinded for outcome assessors.\"Side effects were not monitored but it appeared that those receiving smaller doses received less abdominal discomfort.\"

Footnotes {#CD000053-sec4-0027}
---------

[King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}, [Mott 1985 GHA](#CD000053-bbs2-0017){ref-type="ref-list"}, [King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"} and [Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"} did not report adverse events.

^1^[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"} also reported a treatment arm of 61 participants who received Praziquantel 20 mg/kg and a treatment arm of 73 participants who received Praziquantel 10 mg/kg.

Praziquantel single dose versus split doses: adverse events {#CD000053-sec3-0061}
===========================================================

**Trial IDN (praziquantel treatment arm)Adverse event monitoringBlindingSummary of adverse events findings**[Kardaman 1985 SDN](#CD000053-bbs2-0010){ref-type="ref-list"}N = 220\
114 (Praziquantel 40 mg/kg)\
106 (Praziquantel 2 x 20 mg/kg)Monitoring\
Pre‐treatment clinical examination and interview of all patients by a clinician at the school on the day prior to treatment. recording of pre‐treatment symptoms per group.\
Post‐treatment interview of patients the morning after treatment by clinicians. recording or post‐treatment drug‐induced side‐effects\
per group.\
Second check seven days after treatment.\
Prospective, active surveillance.Unclear80% of children with some mild, transitory drug‐induced side‐effects.\
Most common complaint abdominal pain (63%) (further complaints diarrhoea, nausea, vomiting).\
Vomiting and dizziness significantly less common with a single dose than a split dose (resolved within 24 hours).[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}N = 68\
32 (Praziquantel 40 mg/kg)\
36 (Praziquantel 2 x 20 mg/kg)All children examined clinically before, and four and 24 hours after treatment. Symptoms recorded after both general and specific queries (anorexia, nausea, vomiting, abdominal pain, diarrhoea, giddiness, tiredness, weakness, body pain, headache and fever).\
Prospective, active surveillance, likely to be prospective.UnclearNo side effects related to the drug or to infection intensity.\
Common side effects equally frequent before and after treatment and in treated and placebo groups.[Davis 1981 ZMB](#CD000053-bbs2-0006){ref-type="ref-list"}N = 98\
45 (Praziquantel 40 mg/kg),\
53 (Praziquantel 2 x 20 mg/kg)Active surveillance of frequency and severity of side effects after treatment direct questioning.\
Prospective monitoring: paired examinations of pre and post treatment measurements and haematological and clinical chemical variables before and after treatment.Single blind\
No blinding of outcome assessorsVery good tolerance and patient acceptability for praziquantel. Low incidence and severity of side effects.

Metrifonate 3 doses two weeks apart: 7.5 mg/kg versus 5 mg/kg: adverse events {#CD000053-sec3-0062}
=============================================================================

**Trial IDN (metrifonate treatment arm)Adverse event monitoringBlindingSummary of adverse events findings**[Abden Abdi 1989 SOM](#CD000053-bbs2-0001){ref-type="ref-list"}N = 201\
100 (3 x 7.5 mg/kg)\
101 (3 x 5 mg/kg)Patients left as soon as they had received the drug; good monitoring during the first day (3 x 5 mg/kg given in one day)\
Questioning about side effects when patient returned for the next treatment with a check list; spontaneous reports were also noted (active and passive surveillance).Double blindedSide effects in 7% of patients in the 3 x 7.5 mg/kg treatment group and 9% patients in the 3 x 5 mg/kg treatment group; mostly mild and transient, headache and abdominal pain were most frequently noted ([Analysis 9.2](#CD000053-fig-00902){ref-type="fig"}).

Praziquantel 40 mg/kg single dose versus 3 x metrifonate 10 mg/kg: adverse events {#CD000053-sec3-0063}
=================================================================================

**Trial IDN (metrifonate treatment arm)Adverse event monitoringBlindingSummary of adverse events findings**[Al Aska 1990 SAU](#CD000053-bbs2-0002){ref-type="ref-list"}N = 100\
50 (metrifonate 3 x 10 mg/kg)\
50 (praziquantel 1 x 40 mg/kg)Recording of drug side effects at the second visit (time point unclear)UnclearDizziness was more common in the praziquantel group (20%) than in the metrifonate group (10%). No difference between groups for abdominal pain (12% in both groups ).

[de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"} did not comment on adverse events.

Praziquantel 30 mg/kg single dose versus 3 x metrifonate 10 mg/kg: adverse events {#CD000053-sec3-0064}
=================================================================================

**Trial IDN (metrifonate treatment arm)Adverse event monitoringBlindingSummary of adverse events findings**[McMahon 1983 TZA](#CD000053-bbs2-0016){ref-type="ref-list"}N = 60\
30 (metrifonate 3 x 10 mg/kg)\
30 (praziquantel 1 x 30 mg/kg)---NoNo major side effects.\
\"Abdominal pain was more common and more severe after metrifonate.\"

Artesunate versus placebo, praziquantel and artesunate versus praziquantel: adverse events {#CD000053-sec3-0065}
==========================================================================================

**Trial IDN (treatment arms)Adverse event monitoringBlinding of participants and staffSummary of adverse events findings**[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}N = 300\
90 (praziquantel 40 mg/kg)\
90 (artesunate 4 mg/kg for 3 days)\
90 (praziquantel 40 mg/kg and\
artesunate 4 mg/kg for 3 days)\
30 (placebo)Adverse events recorded on day 1, 3 and 7\
(changes in the participants condition, compared with baseline).\
Prospective surveillance.\
Unclear if active or passive monitoring.Blinded for participants and cliniciansAll treatment regimens well tolerated. Six moderate and 127 mild adverse events reported.\
No difference between treatment groups regarding the number of adverse events, or distribution of particular adverse events, most common adverse events: abdominal pain (overall 14%) and headache (12%).[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}N = 312\
104 (praziquantel; 52 with placebo, 52 without placebo)\
104 (artesunate 4 mg/kg for 3 days; 52 with placebo, 52 without placebo)\
52 (praziquantel 40 mg/kg and artesunate 4 mg/kg for 3 days)\
52 (placebo)Careful monitoring for adverse events by trial physician, any potential adverse events were noted and monitored for up to 72 hours post treatment, excellent compliance for reporting.\
Final assessment on day 56 for 2 consecutive days.\
Unclear if active or passive monitoring.UnclearNo difference between treatment groups.\
No severe adverse events reported within one hour of medication, no child required immediate medical care.\
97 incidences of adverse events reported\
33 cases of headache\
Good tolerance of all treatment regimens

Praziquantel versus artesunate: adverse events {#CD000053-sec3-0066}
==============================================

**Trial IDN (treatment arms)Adverse event monitoringBlinding of participants and staffSummary of adverse events findings**[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}N = 83\
19 (mefloquine 25 mg/kg)\
18 (artesunate 3 x 100 mg and mefloquine 250 mg FDC)\
20 (artesunate 4 mg/kg for 3 days)\
26 (praziquantel 40 mg/kg)\
No placebo armObservation for AE for 3 hours after the first dose AE monitoring until 96 hours after the first dosing.\
Interview with standardized questionnaire at 24, 48, 72 and 96 hours.\
Clinical examination in case AE occurred.\
Classification of AE as mild, moderate, severe or life threatening.Not blindedNo difference between the four treatment groups (headache, coughing, vomiting, vertigo or chills).\
Abdominal pain more frequent in the mefloquine group (98%, P \< 0.001), mefloquine‐artesunate (83%, P = 0.008, artesunate (60%, P = 0.37) than in the praziquantel group (46%).\
More participants had at least one AE in any of the assessments in the mefloquine group (100%), in the mefloquine‐artesunate group (94%) and in the artesunate group (80%) than in the praziquantel group (61%),\
No serious or life‐threatening adverse events, no hospital admissions due to AE\
no neuropsychological AE, no trial discontinuation due to AE.[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}N = 300\
90 (praziquantel 40 mg/kg)\
90 (artesunate 4 mg/kg for 3 days)\
90 (praziquantel 40 mg/kg and artesunate 4 mg/kg for 3 days)\
30 (placebo)Adverse events recorded on day 1, 3 and 7\
(changes in the participants condition, compared with baseline).\
Prospective surveillance.Blinded for participants and cliniciansAll treatment regimens well tolerated. Six moderate and 127 mild adverse events were reported.\
No difference between treatment groups regarding the number of adverse events, or distribution of particular adverse events, most common adverse events: abdominal pain (overall 14%) and headache (12%).[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}N = 312\
104 (praziquantel; 52 with placebo, 52 without placebo)\
104 (artesunate 4 mg/kg for 3 days; 52 with placebo, 52 without placebo.\
52 (praziquantel 40 mg/kg and\
artesunate 4 mg/kg for 3 days)\
52 (placebo)Careful monitoring for adverse events by trial physician, any potential adverse events were noted and monitored for up to 72 hours post treatment.\
Final assessment on day 56 for two consecutive days.\
Unclear if active or passive surveillanceUnclearNo difference between treatment groups\
No severe adverse events reported within one hour of medication, no child required immediate medical care.\
97 incidences of adverse events reported\
33 cases of headache\
Good tolerance of all treatment regimens

Praziquantel versus mefloquine: adverse events {#CD000053-sec3-0067}
==============================================

**Trial IDN (treatment arms)Adverse event monitoringBlinding of participants and staffSummary of adverse events findings**[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}N = 83\
19 (mefloquine 25 mg/kg)\
18 (artesunate 3 x 100 mg and mefloquine 250 mg FDC)\
20 (artesunate 4 mg/kg for 3 days)\
26 (praziquantel 40 mg/kg)\
No placebo armObservation for AE for 3 hours after the first dose AE monitoring until 96 hours after the first dosing\
interview with standardized questionnaire at 24, 48, 72 and 96 hours.\
Clinical examination in case AE occurred.\
Classification of AEs as mild, moderate, severe or life threatening.Not blindedNo difference between the four treatment groups (headache, coughing, vomiting, vertigo or chills),\
abdominal pain more frequent in the mefloquine group (98%, P \< 0.001), mefloquine‐artesunate (83%, P = 0.008, artesunate (60%, P = 0.37) than in the praziquantel group (46%).\
More participants had at least one AE in any of the assessments in the mefloquine group (100%), in the mefloquine‐artesunate group (94%) and in the artesunate group (80%) than in the praziquantel group (61%).\
No serious or life‐threatening adverse events, no hospital admissions due to AE,\
no neuropsychological AE, no trial discontinuation due to AE.

Praziquantel versus Praziquantel and ALB: adverse events {#CD000053-sec3-0068}
========================================================

**Trial IDParticipantsAdverse events monitoringBlindingSummary of adverse events findings**[Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}N = 193\
98 (Praziquantel and albendazole)\
95 (Praziquantel)AE monitoring for 48 hours for pre‐defined AEDouble blind65% of side effects for *S. haematobium* reported within four to six hours. Symptoms usually resolved within two hours with or without relief medication.\
Data not reported for *S. haematobium* separately.

Praziquantel 40 mg/kg single dose versus 20 mg/kg single dose: ultrasound findings {#CD000053-sec3-0069}
==================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg (SD)Praziquantel 20 mg/kg (SD)BaselineFollow‐upBaselineFollow‐up**[King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}^1^9 monthsNumber of participants with haematuria/total\
N = 264 for both groups22/32 (69%)16/32 (50%)20/32 (62%)17/32 (53%)Mild hydronephrosis (%)25%15%21%18%Moderate hydronephrosis (%)5%4%11%0%Severe hydronephrosis (%)5%2%3%2%Mild bladder abnormalities (%)11%4%17%6%Severe bladder abnormalities (%)8%0%6%0%

^1^Haematuria measured by urine dipstick, \"no statistical difference\", \"study might be underpowered, for ultrasound findings\" all severe bladder abnormalities were eliminated.

Praziquantel 40 mg/kg 1x/year versus metrifonate 10 mg/kg 3x/year: ultrasound findings {#CD000053-sec3-0070}
======================================================================================

**Trial IDTime pointMeasurePraziquantel 40 mg/kg**\
**1x/yearMetrifonate 10 mg/kg**\
**3x/yearComments**[King 1990 KEN](#CD000053-bbs2-0013){ref-type="ref-list"}12 monthsBladder wall thickness35% improvement\
8% deterioration29% improvement\
9% deteriorationSubsample N = 373\
Praziquantel N = 141\
Metrifonate N = 126Bladder deformity (granulomata)21% improvement\
6% deterioration15% improvement\
2% deteriorationHydronephrosis12% improvement\
13% deterioration9% improvement\
7% deterioration

###### Praziquantel 40 mg/kg single dose versus placebo

  Outcome or subgroup title                                            No. of studies   No. of participants   Statistical method                     Effect size
  -------------------------------------------------------------------- ---------------- --------------------- -------------------------------------- -----------------------
  [1 Parasitological failure](#CD000053-fig-00101){ref-type="fig"}     8                                      Risk Ratio (M‐H, Random, 95% CI)       Subtotals only
  1.1 at one month to two months                                       7                864                   Risk Ratio (M‐H, Random, 95% CI)       0.42 \[0.29, 0.59\]
  1.2 at three months                                                  3                354                   Risk Ratio (M‐H, Random, 95% CI)       0.51 \[0.34, 0.77\]
  1.3 at five months                                                   1                54                    Risk Ratio (M‐H, Random, 95% CI)       0.73 \[0.58, 0.91\]
  1.4 at six months                                                    3                332                   Risk Ratio (M‐H, Random, 95% CI)       0.42 \[0.10, 1.84\]
  1.5 at eight months                                                  1                209                   Risk Ratio (M‐H, Random, 95% CI)       0.14 \[0.08, 0.22\]
  [2 Haematuria at eight weeks](#CD000053-fig-00102){ref-type="fig"}   1                119                   Risk Ratio (M‐H, Fixed, 95% CI)        0.53 \[0.33, 0.84\]
  [3 Haemoglobin](#CD000053-fig-00103){ref-type="fig"}                 2                                      Mean Difference (IV, Random, 95% CI)   Subtotals only
  3.1 at baseline                                                      2                727                   Mean Difference (IV, Random, 95% CI)   ‐0.17 \[‐0.35, 0.02\]
  3.2 at six to eight months                                           2                727                   Mean Difference (IV, Random, 95% CI)   ‐0.08 \[‐0.24, 0.09\]
  [4 Adverse events](#CD000053-fig-00104){ref-type="fig"}              2                                      Risk Ratio (M‐H, Fixed, 95% CI)        Subtotals only
  4.1 Diarrhoea                                                        1                156                   Risk Ratio (M‐H, Fixed, 95% CI)        0.0 \[0.0, 0.0\]
  4.2 Vomiting                                                         2                226                   Risk Ratio (M‐H, Fixed, 95% CI)        0.67 \[0.15, 2.87\]
  4.3 Dizziness                                                        2                226                   Risk Ratio (M‐H, Fixed, 95% CI)        0.37 \[0.11, 1.27\]
  4.4 Anorexia                                                         1                70                    Risk Ratio (M‐H, Fixed, 95% CI)        0.20 \[0.05, 0.85\]
  4.5 Abdominal pain                                                   2                226                   Risk Ratio (M‐H, Fixed, 95% CI)        0.50 \[0.22, 1.14\]
  4.6 Tiredness                                                        1                70                    Risk Ratio (M‐H, Fixed, 95% CI)        0.48 \[0.14, 1.71\]
  4.7 Weakness                                                         1                70                    Risk Ratio (M‐H, Fixed, 95% CI)        0.96 \[0.36, 2.57\]
  4.8 Headache                                                         2                226                   Risk Ratio (M‐H, Fixed, 95% CI)        0.19 \[0.02, 1.47\]
  4.9 Fever                                                            2                226                   Risk Ratio (M‐H, Fixed, 95% CI)        1.12 \[0.07, 17.22\]
  4.10 Pain in limbs                                                   1                70                    Risk Ratio (M‐H, Fixed, 95% CI)        5.59 \[0.28, 112.34\]
  4.11 Itching                                                         1                156                   Risk Ratio (M‐H, Fixed, 95% CI)        1.0 \[0.19, 5.28\]
  4.12 Cough                                                           1                156                   Risk Ratio (M‐H, Fixed, 95% CI)        1.0 \[0.09, 10.78\]
  4.13 Chills                                                          1                156                   Risk Ratio (M‐H, Fixed, 95% CI)        1.5 \[0.16, 14.07\]
  4.14 Nausea                                                          1                156                   Risk Ratio (M‐H, Fixed, 95% CI)        1.0 \[0.09, 10.78\]
  4.15 Constipation                                                    1                156                   Risk Ratio (M‐H, Fixed, 95% CI)        1.51 \[0.06, 36.54\]

![Analysis\
Comparison 1 Praziquantel 40 mg/kg single dose versus placebo, Outcome 1 Parasitological failure.](nCD000053-CMP-001-01){#CD000053-fig-00101}

![Analysis\
Comparison 1 Praziquantel 40 mg/kg single dose versus placebo, Outcome 2 Haematuria at eight weeks.](nCD000053-CMP-001-02){#CD000053-fig-00102}

![Analysis\
Comparison 1 Praziquantel 40 mg/kg single dose versus placebo, Outcome 3 Haemoglobin.](nCD000053-CMP-001-03){#CD000053-fig-00103}

![Analysis\
Comparison 1 Praziquantel 40 mg/kg single dose versus placebo, Outcome 4 Adverse events.](nCD000053-CMP-001-04){#CD000053-fig-00104}

###### Praziquantel 40 mg/kg single dose versus lower doses

  Outcome or subgroup title                                                                 No. of studies   No. of participants   Statistical method                 Effect size
  ----------------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ----------------------
  [1 Parasitological failure at four to six weeks](#CD000053-fig-00201){ref-type="fig"}     5                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  1.1 versus 30 mg/kg                                                                       4                401                   Risk Ratio (M‐H, Fixed, 95% CI)    0.76 \[0.59, 0.99\]
  1.2 versus 20 mg/kg                                                                       2                338                   Risk Ratio (M‐H, Fixed, 95% CI)    0.74 \[0.59, 0.93\]
  1.3 versus 10 mg/kg                                                                       1                150                   Risk Ratio (M‐H, Fixed, 95% CI)    0.66 \[0.53, 0.84\]
  [2 Parasitological failure at two to three months](#CD000053-fig-00202){ref-type="fig"}   6                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  2.1 versus 30 mg/kg                                                                       5                517                   Risk Ratio (M‐H, Fixed, 95% CI)    0.95 \[0.72, 1.24\]
  2.2 versus 20 mg/kg                                                                       3                330                   Risk Ratio (M‐H, Fixed, 95% CI)    0.72 \[0.56, 0.92\]
  2.3 versus 10 mg/kg                                                                       3                339                   Risk Ratio (M‐H, Fixed, 95% CI)    0.48 \[0.39, 0.60\]
  [3 Parasitological failure at six to seven months](#CD000053-fig-00203){ref-type="fig"}   6                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  3.1 versus 30 mg/kg                                                                       6                669                   Risk Ratio (M‐H, Fixed, 95% CI)    0.97 \[0.76, 1.23\]
  3.2 versus 20 mg/kg                                                                       1                138                   Risk Ratio (M‐H, Fixed, 95% CI)    0.87 \[0.53, 1.44\]
  3.3 versus 10 mg/kg                                                                       1                150                   Risk Ratio (M‐H, Fixed, 95% CI)    0.43 \[0.29, 0.64\]
  [4 Haematuria at three months](#CD000053-fig-00204){ref-type="fig"}                       1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  4.1 versus 30 mg/kg                                                                       1                117                   Risk Ratio (M‐H, Fixed, 95% CI)    0.89 \[0.47, 1.67\]
  4.2 versus 20 mg/kg                                                                       1                122                   Risk Ratio (M‐H, Fixed, 95% CI)    1.18 \[0.60, 2.33\]
  4.3 versus 10 mg/kg                                                                       1                119                   Risk Ratio (M‐H, Fixed, 95% CI)    0.35 \[0.21, 0.58\]
  [5 Proteinuria at three months](#CD000053-fig-00205){ref-type="fig"}                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  5.1 versus 30 mg/kg                                                                       1                117                   Risk Ratio (M‐H, Fixed, 95% CI)    0.85 \[0.34, 2.12\]
  5.2 versus 20 mg/kg                                                                       1                122                   Risk Ratio (M‐H, Fixed, 95% CI)    0.92 \[0.36, 2.30\]
  5.3 versus 10 mg/kg                                                                       1                119                   Risk Ratio (M‐H, Fixed, 95% CI)    0.25 \[0.12, 0.51\]
  [6 Haematuria at six weeks](#CD000053-fig-00206){ref-type="fig"}                          1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  6.1 versus 20 mg/kg                                                                       1                245                   Risk Ratio (M‐H, Fixed, 95% CI)    0.63 \[0.47, 0.86\]
  [7 Proteinuria at six weeks](#CD000053-fig-00207){ref-type="fig"}                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  7.1 versus 20 mg/kg                                                                       1                245                   Risk Ratio (M‐H, Fixed, 95% CI)    0.66 \[0.46, 0.96\]
  [8 Haematuria at nine months](#CD000053-fig-00208){ref-type="fig"}                        1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  8.1 versus 20 mg/kg                                                                       1                215                   Risk Ratio (M‐H, Fixed, 95% CI)    0.59 \[0.44, 0.78\]
  [9 Proteinuria at nine months](#CD000053-fig-00209){ref-type="fig"}                       1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  9.1 versus 20 mg/kg                                                                       1                214                   Risk Ratio (M‐H, Fixed, 95% CI)    0.67 \[0.50, 0.90\]
  [10 Adverse events](#CD000053-fig-00210){ref-type="fig"}                                  2                                      Risk Ratio (M‐H, Random, 95% CI)   Subtotals only
  10.1 Vomiting                                                                             2                163                   Risk Ratio (M‐H, Random, 95% CI)   0.79 \[0.05, 13.51\]
  10.2 Dizziness                                                                            2                163                   Risk Ratio (M‐H, Random, 95% CI)   0.73 \[0.11, 4.62\]
  10.3 Anorexia                                                                             1                65                    Risk Ratio (M‐H, Random, 95% CI)   4.85 \[0.24, 97.31\]
  10.4 Abdominal pain                                                                       2                163                   Risk Ratio (M‐H, Random, 95% CI)   1.14 \[0.23, 5.56\]
  10.5 Tiredness                                                                            1                65                    Risk Ratio (M‐H, Random, 95% CI)   0.32 \[0.10, 1.09\]
  10.6 Weakness                                                                             1                65                    Risk Ratio (M‐H, Random, 95% CI)   1.16 \[0.39, 3.44\]
  10.7 Headache                                                                             2                163                   Risk Ratio (M‐H, Random, 95% CI)   0.49 \[0.08, 2.85\]
  10.8 Fever                                                                                1                65                    Risk Ratio (M‐H, Random, 95% CI)   2.91 \[0.12, 68.95\]
  10.9 Pain in limbs                                                                        1                65                    Risk Ratio (M‐H, Random, 95% CI)   0.39 \[0.08, 1.86\]

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 1 Parasitological failure at four to six weeks.](nCD000053-CMP-002-01){#CD000053-fig-00201}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 2 Parasitological failure at two to three months.](nCD000053-CMP-002-02){#CD000053-fig-00202}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 3 Parasitological failure at six to seven months.](nCD000053-CMP-002-03){#CD000053-fig-00203}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 4 Haematuria at three months.](nCD000053-CMP-002-04){#CD000053-fig-00204}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 5 Proteinuria at three months.](nCD000053-CMP-002-05){#CD000053-fig-00205}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 6 Haematuria at six weeks.](nCD000053-CMP-002-06){#CD000053-fig-00206}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 7 Proteinuria at six weeks.](nCD000053-CMP-002-07){#CD000053-fig-00207}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 8 Haematuria at nine months.](nCD000053-CMP-002-08){#CD000053-fig-00208}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 9 Proteinuria at nine months.](nCD000053-CMP-002-09){#CD000053-fig-00209}

![Analysis\
Comparison 2 Praziquantel 40 mg/kg single dose versus lower doses, Outcome 10 Adverse events.](nCD000053-CMP-002-10){#CD000053-fig-00210}

###### Praziquantel 40 mg/kg single dose versus 2 x 20 mg/kg split dose

  Outcome or subgroup title                                          No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ----------------------
  [1 Parasitological failure](#CD000053-fig-00301){ref-type="fig"}   4                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  1.1 at one month                                                   3                374                   Risk Ratio (M‐H, Fixed, 95% CI)   0.75 \[0.51, 1.11\]
  1.2 at three months                                                3                361                   Risk Ratio (M‐H, Fixed, 95% CI)   0.74 \[0.45, 1.20\]
  1.3 at six to seven months                                         3                234                   Risk Ratio (M‐H, Fixed, 95% CI)   0.83 \[0.51, 1.35\]
  [2 Adverse events](#CD000053-fig-00302){ref-type="fig"}            3                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  2.1 Blood in stool                                                 1                215                   Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  2.2 Vomiting                                                       3                373                   Risk Ratio (M‐H, Fixed, 95% CI)   0.50 \[0.29, 0.86\]
  2.3 Dizziness                                                      3                373                   Risk Ratio (M‐H, Fixed, 95% CI)   0.39 \[0.16, 0.94\]
  2.4 Anorexia                                                       1                69                    Risk Ratio (M‐H, Fixed, 95% CI)   2.18 \[0.21, 22.96\]
  2.5 Abdominal pain                                                 3                373                   Risk Ratio (M‐H, Fixed, 95% CI)   1.02 \[0.83, 1.25\]
  2.6 Tiredness                                                      1                69                    Risk Ratio (M‐H, Fixed, 95% CI)   0.41 \[0.12, 1.41\]
  2.7 Weakness                                                       1                69                    Risk Ratio (M‐H, Fixed, 95% CI)   0.94 \[0.35, 2.50\]
  2.8 Headache                                                       2                158                   Risk Ratio (M‐H, Fixed, 95% CI)   0.51 \[0.20, 1.33\]
  2.9 Fever                                                          2                284                   Risk Ratio (M‐H, Fixed, 95% CI)   0.53 \[0.23, 1.23\]
  2.10 Pain in limbs                                                 1                69                    Risk Ratio (M‐H, Fixed, 95% CI)   0.44 \[0.09, 2.10\]
  2.11 Diarrhoea                                                     1                215                   Risk Ratio (M‐H, Fixed, 95% CI)   1.07 \[0.67, 1.73\]
  2.12 Skin reaction                                                 1                215                   Risk Ratio (M‐H, Fixed, 95% CI)   1.84 \[0.34, 9.83\]

![Analysis\
Comparison 3 Praziquantel 40 mg/kg single dose versus 2 x 20 mg/kg split dose, Outcome 1 Parasitological failure.](nCD000053-CMP-003-01){#CD000053-fig-00301}

![Analysis\
Comparison 3 Praziquantel 40 mg/kg single dose versus 2 x 20 mg/kg split dose, Outcome 2 Adverse events.](nCD000053-CMP-003-02){#CD000053-fig-00302}

###### Praziquantel 40 mg/kg single dose versus praziquantel 2 x 40 mg/kg or 3 x 40 mg/kg

  Outcome or subgroup title                                                                                                                 No. of studies   No. of participants   Statistical method                Effect size
  ----------------------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Praziquantel 40 mg/single dose versus praziquantel 2 x 40 mg/kg: parasitological failure](#CD000053-fig-00401){ref-type="fig"}         2                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  1.1 at six weeks                                                                                                                          1                269                   Risk Ratio (M‐H, Fixed, 95% CI)   0.82 \[0.50, 1.34\]
  1.2 at nine weeks to three months                                                                                                         2                686                   Risk Ratio (M‐H, Fixed, 95% CI)   1.06 \[0.91, 1.25\]
  1.3 at six months                                                                                                                         1                556                   Risk Ratio (M‐H, Fixed, 95% CI)   1.12 \[0.95, 1.31\]
  [2 Praziquantel 40 mg/kg single dose versus praziquantel 3 x 40 mg/kg: parasitological failure](#CD000053-fig-00402){ref-type="fig"}      1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  2.1 at nine weeks                                                                                                                         1                185                   Risk Ratio (M‐H, Fixed, 95% CI)   0.94 \[0.42, 2.12\]
  [3 Praziquantel 40 mg/single dose versus praziquantel 2 x 40 mg/kg: microhaematuria at six months](#CD000053-fig-00403){ref-type="fig"}   1                300                   Risk Ratio (M‐H, Fixed, 95% CI)   1.17 \[0.88, 1.56\]

![Analysis\
Comparison 4 Praziquantel 40 mg/kg single dose versus praziquantel 2 x 40 mg/kg or 3 x 40 mg/kg, Outcome 1 Praziquantel 40 mg/single dose versus praziquantel 2 x 40 mg/kg: parasitological failure.](nCD000053-CMP-004-01){#CD000053-fig-00401}

![Analysis\
Comparison 4 Praziquantel 40 mg/kg single dose versus praziquantel 2 x 40 mg/kg or 3 x 40 mg/kg, Outcome 2 Praziquantel 40 mg/kg single dose versus praziquantel 3 x 40 mg/kg: parasitological failure.](nCD000053-CMP-004-02){#CD000053-fig-00402}

![Analysis\
Comparison 4 Praziquantel 40 mg/kg single dose versus praziquantel 2 x 40 mg/kg or 3 x 40 mg/kg, Outcome 3 Praziquantel 40 mg/single dose versus praziquantel 2 x 40 mg/kg: microhaematuria at six months.](nCD000053-CMP-004-03){#CD000053-fig-00403}

###### Praziquantel 40 mg/kg single dose versus multiple doses

  Outcome or subgroup title                                          No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ---------------------
  [1 Parasitological failure](#CD000053-fig-00501){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  1.1 at two years                                                   1                62                    Risk Ratio (M‐H, Fixed, 95% CI)   2.71 \[1.47, 5.00\]
  1.2 at three years                                                 1                43                    Risk Ratio (M‐H, Fixed, 95% CI)   0.92 \[0.59, 1.42\]
  [2 Haematuria](#CD000053-fig-00502){ref-type="fig"}                1                43                    Risk Ratio (M‐H, Fixed, 95% CI)   0.70 \[0.42, 1.17\]

![Analysis\
Comparison 5 Praziquantel 40 mg/kg single dose versus multiple doses, Outcome 1 Parasitological failure.](nCD000053-CMP-005-01){#CD000053-fig-00501}

![Analysis\
Comparison 5 Praziquantel 40 mg/kg single dose versus multiple doses, Outcome 2 Haematuria.](nCD000053-CMP-005-02){#CD000053-fig-00502}

###### Metrifonate single dose (10 mg/kg) versus placebo

  Outcome or subgroup title                                          No. of studies   No. of participants   Statistical method                    Effect size
  ------------------------------------------------------------------ ---------------- --------------------- ------------------------------------- ----------------------
  [1 Parasitological failure](#CD000053-fig-00601){ref-type="fig"}   2                                      Risk Ratio (M‐H, Random, 95% CI)      Subtotals only
  1.1 at one month                                                   1                142                   Risk Ratio (M‐H, Random, 95% CI)      0.83 \[0.74, 0.94\]
  1.2 at two and a half to three months                              1                122                   Risk Ratio (M‐H, Random, 95% CI)      0.92 \[0.85, 0.99\]
  1.3 at six months                                                  1                102                   Risk Ratio (M‐H, Random, 95% CI)      0.94 \[0.87, 1.02\]
  1.4 at eight months                                                1                210                   Risk Ratio (M‐H, Random, 95% CI)      0.63 \[0.54, 0.73\]
  [2 Haemoglobin](#CD000053-fig-00602){ref-type="fig"}               1                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  2.1 at baseline                                                    1                207                   Mean Difference (IV, Fixed, 95% CI)   0.0 \[‐0.33, 0.33\]
  2.2 at eight months                                                1                207                   Mean Difference (IV, Fixed, 95% CI)   0.30 \[‐0.05, 0.65\]

![Analysis\
Comparison 6 Metrifonate single dose (10 mg/kg) versus placebo, Outcome 1 Parasitological failure.](nCD000053-CMP-006-01){#CD000053-fig-00601}

![Analysis\
Comparison 6 Metrifonate single dose (10 mg/kg) versus placebo, Outcome 2 Haemoglobin.](nCD000053-CMP-006-02){#CD000053-fig-00602}

###### Metrifonate multiple doses versus placebo

  Outcome or subgroup title                                          No. of studies   No. of participants   Statistical method                     Effect size
  ------------------------------------------------------------------ ---------------- --------------------- -------------------------------------- -----------------------
  [1 Parasitological failure](#CD000053-fig-00701){ref-type="fig"}   3                                      Risk Ratio (M‐H, Random, 95% CI)       Subtotals only
  1.1 at one month                                                   1                50                    Risk Ratio (M‐H, Random, 95% CI)       0.84 \[0.65, 1.09\]
  1.2 at 11 weeks                                                    1                93                    Risk Ratio (M‐H, Random, 95% CI)       0.41 \[0.30, 0.56\]
  1.3 at five months                                                 1                51                    Risk Ratio (M‐H, Random, 95% CI)       0.89 \[0.76, 1.03\]
  1.4 at six months                                                  1                400                   Risk Ratio (M‐H, Random, 95% CI)       0.30 \[0.24, 0.37\]
  [2 Haemoglobin](#CD000053-fig-00702){ref-type="fig"}               1                                      Mean Difference (IV, Random, 95% CI)   Subtotals only
  2.1 at baseline                                                    1                400                   Mean Difference (IV, Random, 95% CI)   ‐0.17 \[‐0.45, 0.11\]
  2.2 at six months                                                  1                391                   Mean Difference (IV, Random, 95% CI)   0.30 \[0.14, 0.46\]

![Analysis\
Comparison 7 Metrifonate multiple doses versus placebo, Outcome 1 Parasitological failure.](nCD000053-CMP-007-01){#CD000053-fig-00701}

![Analysis\
Comparison 7 Metrifonate multiple doses versus placebo, Outcome 2 Haemoglobin.](nCD000053-CMP-007-02){#CD000053-fig-00702}

###### Metrifonate multiple doses versus single dose

  Outcome or subgroup title                                                         No. of studies   No. of participants   Statistical method                Effect size
  --------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Parasitological failure at one month](#CD000053-fig-00801){ref-type="fig"}     1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  1.1 20 mg/kg versus 10 mg/kg                                                      1                112                   Risk Ratio (M‐H, Fixed, 95% CI)   0.75 \[0.50, 1.13\]
  1.2 30 mg/kg versus 10 mg/kg                                                      1                93                    Risk Ratio (M‐H, Fixed, 95% CI)   0.36 \[0.17, 0.77\]
  [2 Parasitological failure at four months](#CD000053-fig-00802){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  2.1 20 mg/kg versus 10 mg/kg                                                      1                133                   Risk Ratio (M‐H, Fixed, 95% CI)   0.78 \[0.58, 1.06\]
  2.2 30 mg/kg versus 10 mg/kg                                                      1                111                   Risk Ratio (M‐H, Fixed, 95% CI)   0.67 \[0.45, 0.99\]

![Analysis\
Comparison 8 Metrifonate multiple doses versus single dose, Outcome 1 Parasitological failure at one month.](nCD000053-CMP-008-01){#CD000053-fig-00801}

![Analysis\
Comparison 8 Metrifonate multiple doses versus single dose, Outcome 2 Parasitological failure at four months.](nCD000053-CMP-008-02){#CD000053-fig-00802}

###### Metrifonate 3 doses 2 weeks apart: 7.5 mg/kg versus 5 mg/kg

  Outcome or subgroup title                                          No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------ ---------------- --------------------- --------------------------------- ----------------------
  [1 Parasitological failure](#CD000053-fig-00901){ref-type="fig"}   1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  1.1 at one month                                                   1                201                   Risk Ratio (M‐H, Fixed, 95% CI)   0.91 \[0.69, 1.21\]
  1.2 at two months                                                  1                165                   Risk Ratio (M‐H, Fixed, 95% CI)   0.97 \[0.72, 1.30\]
  1.3 at three months                                                1                133                   Risk Ratio (M‐H, Fixed, 95% CI)   0.92 \[0.67, 1.26\]
  1.4 at six months                                                  1                139                   Risk Ratio (M‐H, Fixed, 95% CI)   1.43 \[0.99, 2.05\]
  [2 Adverse events](#CD000053-fig-00902){ref-type="fig"}            1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Subtotals only
  2.1 Nausea                                                         1                201                   Risk Ratio (M‐H, Fixed, 95% CI)   0.51 \[0.05, 5.48\]
  2.2 Vomiting                                                       1                201                   Risk Ratio (M‐H, Fixed, 95% CI)   1.01 \[0.06, 15.93\]
  2.3 Dizziness                                                      1                201                   Risk Ratio (M‐H, Fixed, 95% CI)   1.01 \[0.06, 15.93\]
  2.4 Abdominal pain                                                 1                201                   Risk Ratio (M‐H, Fixed, 95% CI)   3.03 \[0.32, 28.64\]
  2.5 Headache                                                       1                201                   Risk Ratio (M‐H, Fixed, 95% CI)   0.34 \[0.04, 3.18\]
  2.6 Heaviness of the tongue                                        1                201                   Risk Ratio (M‐H, Fixed, 95% CI)   2.02 \[0.19, 21.92\]

![Analysis\
Comparison 9 Metrifonate 3 doses 2 weeks apart: 7.5 mg/kg versus 5 mg/kg, Outcome 1 Parasitological failure.](nCD000053-CMP-009-01){#CD000053-fig-00901}

![Analysis\
Comparison 9 Metrifonate 3 doses 2 weeks apart: 7.5 mg/kg versus 5 mg/kg, Outcome 2 Adverse events.](nCD000053-CMP-009-02){#CD000053-fig-00902}

###### Praziquantel versus metrifonate

  Outcome or subgroup title                                                                                                                                     No. of studies   No. of participants   Statistical method                    Effect size
  ------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------- ------------------------------------- ------------------------
  [1 Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose: parasitological failure](#CD000053-fig-01001){ref-type="fig"}                   3                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  1.1 at one month                                                                                                                                              1                183                   Risk Ratio (M‐H, Fixed, 95% CI)       0.46 \[0.34, 0.61\]
  1.2 at two to three months                                                                                                                                    2                243                   Risk Ratio (M‐H, Fixed, 95% CI)       0.67 \[0.57, 0.79\]
  1.3 at six months                                                                                                                                             1                149                   Risk Ratio (M‐H, Fixed, 95% CI)       0.89 \[0.79, 1.01\]
  1.4 at eight months                                                                                                                                           1                208                   Risk Ratio (M‐H, Fixed, 95% CI)       0.21 \[0.13, 0.36\]
  [2 Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose: haemoglobin](#CD000053-fig-01002){ref-type="fig"}                               1                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  2.1 at baseline                                                                                                                                               1                208                   Mean Difference (IV, Fixed, 95% CI)   ‐0.30 \[‐0.52, ‐0.08\]
  2.2 at eight months                                                                                                                                           1                208                   Mean Difference (IV, Fixed, 95% CI)   ‐0.40 \[‐0.66, ‐0.14\]
  [3 Praziquantel 40 mg/kg single dose versus metrifonate 20 and 30 mg/kg given as split doses: parasitological failure](#CD000053-fig-01003){ref-type="fig"}   2                                      Risk Ratio (M‐H, Random, 95% CI)      Subtotals only
  3.1 2 x 10 mg/kg Metrifonate at one month                                                                                                                     1                72                    Risk Ratio (M‐H, Random, 95% CI)      1.03 \[0.80, 1.34\]
  3.2 2 x 10 mg/kg Metrifonate at five months                                                                                                                   1                67                    Risk Ratio (M‐H, Random, 95% CI)      0.82 \[0.64, 1.05\]
  3.3 3 x 10 mg/kg Metrifonate at three months                                                                                                                  1                100                   Risk Ratio (M‐H, Random, 95% CI)      0.33 \[0.07, 1.57\]
  3.4 3 x 10 mg/kg Metrifonate at six months                                                                                                                    1                100                   Risk Ratio (M‐H, Random, 95% CI)      0.2 \[0.02, 1.65\]
  [4 Praziquantel 40 mg/kg single dose versus metrifonate 30 mg/kg given as split dose: adverse events](#CD000053-fig-01004){ref-type="fig"}                    1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Totals not selected
  4.1 Dizziness                                                                                                                                                 1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.2 Abdominal pain                                                                                                                                            1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.3 Joint pain                                                                                                                                                1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.4 Nausea                                                                                                                                                    1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.5 Rash                                                                                                                                                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.6 Vomiting                                                                                                                                                  1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.7 Itching                                                                                                                                                   1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.8 Fatigue                                                                                                                                                   1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.9 Hair loss                                                                                                                                                 1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.10 Change in taste                                                                                                                                          1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.11 Diarrhoea                                                                                                                                                1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  4.12 Convulsion                                                                                                                                               1                                      Risk Ratio (M‐H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  [5 Praziquantel 30 mg/kg single dose versus metrifonate 30 mg/kg given as split dose: parasitological failure](#CD000053-fig-01005){ref-type="fig"}           1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  5.1 at two months                                                                                                                                             1                54                    Risk Ratio (M‐H, Fixed, 95% CI)       0.53 \[0.17, 1.68\]
  5.2 at four months                                                                                                                                            1                52                    Risk Ratio (M‐H, Fixed, 95% CI)       0.24 \[0.07, 0.80\]
  [6 Praziquantel 30 mg/kg single dose versus metrifonate 30 mg/kg given as split dose: adverse events](#CD000053-fig-01006){ref-type="fig"}                    1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  6.1 Nausea                                                                                                                                                    1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       3.0 \[0.13, 70.83\]
  6.2 Vomiting                                                                                                                                                  1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       0.2 \[0.01, 4.00\]
  6.3 Abdominal pain                                                                                                                                            1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       0.33 \[0.12, 0.92\]
  6.4 Headache                                                                                                                                                  1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       0.33 \[0.01, 7.87\]
  6.5 Fever                                                                                                                                                     1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       0.33 \[0.01, 7.87\]
  6.6 Loose bowel motions                                                                                                                                       1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       1.0 \[0.07, 15.26\]
  6.7 Dizziness                                                                                                                                                 1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       1.0 \[0.07, 15.26\]
  6.8 Itching                                                                                                                                                   1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       1.0 \[0.07, 15.26\]
  6.9 Body pain                                                                                                                                                 1                60                    Risk Ratio (M‐H, Fixed, 95% CI)       1.0 \[0.07, 15.26\]
  [7 Praziquantel 40 mg/kg once a year versus metrifonate 10 mg/kg every 4 months](#CD000053-fig-01007){ref-type="fig"}                                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  7.1 Parasitological failure at one year                                                                                                                       1                1436                  Risk Ratio (M‐H, Fixed, 95% CI)       1.05 \[1.00, 1.11\]
  7.2 Haematuria at one year                                                                                                                                    1                1400                  Risk Ratio (M‐H, Fixed, 95% CI)       1.08 \[0.85, 1.36\]
  7.3 Proteinuria at one year                                                                                                                                   1                1400                  Risk Ratio (M‐H, Fixed, 95% CI)       0.93 \[0.79, 1.11\]
  [8 Praziquantel 40 mg/kg once a year versus metrifonate 10 mg/kg every 4 months: parasitological failure](#CD000053-fig-01008){ref-type="fig"}                1                                      Risk Ratio (M‐H, Fixed, 95% CI)       Subtotals only
  8.1 at one year                                                                                                                                               1                1018                  Risk Ratio (M‐H, Fixed, 95% CI)       0.78 \[0.61, 1.00\]
  8.2 at two years                                                                                                                                              1                1025                  Risk Ratio (M‐H, Fixed, 95% CI)       0.77 \[0.53, 1.11\]
  8.3 at three years                                                                                                                                            1                827                   Risk Ratio (M‐H, Fixed, 95% CI)       0.62 \[0.42, 0.93\]
  [9 Praziquantel 40 mg/kg versus praziquantel 10 mg/kg and metrifonate 10 mg/kg](#CD000053-fig-01009){ref-type="fig"}                                          1                72                    Risk Ratio (M‐H, Random, 95% CI)      0.59 \[0.34, 1.03\]

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 1 Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose: parasitological failure.](nCD000053-CMP-010-01){#CD000053-fig-01001}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 2 Praziquantel 40 mg/kg single dose versus metrifonate 10 mg/kg single dose: haemoglobin.](nCD000053-CMP-010-02){#CD000053-fig-01002}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 3 Praziquantel 40 mg/kg single dose versus metrifonate 20 and 30 mg/kg given as split doses: parasitological failure.](nCD000053-CMP-010-03){#CD000053-fig-01003}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 4 Praziquantel 40 mg/kg single dose versus metrifonate 30 mg/kg given as split dose: adverse events.](nCD000053-CMP-010-04){#CD000053-fig-01004}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 5 Praziquantel 30 mg/kg single dose versus metrifonate 30 mg/kg given as split dose: parasitological failure.](nCD000053-CMP-010-05){#CD000053-fig-01005}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 6 Praziquantel 30 mg/kg single dose versus metrifonate 30 mg/kg given as split dose: adverse events.](nCD000053-CMP-010-06){#CD000053-fig-01006}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 7 Praziquantel 40 mg/kg once a year versus metrifonate 10 mg/kg every 4 months.](nCD000053-CMP-010-07){#CD000053-fig-01007}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 8 Praziquantel 40 mg/kg once a year versus metrifonate 10 mg/kg every 4 months: parasitological failure.](nCD000053-CMP-010-08){#CD000053-fig-01008}

![Analysis\
Comparison 10 Praziquantel versus metrifonate, Outcome 9 Praziquantel 40 mg/kg versus praziquantel 10 mg/kg and metrifonate 10 mg/kg.](nCD000053-CMP-010-09){#CD000053-fig-01009}

###### Artesunate versus placebo

  Outcome or subgroup title                                                         No. of studies   No. of participants   Statistical method                 Effect size
  --------------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 Parasitological failure at eight weeks](#CD000053-fig-01101){ref-type="fig"}   2                251                   Risk Ratio (M‐H, Random, 95% CI)   0.53 \[0.16, 1.71\]
  [2 Haematuria](#CD000053-fig-01102){ref-type="fig"}                               1                119                   Risk Ratio (M‐H, Fixed, 95% CI)    1.22 \[0.85, 1.76\]
  [3 Adverse events](#CD000053-fig-01103){ref-type="fig"}                           1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Totals not selected
  3.1 Headache                                                                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.2 Vomiting                                                                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.3 Fever                                                                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.4 Itching                                                                       1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.5 Cough                                                                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.6 Diarrhoea                                                                     1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.7 Chills                                                                        1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.8 Nausea                                                                        1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.9 Dizziness                                                                     1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.10 Abdominal pain                                                               1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.11 Constipation                                                                 1                                      Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]

![Analysis\
Comparison 11 Artesunate versus placebo, Outcome 1 Parasitological failure at eight weeks.](nCD000053-CMP-011-01){#CD000053-fig-01101}

![Analysis\
Comparison 11 Artesunate versus placebo, Outcome 2 Haematuria.](nCD000053-CMP-011-02){#CD000053-fig-01102}

![Analysis\
Comparison 11 Artesunate versus placebo, Outcome 3 Adverse events.](nCD000053-CMP-011-03){#CD000053-fig-01103}

###### Praziquantel versus artesunate

  Outcome or subgroup title                                          No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ---------------------
  [1 Parasitological failure](#CD000053-fig-01201){ref-type="fig"}   3                                      Risk Ratio (M‐H, Random, 95% CI)   Subtotals only
  1.1 at day 28                                                      1                46                    Risk Ratio (M‐H, Random, 95% CI)   0.15 \[0.05, 0.46\]
  1.2 at day 56                                                      2                352                   Risk Ratio (M‐H, Random, 95% CI)   0.58 \[0.23, 1.44\]
  [2 Haematuria](#CD000053-fig-01202){ref-type="fig"}                1                178                   Risk Ratio (M‐H, Random, 95% CI)   0.43 \[0.30, 0.62\]
  [3 Adverse events](#CD000053-fig-01203){ref-type="fig"}            1                                      Risk Ratio (M‐H, Fixed, 95% CI)    Subtotals only
  3.1 Abdominal pain                                                 1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.2 Dizziness                                                      1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.3 Headache                                                       1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    1.0 \[0.43, 2.30\]
  3.4 Vomiting                                                       1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    1.0 \[0.26, 3.89\]
  3.5 Fever                                                          1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    1.17 \[0.41, 3.35\]
  3.6 Itching                                                        1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    1.0 \[0.26, 3.89\]
  3.7 Cough                                                          1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    1.0 \[0.14, 6.97\]
  3.8 Diarrhoea                                                      1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    0.0 \[0.0, 0.0\]
  3.9 Chills                                                         1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    1.5 \[0.26, 8.79\]
  3.10 Nausea                                                        1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    1.0 \[0.14, 6.97\]
  3.11 Constipation                                                  1                208                   Risk Ratio (M‐H, Fixed, 95% CI)    3.0 \[0.12, 72.80\]

![Analysis\
Comparison 12 Praziquantel versus artesunate, Outcome 1 Parasitological failure.](nCD000053-CMP-012-01){#CD000053-fig-01201}

![Analysis\
Comparison 12 Praziquantel versus artesunate, Outcome 2 Haematuria.](nCD000053-CMP-012-02){#CD000053-fig-01202}

![Analysis\
Comparison 12 Praziquantel versus artesunate, Outcome 3 Adverse events.](nCD000053-CMP-012-03){#CD000053-fig-01203}

###### Praziquantel and artesunate versus praziquantel

  Outcome or subgroup title                                                         No. of studies   No. of participants   Statistical method                Effect size
  --------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Parasitological failure at eight weeks](#CD000053-fig-01301){ref-type="fig"}   2                265                   Risk Ratio (M‐H, Fixed, 95% CI)   0.62 \[0.38, 0.99\]
  [2 Haematuria at eight weeks](#CD000053-fig-01302){ref-type="fig"}                1                177                   Risk Ratio (M‐H, Fixed, 95% CI)   0.69 \[0.40, 1.18\]
  [3 Adverse events](#CD000053-fig-01303){ref-type="fig"}                           1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Totals not selected
  3.1 Abdominal pain                                                                1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.2 Dizziness                                                                     1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.3 Headache                                                                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.4 Vomiting                                                                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.5 Fever                                                                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.6 Itching                                                                       1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.7 Cough                                                                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.8 Diarrhoea                                                                     1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.9 Chills                                                                        1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.10 Nausea                                                                       1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.11 Constipation                                                                 1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 13 Praziquantel and artesunate versus praziquantel, Outcome 1 Parasitological failure at eight weeks.](nCD000053-CMP-013-01){#CD000053-fig-01301}

![Analysis\
Comparison 13 Praziquantel and artesunate versus praziquantel, Outcome 2 Haematuria at eight weeks.](nCD000053-CMP-013-02){#CD000053-fig-01302}

![Analysis\
Comparison 13 Praziquantel and artesunate versus praziquantel, Outcome 3 Adverse events.](nCD000053-CMP-013-03){#CD000053-fig-01303}

###### Mefloquine versus placebo

  Outcome or subgroup title                                                       No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Parasitological failure at six weeks](#CD000053-fig-01401){ref-type="fig"}   1                44                    Risk Ratio (M‐H, Fixed, 95% CI)   0.57 \[0.40, 0.83\]

![Analysis\
Comparison 14 Mefloquine versus placebo, Outcome 1 Parasitological failure at six weeks.](nCD000053-CMP-014-01){#CD000053-fig-01401}

###### Praziquantel versus mefloquine

  Outcome or subgroup title                                                       No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Parasitological failure at one month](#CD000053-fig-01501){ref-type="fig"}   1                45                    Risk Ratio (M‐H, Fixed, 95% CI)   0.15 \[0.05, 0.43\]

![Analysis\
Comparison 15 Praziquantel versus mefloquine, Outcome 1 Parasitological failure at one month.](nCD000053-CMP-015-01){#CD000053-fig-01501}

###### Praziquantel versus artesunate and mefloquine

  Outcome or subgroup title                                                       No. of studies   No. of participants   Statistical method                Effect size
  ------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Parasitological failure at one month](#CD000053-fig-01601){ref-type="fig"}   1                44                    Risk Ratio (M‐H, Fixed, 95% CI)   0.23 \[0.07, 0.74\]

![Analysis\
Comparison 16 Praziquantel versus artesunate and mefloquine, Outcome 1 Parasitological failure at one month.](nCD000053-CMP-016-01){#CD000053-fig-01601}

###### Praziquantel versus praziquantel and albendazole

  Outcome or subgroup title                                          No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------ ---------------- --------------------- ---------------------------------- ---------------------
  [1 Parasitological failure](#CD000053-fig-01701){ref-type="fig"}   1                193                   Risk Ratio (M‐H, Random, 95% CI)   0.90 \[0.62, 1.30\]

![Analysis\
Comparison 17 Praziquantel versus praziquantel and albendazole, Outcome 1 Parasitological failure.](nCD000053-CMP-017-01){#CD000053-fig-01701}

###### Praziquantel versus praziquantel and artesunate

  Outcome or subgroup title                                                         No. of studies   No. of participants   Statistical method                Effect size
  --------------------------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  [1 Parasitological failure at eight weeks](#CD000053-fig-01801){ref-type="fig"}   2                265                   Risk Ratio (M‐H, Fixed, 95% CI)   1.62 \[1.01, 2.60\]
  [2 Haematuria at eight weeks](#CD000053-fig-01802){ref-type="fig"}                1                177                   Risk Ratio (M‐H, Fixed, 95% CI)   1.45 \[0.85, 2.50\]
  [3 Adverse events](#CD000053-fig-01803){ref-type="fig"}                           1                                      Risk Ratio (M‐H, Fixed, 95% CI)   Totals not selected
  3.1 Abdominal pain                                                                1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.2 Dizziness                                                                     1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.3 Headache                                                                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.4 Vomiting                                                                      1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.5 Fever                                                                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.6 Itching                                                                       1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.7 Cough                                                                         1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.8 Diarrhoea                                                                     1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.9 Chills                                                                        1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.10 Nausea                                                                       1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.11 Constipation                                                                 1                                      Risk Ratio (M‐H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]

![Analysis\
Comparison 18 Praziquantel versus praziquantel and artesunate, Outcome 1 Parasitological failure at eight weeks.](nCD000053-CMP-018-01){#CD000053-fig-01801}

![Analysis\
Comparison 18 Praziquantel versus praziquantel and artesunate, Outcome 2 Haematuria at eight weeks.](nCD000053-CMP-018-02){#CD000053-fig-01802}

![Analysis\
Comparison 18 Praziquantel versus praziquantel and artesunate, Outcome 3 Adverse events.](nCD000053-CMP-018-03){#CD000053-fig-01803}

Characteristics of included studies \[ordered by study ID\] {#CD000053-sec2-0024}
===========================================================

[Abden Abdi 1989 SOM](#CD000053-bbs2-0001){ref-type="ref-list"}MethodsRCT\
Diagnostics: egg excretion in a single, mid‐day urine sample, mixing an aliquot of 10 mL urine, filtration (nucleopore)\
Follow‐up at 1, 2, 3 and 6 monthsParticipantsChildren aged 11 to 12 years on average\
Number randomized 300\
Number analysed for primary outcome at one month 201, at six months 139\
Inclusion criteria: excreting 20 or more *S. haematobium* eggs per 10 mL urine\
Exclusion criteria: concomitant diseaseInterventions1. Metrifonate 3 x 7.5 mg/kg dose interval two weeks\
2. Metrifonate 3 x 5 mg/kg within one day\
3. PlaceboOutcomesCure rate\
Percentage egg reduction\
Adverse eventsNotesLocation: Somalia, southern part\
Setting: rural, five villages\
Endemicity: high\
Dates: not stated\
Source of funding: SAREC (Swedish agency for research cooperation with developing countries)\
Authors\' conclusion: Both metrifonate regimens have similar efficacy***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomized, randomly assigned, table of random numbers.Allocation concealment (selection bias)Low riskAll doses were kept in coded envelopes.Blinding of participants and personnel (performance bias)   All outcomesLow riskDouble blind, placebo controlled \"and the distributor of the drug and the participants were all blind to the type of treatment.\"Blinding of outcome assessment (detection bias)   All outcomesLow riskBlinding of the lab technician.Incomplete outcome data (attrition bias)   All outcomesHigh riskHigh loss to follow‐up, 33% at one month, 53% at six months, balanced between treatment armsSelective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias.[Al Aska 1990 SAU](#CD000053-bbs2-0002){ref-type="ref-list"}MethodsRCT\
Diagnostics: ova excretion in 10 mL midday urine after sedimentation\
Follow‐up: three and six monthsParticipantsAdult patients referred to hospital, age not stated. Saudi and Jemeni\
Number randomized: not reported\
Number analysed: 100\
Inclusion criteria: *S. haematobium* infection\
Exclusion criteria: none stated\
Co‐infection with *S. mansoni*Interventions1. Praziquantel 40 mg/kg single dose\
2. Metrifonate 10 mg/kg three doses in intervals of two weeksOutcomesCure rates\
Failure ratesNotesLocation: Saudi Arabia\
Setting: King Abdul Aziz University hospital, Riyadh. Patient referral\
Endemicity: not reported\
Dates: not stated\
Funding: not stated\
Authors\' conclusion: Metrifonate and praziquantel in the stated dosage are effective against *S. haematobium*, side effectives are minor and transient***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"allocated randomly\".Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot mentioned, no placebo mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up not reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskFew baseline characteristics reported.[Basra 2012 GAB](#CD000053-bbs2-0003){ref-type="ref-list"}MethodsRCT\
Diagnostics: Ova excretion, microscopy in 10 mL urine after filtration, AMEC\
Follow‐up: six weeksParticipantsPregnant women attending ANC clinics, aged 19 to 25 years\
Number randomized 65\
Number analysed 44\
Inclusion criteria: *S. haematobium* infection, pregnancy\
Exclusion criteria: intake of antihelminthic and antimalarial drug within the previous two months, HIV posInterventions1. Praziquantel 40 mg/kg single dose\
2. Metrifonate 10 mg/kg two doses, dose interval two weeksOutcomesCure rates\
Failure rates\
Egg counts at baseline, four and six weeksNotesLocation: Gabon\
Setting: two ANC health care centres\
Endemicity: highly endemic for *S. haematobium* and malaria\
Dates: Sept 2009 to Dec 2011\
Funding: European and Developing Countries Clinical Trial Partnership (EDCCTP), Malaria in Prengnancy consortium, Karl Landsteiner Gesellschaft\
Authors\' conclusion: Mefloquine IPTp is effective against *S. haematobium* in pregnant women.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe randomizations list was computer‐generated and provided by the independent MIPPAD trial management team.Allocation concealment (selection bias)Low riskTrial assignment was concealed via sealed opaque envelopes which were opened only after enrolment of a patient by a trial investigator.Blinding of participants and personnel (performance bias)   All outcomesHigh riskOpen‐label.Blinding of outcome assessment (detection bias)   All outcomesLow riskBlinding of outcome assessors.Incomplete outcome data (attrition bias)   All outcomesHigh riskHigh loss to follow‐up, unbalanced (in the intervention group 18/48 = 37.5%, in the control group 3/48 = 6.25%) reasons partly stated.Selective reporting (reporting bias)Low riskNo evidence of selective outcome reporting.Other biasLow riskNo risk of other bias.[Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}MethodsRCT\
Diagnostics: urine sample preserved with 5 mg sodium azide, sedimentation for one hour, examination of sediment, egg count\
Follow‐up: six months (as only time point)ParticipantsMale primary school students, aged six to 15 years\
Number randomized 653, 436 in groups of interest for this review\
Exclusion: heavy *S. haematobium* infections (\> 499 eggs/10 mL)\
Inclusion: positive for *S. haematobium*Interventions1. Praziquantel 40 mg/kg single dose\
2. PlaceboOutcomesGeometric mean egg counts\
Weight\
Height\
Height for age\
Weigth for age\
Weight for height\
MUAC\
Triceps skinfold thickness\
Mean muscle mass\
Hb (reported in a separate publication Befidi Mengue 1993, see reference [Befidi Mengue 1992 CMR](#CD000053-bbs2-0004){ref-type="ref-list"}) with slightly higher numbers of participants: 771 randomized, 518 in treatment groups of interest of this review).NotesLocation: Cameron, Eastern Province, Bertuoa\
Setting: urban (capital city of Eastern province), primary school\
Endemicity: polyparasitism is common\
Dates: not reported\
Funding: USAID Cameroon health constraints to rural production project 1608 ‐ 1408\
Authors\' conclusion: only demonstrable effect of a single praziquantel treatment on MUAC***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly assigned, method not stated.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe placebo tablets were physically identical to the praziquantel tablets.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot stated.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up unclear, as numbers followed up not reported.Selective reporting (reporting bias)Low riskNo evidence for selective reporting.Other biasLow riskNo evidence for other bias.[Borrmann 2001 GAB](#CD000053-bbs2-0005){ref-type="ref-list"}MethodsRCT\
Diagnostics: two urine samples. filtration of 10 mL of urine through polycarbonate filters (Millipore), staining with Trypan blue\
Follow‐up at day 56 (as only time point)ParticipantsSchool children aged six to 15 years\
Participants randomized: 300\
Inclusion: *S. haematobium* positive, asymptomatic *S. haematobium* infection\
Exclusion: symptomatic schistosomiasis, recent schistosomiasis treatment, serious underlying disease, pregnancy or lactation, anaemia (Hb \< 7 G/dL)Interventions1. Praziquantel 40 mg/kg single dose\
2. Artesunate 4 mg/kg once daily for three days\
3. Artesunate 4 mg/kg once daily for three days and praziquantel 40 mg/kg single dose\
4. PlaceboOutcomesCure rates\
Failure rates\
Egg reduction rates\
Microhaematuria\
(Adverse events day seven)NotesLocation: Gabon, province Moyen Ogone\
Setting: rural villages\
Endemicity: high (prevalence 80% in school children)\
Dates: Oct. 2000 to Feb 2001\
Funding: tablet donation Sanofi (Artesunate), Medochemie (Praziquantel)\
Authors\' conclusions: Efficacy of artesunate for *S. haematobium* treatment as single medication or in combination is low.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe randomization code was generated by computer.Allocation concealment (selection bias)Low riskThe trial drugs were prepared in plastic bags, which were labelled sequentially with treatment numbers according to the randomization code.Blinding of participants and personnel (performance bias)   All outcomesLow riskDouble blind.\
Praziquantel placebo and artesunate placebo were identical in appearance to the respective active substance tablets.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesLow riskLow loss to follow‐up (7.6%).Selective reporting (reporting bias)Unclear riskHaemoglobin measurements, proteinuria and leucocyturia at day 56 not reported.Other biasLow riskNo evidence for other bias.[Davis 1981 ZMB](#CD000053-bbs2-0006){ref-type="ref-list"}MethodsRCT\
Diagnostics: three successive daily schistosome egg counts made on a random 10 mL urine sub sample of the total bladder content by a filtration staining technique; quantitative hatching technique (enumeration of miracidia, recently dead eggs and black eggs)\
Follow‐up: three consecutive daily urine samples, quantitative hatching test\
Follow‐up: at 1, 3, 7, 12 and 24 monthsParticipantsSchool children aged seven to 17 years\
Number followed up after one month 151, number randomized not reported\
Inclusion: *S. haematobium* positive\
Exclusion: pregnant or lactating women, no serious acute coexistent diseases or complications, no other treatment during the past six months, older than six yearsInterventions1. Praziquantel 30 mg/kg single dose\
2. Praziquantel 40 mg/kg single dose\
3. Praziquantel 20 mg/kg 2 x dailyOutcomesCure rate\
Failure rateNotesLocation: Zambia, Ndola\
Setting: eight rural schools\
Dates: not reported\
Endemicity: high\
Funding: Parasitic Disease Programme for Research and Training in Tropical diseases\
Authors\' conclusion: treatment groups clinically and statistically comparable***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomly assigned, random number table.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesLow riskSingle blind technique.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesLow riskLow loss to follow‐up (3.7% to 6%) at 1, 3 and 7 months.Selective reporting (reporting bias)Low riskNo evidence of selective reporting (some investigations at baseline not reported).Other biasLow riskNo evidence of other bias.[de Jonge 1990 SDN](#CD000053-bbs2-0007){ref-type="ref-list"}MethodsRCT\
Diagnostics: urine collection after 250 mL soda drink at midday. Trypan blue staining technique (if the egg concentration was less than 10 eggs per 10 mL urine, the whole volume (up to 350 mL) was filtered).\
Follow‐up one and five monthsParticipantsMale primary school children aged six to 11 years\
Patients randomized 160, participants randomized into treatment groups of interest for this review: 107\
Inclusion: co‐infection with *S. haematobium* and *S. mansoni*\
Exclusion: not reportedInterventions1. Praziquantel 40 mg/kg single dose\
2. Metrifonate 2 x 10 mg/kg, dose interval 14 weeks\
3. Oxaminique 60 mg/kg single dose\
4. Multivitamin single doseOutcomesFailure\
Egg countNotesLocation: Sudan Gezira\
Setting: rural, village primary schools\
Funding: Science and Technology for Development, EC, WHO, UNDP, World bank, Special Programme for Training & Research. Gesellschaft für technische Zusammenarbeit\
Dates: not reported\
Endemicity: high for both *S. mansoni* and *S. haematobium*\
Authors\' conclusion: discussion of correlation of parasitological outcomes and CAA titres***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"randomly divided\".Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskMultivitamin as placebo, but blinding not mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesHigh riskLoss to follow‐up high, at one months up to 23%, at five months up to 28%.Selective reporting (reporting bias)Low riskNo evidence for selective reporting.Other biasLow riskNo evidence for other bias.[Inyang Etoh 2009 NGA](#CD000053-bbs2-0008){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of two urine samples at midday (12.00 to 14.00) after exercise on two consecutive days, agitation of urine sample, preservation of eggs, staining (1% aqueous solution, carbol fuchsin), filtration, egg counts\
Follow‐up at eight weeks (as only time point)ParticipantsSchool children aged four to 20 years (nursery school, primary and junior secondary schools, students)\
Number randomized 260 children into five groups\
Inclusion: healthy, able to swallow the medication\
Exclusion: serious underlying disease, recent treatment for schistosomiasis, \> 20 yrs, \< 4 yrs oldInterventions1. Praziquantel 40 mg/kg single dose and placebo\
2. Praziquantel 40 mg/kg single dose only\
3. Artesunate 4 mg/kg 1 x daily for three days and placebo\
4. Artesunate 4 mg/kg 1 x daily for three days only\
5. Praziquantel 40 mg/kg single dose and artesunate 4 mg/kg 1 x daily for three days\
6. Placebo and placeboOutcomesCure\
Egg counts and egg reduction rate\
Haematuria\
ProteinuriaNotesLocation: Nigeria, Adim community, Cross RIver State\
Setting: school students\
Dates: August 2005 to June 2006\
Endemicity: seasonal transmission\
Funding: partly funded by the management of the University of Calabar\
Authors\' conclusion: both praziquantel and artesunate in the stated doses are safe, well‐tolerated and effective in the trial area. Combined treatment is more effective and single treatment with any of the drugs.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"randomised\".Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskPlacebo not identical in appearance.\
Blinding not mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up of 15.4% and 19.2% at day 56.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias.[Jewsbury 1976 ZWE](#CD000053-bbs2-0009){ref-type="ref-list"}MethodsRCT\
Diagnostics: three urine samples on three consecutive days, determination of egg counts and cure rates\
Follow‐up at week 11 and week 36ParticipantsChildren, aged three to 15 years (and older)\
Number of children randomized: 179\
Number of children analysed 114 (complete case analysis)\
Inclusion: *S. haematobium* positive\
Exclusion: not reportedInterventions1. Metrifonate 7.5 mg x 3, dose interval two weeks\
2. Control: no interventionOutcomesCure rate\
Failure rate\
Median urine egg countsNotesLocation: Zimbabwe near Salibury\
Setting: rural, four farms\
Dates: not reported\
Endemicity: high (pre‐infection rate with *S. haematobium* 80%)\
Funding: Drug donation by Bayer\
Authors\' conclusion: Metrifonate is safe and effective for the treatment of *S. haematobium****Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"randomised\".Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesHigh riskParticipant numbers not reported at week 11, high loss to follow‐up of 46% at week 36.Selective reporting (reporting bias)Unclear riskData of week 11 not reported.Other biasHigh riskBaseline imbalance; for the infected, untreated control group, an infection rate of 89.4% is given at baseline.[Kardaman 1985 SDN](#CD000053-bbs2-0010){ref-type="ref-list"}MethodsRCT\
Diagnostics: centrifugation, sediment taken for egg counts\
Follow‐up at five weeks and three monthsParticipantsSchool children aged seven to 11 years\
Number of children included: 237\
Inclusion: co‐infection *S. haematobium* and *S. mansoni*\
Exclusion: receiving medication for any other infection, treatment for schistosomiasis during the preceding 6 months.Interventions1. Praziquantel 40 mg/kg single dose\
2. Praziquantel 2 x 20 mg/kg in one day, dose interval four to six hoursOutcomesCure\
Failure\
Adverse eventsNotesLocation: Sudan, Galaga Village\
Setting: rural, primary schools\
Dates: not reported\
Endemicity: high (mixed infections common)\
Funding: Parasitic disease programme, WHO\
Authors\' conclusion: Results of two regimens not significantly different. Treatment for this setting has to be repeated every six months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly assigned.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesLow riskLoss to follow‐up at five weeks up to 4.7%, at three months up to 8.4%.Selective reporting (reporting bias)Low riskNo evidence for selective reporting.Other biasLow riskNo evidence for other bias.[Keiser 2010 CIV](#CD000053-bbs2-0011){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of two urine specimen at midday (10.00 to 14.00), samples were rigorously shaken, filtration of 10 mL through a 13 mL filter with 25 µm diameter\
Follow‐up at 26 daysParticipantsSchool children aged eight to 12 years\
Participants randomized 83\
Inclusion: confirmed *S. haematobium* infection\
Exclusion: not reportedInterventions1. Praziquantel 40 mg/kg single dose\
2. Mefloquine 25 mg/kg single dose\
3. Artesunate 4 mg/kg 1 x daily for three days\
4. Artesunate 3 x 100 mg and mefloquine 250 mgOutcomesCure rates\
Failure rate\
Egg count\
Egg reduction rate\
Adverse effectsNotesLocation: Cote d\' Ivoire, district Agboville\
Setting: rural, school children\
Dates: November to December 2009\
Funding: support Dafra Pharma, Mepha for drug donations\
Endemicity: highly endemic, 40% among school children\
Authors\' conclusion: High cure rates with praziquantel, promising results for mefloquine ‐ artesunate (in the standard dose for malaria)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"using a computer generated randomisation code\". Seven children were added to one treatment group in a non‐randomized manner.Allocation concealment (selection bias)High riskNot implemented (email correspondence with author).Blinding of participants and personnel (performance bias)   All outcomesHigh riskOpen label.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesLow riskNo loss to follow‐up during the trial (day 26).Selective reporting (reporting bias)Low riskUrinary findings day 26 not reported (not available, email correspondence with author).Other biasLow riskNo evidence of other sources of bias.[King 1989 KEN](#CD000053-bbs2-0012){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of midday urine sample (10.00 to 13.00), urine filtration technique with nucleopore filters, egg count\
Follow‐up at two to three monthsParticipantsPrimary school students aged five to 17 years and adult participants over 20 years\
Number of patients randomized 280 (34 adults, 246 children)\
Inclusion: egg count \> 50 eggs/10 mL urine\
Exclusion: not reportedInterventions1. Praziquantel 10 mg/kg single dose\
2. Praziquantel 20 mg/kg single dose\
3. Praziquantel 30 mg/kg single dose\
4. Praziquantel 40 mg/kg single doseOutcomesCure\
Egg counts\
Severity of infection\
Proteinuria\
HaematuriaNotesLocation: Kenya, Kwale district\
Setting: rural, primary schools\
Dates: not reported\
Endemicity: high\
Funding: Edna McConnell Clark Foundation\
Authors\' conclusion: low dose (20 mg/kg) is as effective as standard dose (40 mg/kg) of praziquantel (reductions in parasite burden and morbidity) for population based control programmes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom allocation, pre‐randomized cards.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesHigh riskClinicians not blinded to the intervention.Blinding of outcome assessment (detection bias)   All outcomesLow riskOutcome assessors and laboratory staff blinded to the intervention.Incomplete outcome data (attrition bias)   All outcomesLow riskLoss to follow‐up at two to three months 9% to 14%, balanced between groups.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence for other sources of bias.[King 1990 KEN](#CD000053-bbs2-0013){ref-type="ref-list"}MethodsRCT\
Diagnostics: sample collection of midday urine (10.00 to 13.00), nucleopore filtration, egg counts\
Follow‐up at one, two and three yearsParticipantsPrimary school children aged four to 21 years\
Number randomized 1813\
Inclusion: *S. haematobium* positive\
Exclusion: not reportedInterventions1. Praziquantel 40 mg/kg single dose once a year\
2. Metrifonate 10 mg/kg single dose three times a year, dose interval four monthsOutcomesHaematuria\
Proteinuria\
Ultrasound (hydronephrosis, bladder thickening, bladder deformity)NotesLocation: Kenya, Coast Province, Kwale Province, Msambweni Area\
Setting: rural, primary schools, nine villages\
Dates: 1984\
Endemicity: high (prevalence in school children 60% to 85%)\
Funding: Edna McConnell Clark Foundation, WHO, Rockefeller Foundation\
Authors\' conclusion: Both regimens had significant effects on the prevalence of hematuria, proteinuria, and bladder abnormalities. no significant differences between the two drugs. No effect on hydronephrosis at twelve months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom allocation with pre‐randomized cards.Allocation concealment (selection bias)High risk\"Treatment allocation was not concealed to the investigators\" (email correspondence with author).Blinding of participants and personnel (performance bias)   All outcomesHigh riskBlinding of participants (different taste and appearance of commercially purchased drugs) email response).\
no blinding of cliniciansBlinding of outcome assessment (detection bias)   All outcomesLow riskEvaluators were effectively blinded to the treatment status of the children they were testing (email correspondence with author).Incomplete outcome data (attrition bias)   All outcomesUnclear riskUnclear.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias.[King 2002 KEN](#CD000053-bbs2-0014){ref-type="ref-list"}MethodsRCT\
Diagnostics: Collection of two mid‐day (10:00 to 14:00) on different days, filtration, Nucleopore) Intensity of infection assigned according to the highest one day egg count in the repeated daily testing.\
Follow‐up at six weeks and nine monthsParticipantsSchool children and adults, aged four to 23 years\
Number of participants randomized 291\
Inclusion: *S. haematobium* positive\
Exclusion: not reportedInterventions1. Praziquantel 40 mg/kg single dose\
2. Praziquantel 20 mg/kg single doseOutcomesCure\
Egg count\
Ultrasound findings (Hydronephrosis, bladder thickening and bladder irregularity)NotesLocation: Kenya, Coastal Province, Kwale District\
Setting: rural, village schools\
Dates: 1992 to 1993\
Endemicity: high\
Funding: WHO, TDR, Rockefeller Foundation Joint Funding Venture and National Institutes of Health\
Authors\' conclusion: Praziquantel 20 mg and praziquantel 40 mg are equally effective in reducing structural urinary tract morbidity over nine months. A praziquantel dose of 20 mg/kg may be sufficient for practical control of renal and bladder morbidity due to *S. haematobium* in certain settings: not reported\
(trial might be underpowered for ultrasound findings).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Infected students were then individually randomised to therapy\...by computer random number generation.\"Allocation concealment (selection bias)High riskAllocation was not concealed.Blinding of participants and personnel (performance bias)   All outcomesHigh riskNo blinding of personnel: \"Dosing assignment lists were transmitted to clinical staff responsible for treatment\".Blinding of outcome assessment (detection bias)   All outcomesLow riskBlinding of outcome assessors (clinicians, parasitologists).\
\"Assignments were masked form staff parasitologists and physicians responsible for follow‐up until the end of the study.\"Incomplete outcome data (attrition bias)   All outcomesHigh riskLoss to follow‐up 31% at six weeks.Selective reporting (reporting bias)Low riskNo evidence of selective outcome reporting.Other biasLow riskImportant baseline characteristics (egg counts) not reported at baseline.[McMahon 1979 TZA](#CD000053-bbs2-0015){ref-type="ref-list"}MethodsRCT\
Diagnostics: Collection of three midday (10.00 to 13.00) urine samples on three consecutive days, sedimentation in a conical flask for 30 mins, taking of a 10 mL sample of the bottom of the flask, centrifugation and processing of the deposit 5 mL boiled, cooled water added to deposit, miracidia hatching test, fixing and staining of miracidia (alcohol and eosin), microscopy and count.\
Follow‐up at one, three and six months.ParticipantsSchool children aged seven to 15 years\
No. of children randomized: 138\
Inclusion: *S. haematobium* positive\
Exclusion: not reportedInterventions1. Praziquantel 30 mg/kg single dose\
2. Praziquantel 40 mg/kg single dose\
3. Praziquantel 2 x 20 mg in one day, dose interval four hours\
4. PlaceboOutcomesCure\
Egg counts\
Adverse effectsNotesLocation: Tanzania, Tanga region\
Setting: school, rural area\
Endemicity: high, transmission may vary greatly form year to year and season to season.\
Dates: not reported\
Funding: MRC/WHO/Tanzania Helminthiasis Research Unit, Tanga\
Authors\' conclusion: Praziquantel in the given doses is not toxic. Praziquantel 40 mg did not affect the therapeutic response in children with large egg loads.\
As cure rates are influenced by pre‐treatment egg loads, trials of higher doses in patients with high egg loads needed.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomly sub‐divided into four groups according to previously arranged blocks.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up 10% to 15% at 1, 3 and 6 months.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskBaseline characteristics not reported.[McMahon 1983 TZA](#CD000053-bbs2-0016){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of two midday (10.00 to 14.00) samples on two consecutive days for initial diagnosis, of three samples for follow‐up), quantitative hatching technique, sedimentation of 10 mL urine\
Follow‐up at two and four monthsParticipantsSchool children and adults\
Number of participants randomized: 90\
Inclusion: 250 miracidia/10 mL urine\
Exclusion: not reportedInterventions1. Praziquantel 30 mg/kg single dose\
2. Metrifonate 10 mg/kg 1 x daily, dose interval 14 days\
3. Niridazole 25 mg/kg 1 x daily for six days, dose interval one dayOutcomesCure rates\
Egg reduction rates\
Adverse effectsNotesLocation: Tanzania, Tanga region\
Setting: not stated\
Endemicity: high\
Dates: not reported\
Funding: MRC/WHO/Tazania Helminthiasis Research unit, Tanga, Biltricide (Praziqantel) was supplied by Bayer.\
Authors conclusion: Praziquantel was more effective than metrifonate and niridazole. Side effects were minor.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly allocated.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesHigh riskNot mentioned; use of different regimens, no use of placebo.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesHigh riskLoss to follow‐up partly high, not balanced (at four months 0% in the praziquantel group, 26% in the metrifonate and 30% in the niridazole group.Selective reporting (reporting bias)Unclear riskNo evidence of selective reporting.Other biasLow riskFew baseline characteristics reported.[Mott 1985 GHA](#CD000053-bbs2-0017){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection or one urine sample, two random samples out of this urine sample were processed. quantitative urine filtration technique\
Follow‐up at three and six monthsParticipantsResidents \"entire population of five settlements\", aged six years or older\
Number of people randomized 266\
Inclusion: *S. haematobium* infected\
Exclusion: pregnancy, alcoholism, severe debilitating diseaseInterventions1. Praziquantel 30 mg/kg single dose\
2. Praziquantel 40 mg/kg single doseOutcomesCure rate\
Egg count, egg reduction rate\
(Urinary results not reported by treatment group)NotesLocation: Ghana, Lake Volta\
Setting: rural, five settlements\
Dates: not reported\
Endemicity: not reported\
Funding: Parasitic Diseases Programme WHO/UNDP/Wold bank/ WHO Special Programme for Research and Training in Tropical diseases\
Authors\' conclusions: Similar efficacy of Praziquantel 30 mg and 40 mg in this trial. Praziquantel reduces clinical signs (macrohaematuria) and morbidity in urinary schistosomiasis***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly assigned.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesLow riskLoss to follow‐up at six months 11.6%.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskBaseline characteristics not reported per group.[Olds 1999 KEN](#CD000053-bbs2-0018){ref-type="ref-list"}MethodsRCT\
Diagnostics: Eggs from 2 x 10 mL samples were filtered on membranes (Nucleopore)\
Follow at 45 days, 90 days, six months and one yearParticipantsSchool children aged four to 18 years\
Number of participants pos for *S. haematobium*: 380\
Inclusion: *S. haematobium* positive\
Exclusion: pregnancy or marriage, failure to submit two stool specimens prior to initial therapy, known allergy to praziquantel or albendazole, treatment within the past six monthsInterventions1. Praziquantel 40 mg/kg single dose and albendazole 400 mg single dose\
2. Praziquantel 40 mg/kg single dose and placebo\
3. Albendazole 400 mg single dose and placebo\
4. Placebo and placeboOutcomesCure\
Egg count\
Ultrasound\
Weight, height, skinfold thickness, MUAC\
Hb\
Adverse effectsNotesLocation: Kenya, Kwale District, Coast province for *S. haematobium* (multi centre trial for different *Schistosoma* species, conducted in different countries)\
Setting: rural\
Endemicity: endemic ascariasis, hookworm, trichuris, *S. haematobium*\
Dates: not reported\
Funding: WHO/TDR Tropical disease research\
Authors\' conclusion: Combined mass treatment of children with albendazole and praziquantel produced not more side effects than treatment with praziquantel alone.\
Combined mass treatment should have an important impact on schistosoma and hookworm prevalence and intensity and improves Hb levels.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomized in one of four treatment groups, block design with block size of 80.Allocation concealment (selection bias)Low riskRandomization lists were prepared by WHO/TDR using a randomized block design.Blinding of participants and personnel (performance bias)   All outcomesLow riskDouble blind, placebo controlled; physically identical placebo.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesLow riskLoss to follow‐up 10% at six months, loss to follow‐up 17% at one year (for all groups).Selective reporting (reporting bias)High riskHb values, proteinuria, hematuria, ultrasound findings not reported.Other biasLow riskNo evidence for other bias.[Omer 1981 SDN](#CD000053-bbs2-0019){ref-type="ref-list"}MethodsRCT\
Diagnosis: sedimentation concentration technique, miracidial hatching\
Follow‐up at seven days, one month, three to four months, six monthsParticipantsPatients presenting to the Hospital of Tropical diseases, Karthoum, aged eight to 16 years\
Number of patients randomized: 152\
Inclusion: mixed *S. haematobium* and *S. mansoni* infections\
Exclusion: under eight years of age, advanced stage of disease, severe anaemia, poor general healthInterventions1. Praziquantel 30 mg/kg single dose\
2. Praziquantel 40 mg/kg single dose\
3. Praziquantel 2 x 20 mg/kg within one dayOutcomesCure rates\
Egg counts\
Adverse events\
Laboratory parameters at day 0 or 1 and at day 1 or 2, not of interest for this reviewNotesLocation: Sudan, Karthoum\
Setting: Hospital of Tropical Diseases, Karthoum\
Endemicity: not reported\
Dates: 1978 to 1979\
Funding: not reported\
Authors\' conclusion: Praziquantel is easily applicable, safe and effective in the treatment of mixed (*S. haematobium* and *S. mansoni*) infections***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomized.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskSingle blind.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up at six months 17% to 22%, balanced.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias.[Oyediran 1981 NGA](#CD000053-bbs2-0020){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of a midday urine sample (12.00 to 2.00), taking a 10 mL sub sample, filtration of the urine, staining with Ninhydrin, counting of the eggs retained on the filter paper\
Follow‐up at one, three and six monthsParticipantsPrimary school children aged nine to 16 years\
Participants randomized: 90\
Inclusion criteria: mean egg count 80 eggs/10 mL, viable eggs, aged over six years\
Exclusion criteria: under six years, concurrent acute or serious illness, antischistosomal treatment within the past six monthsInterventionsPraziquantel 30 mg/kg single dose\
Praziquantel 40 mg/kg single dose\
Praziquantel 2 x 20 mg/kg, dose interval three to four hours\
PlaceboOutcomesEgg countsNotesNigeria, Oyo State\
Setting: Primary Schools\
Dates: not reported\
Funding: not reported\
Authors\' conclusion: No significant difference in efficacy between the three dosage regimens, trials on the effects of lower doses required.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskTable of random numbers.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskPlacebo single dose\
The treatment group received a split dose of praziquantel, blinding not mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesHigh riskHigh loss to follow‐up, not balanced (at one month 4 to 17%, at three months 17 to 23%, at six month 26 to38%, at twelve months 76% to 87%).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias.[Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of two midday urine samples on two consecutive days filtration, staining and egg count\
Follow‐up at one, three and six months. Further follow‐up reported at nine, 12, 15 and 24 months in a separate publication ([Pugh 1983 MWI](#CD000053-bbs2-0021){ref-type="ref-list"})ParticipantsSchool children aged five to 18 years\
Number of participants randomized: 499\
Inclusion: mean egg count (*S. haematobium*) \> 19/10 mL\
Exclusion: malaise, febrile illness, treatment with schistosomacidal drugs in the past six monthsInterventions1. Praziquantel 40 mg/kg single dose\
2. Niridazole 25 mg/kg single dose and metrifonate 10 mg/kg single dose\
3. Metrifonate 10 mg/kg single dose\
4. Niridazole 25 mg/kg single dose\
5. PlaceboOutcomesCure\
Geometric mean egg counts\
Egg reduction ratesNotesLocation: Malawi, Pirimiti Area, Phalombe plain\
Setting: rural\
Endemicity: seasonal\
Funding: Overseas Development Administration, U.K. MoH Malawi. Praziquatel supplied by Bayer\
Authors\' conclusion: Praziquantel is superior to the other drugs studied in this trial, it is the most efficient and convenient drug available. Maintained low egg output at 24 months was presumably influenced by low levels of transmission during the second year of the trial, which was very dry.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskUse of a randomized x‐y list.Allocation concealment (selection bias)Low risk\"An independent worker had sole and confidential access to a randomised x‐y list.\"Blinding of participants and personnel (performance bias)   All outcomesLow riskDescribed as double blind.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up low at one months: 0% to 4.1%, at three months 8% to 11% in treatment groups, up to 23% in the placebo group; at six months 20% in the treatment group. Loss to follow‐up high at 24 months, about 40% to 70 %.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasHigh riskBaseline imbalance in terms of intensity of infection.\
\"In accordance to with local ethical guidelines the placebo group consisted only of children with light (20‐124 ova/10mL or moderate (125 to 4999 ova/10 mL) infections before treatment. Important baseline characteristics not reported (age, weight).[Rey 1983 NER](#CD000053-bbs2-0022){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of two urine samples, filtration (Swinex 13 Filter Millipore, 13 mm diameter), fixation and staining (Lugol), egg counts\
Length of follow‐up: one, three and six monthsParticipantsParticipants: recruits aged 18 to 20 years and college students aged 15 to 19 years\
Number of participants randomized: 207\
(co‐infection with *S. mansoni* likely, but not investigated)\
Inclusion: *S. haematobium* positive\
Exclusion: not reportedInterventions1. Praziquantel 30 mg/kg daily dose\
2. Praziquantel 40 mg/kg daily dose\
3. Oltipraz 17.5 mg/kg 2 x daily in one dayOutcomesFailure\
Egg reduction ratesNotesLocation: Niger\
Setting: not reported\
Endemicity: not reported\
Dates: not reported\
Funding: not reported\
Authors\' conclusion: No significant difference found between praziquantel 30 mg/kg and praziquantel 40 mg/kg.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomized, tirage au sort.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNot mentioned, no use of placebo.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up acceptable at one month (9% to 15%) and three months 9% to 11%, high at six months (39% to 47%).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskBaseline characteristics not reported.[Rey 1984 NER](#CD000053-bbs2-0023){ref-type="ref-list"}MethodsRCT\
Diagnostics: urine filtration, normal filtration paper, egg counts (no further details given)\
Follow‐up for children (aged five to 15 years) at 1, 5 and 6 months, for adults (\> 15 years) at six months onlyParticipantsChildren older than five years and adults\
Participants treated and controlled: 268 randomized, 143 participants at one month, randomized\
Inclusion: not reported\
Exclusion: not reportedInterventions1. Metrifonate 10 mg/kg single dose\
2. Metrifonate 10 mg/kg two doses with a dose interval of two weeks\
3. Metrifonate 10 mg/kg three doses with a dose interval of two weeksOutcomesCure rate\
Egg reductionNotesLocation: Niger, near Niamey\
Setting: not reported\
Endemicity: high, the trial was conducted in the season of low transmission\
Dates: not reported\
Funding: not reported\
Authors\' conclusions: Recommendation against the combined metrifonate niridazole treatment.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"au hasard \", random number table.Allocation concealment (selection bias)Unclear riskNo comment.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNo comment.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNo comment.Incomplete outcome data (attrition bias)   All outcomesHigh riskLoss to follow‐up high: at one month 50%, at four months 39%.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias, funding not stated.[Sacko 2009 MLI](#CD000053-bbs2-0024){ref-type="ref-list"}MethodsRCT\
Diagnostics: Collection of three urine samples between 10 am and 2 PM on three consecutive days. 10 mL of urine passed through a nucleopore filter, Swinnex filter support. Egg counts.\
Follow‐up at 3, 6 and 18 monthsParticipantsSchool children aged seven to 14 years\
Number of participants randomized: 603\
Inclusion: not reported\
Exclusion: not reportedInterventionsPraziquantel 40 mg/kg single dose\
Praziquantel 40 mg/kg two doses, interval two weeksOutcomesCure rate\
Egg reduction\
HaematuriaNotesLocation: Mali, Niger River Basin\
Setting: rural, primary schools\
Endemicity: not reported\
Dates: not reported\
Funding: not reported\
Authors\' conclusion: Significantly reduced prevalence of microhematuria with praziquantel x 2, this could indicate reduction of morbidity***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomized (SPSS generated random number tables).Allocation concealment (selection bias)Low riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesLow riskDouble blind, placebo‐controlled.\
Placebo tablets were of the same form and colour as praziquantel.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up unclear, as number randomized were not reported, only the numbers at first follow‐up at three months.Selective reporting (reporting bias)Low riskFollow‐up data at six and 18 months reported in graphs, not in numbers.Other biasLow riskNo evidence for other bias.[Stephenson 1985 KEN](#CD000053-bbs2-0025){ref-type="ref-list"}MethodsRCT\
Diagnostics: nucleopore filter method of Peters and others\
collection of a midday urine sample (complete bladder content, 11.00 to 12.00) after 200 mL of fruit drink, nucleopore filter method of Peters and others, staining with 0.5 trypan blue, egg counts in 10 mL of urine adjusted for the total volume of each urine specimen\
Follow‐up for six monthsParticipantsPrimary school children aged six to 16 years\
Number of participants randomized: 400\
Inclusion: light to moderate *S. haematobium* infections at exam 1\
Exclusion: not reportedInterventions1. Metrifonate 7.5 mg/kg three doses, dose interval one to two weeks\
2. Placebo: gelatin capsulesOutcomesParasitological failure and cure\
Egg counts\
Egg reduction rate\
Haemoglobin\
Anthropometric measures weight, height, weight for height, middle upper arm circumference, triceps and subscapular skinfold thickness\
Liver size\
Spleen sizeNotesLocation: Kenya, Kwale District, Coast Province\
Setting: rural, four primary schools\
Endemicity: highly endemic\
Dates: not reported\
Funding: not reported\
Authors\' conclusion: *S. haematobium* infections can precipitate or aggravate anaemia in vulnerable children (poor iron intake, high endemicity of other parasites). *S. haematobium* treatment improves Hb levels.\
*S. haematobium* treatment may improve child growth (in populations were hookworm infections and Protein Energy Malnutrition is common). *S. haematobium* treatment may be associated with regression of splenomegaly and hepatomegaly in children treated for *S. haematobium* infection. Population‐based treatment is recommended.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskAllocated at random.Allocation concealment (selection bias)Unclear riskNot described.Blinding of participants and personnel (performance bias)   All outcomesLow riskUse of placebo.Blinding of outcome assessment (detection bias)   All outcomesLow riskExaminations 1 and 2 were carried out in a blind fashion with the same team of workers.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up unclear, as results were reported as proportions.Selective reporting (reporting bias)Low riskNo evidence of selective outcome reporting.Other biasLow riskNo evidence of other sources of bias.[Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of a midday urine sample (complete bladder content, 11.00 to 12.00) after 200 mL of fruit drink, nucleotome filter method of Peters and others, staining with 0.5 trypan blue, egg counts in 10 mL of urine adjusted for the total volume of each urine specimen\
Follow‐up at eight months (as only time point)\
Latham 1990, a sub‐study nested within [Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}, followed up patients at five weeks (as only time point)ParticipantsPrimary school children, 98% Muslim of the Wadigo tribe, aged eight to 13 years\
Number of participants randomized: not reported\
Number of participants analysed: 312\
Inclusion: light to moderate infections\
Exclusion: anaemia (Hb \< 8 G/dL, severe infections)\
Latham 1990 included 48 boys aged seven to 15 years with no sign of puberty, high egg counts, Hb \> 8 G/dL, cooperation for physical fitness testInterventions1. Praziquantel 40 mg/kg single dose\
2. Metrifonate 10 mg/kg single dose\
3. Placebo\
As a nested study, Latham had the same study arms.OutcomesParasitological failure\
Egg counts (geometric and arithmetic)\
Anthropometric measurements: weight, height, MUAC, triceps skinfold thickness, subscapular skinfold thickness,\
Haemoglobin\
Liver size\
Spleen size\
Latham 1990 (reference see [Stephenson 1989 KEN](#CD000053-bbs2-0026){ref-type="ref-list"}) reports parasitological failure, egg reduction rate and anthropometric measures: weight, height, skinfold thickness, MUAC at five weeks at five weeks, and additionally reports on\
Physical fitness: Harvard Step test,\
Appetite (quantity of porridge consumed)\
Questionnaire of clinical symptomsNotesLocation: Kenya, Kwale district, Coast Province\
Setting: rural, primary schools\
Endemicity: endemic for *S. haematobium*, hookworm and malaria\
Dates: March 1986 to April 1986\
Funding: Edna McConnell Clark Foundation, grant 284‐0120\
Authors\' conclusion: Both metrifonate and praziquantel are effective in reducing egg excretion and are both recommended for population based treatment. Praziquantel is more effective. *S. haematobium* treatment with a single dose of either metrifonate or praziquantel may improve child growth in areas were hookworms and malnutrition are common and appears to have a beneficial effect on hepatomegaly and splenomegaly.\
Treatment of moderate to heavy *S. haematobium* infections with metrifonate or praziquantel in undernourished schoolboys can improve physical fitness, growth rates and appetite within approximately one month.\
Recommendation for widespread population based chemotherapy in highly endemic areas as Kwale district.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskAllocated at random.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesLow riskUse of placebo.Blinding of outcome assessment (detection bias)   All outcomesLow riskExaminations carried out in a blind fashion.Incomplete outcome data (attrition bias)   All outcomesLow riskLoss to follow‐up 10%, 3 participants not accounted for.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence for other source of bias.[Taylor 1988 ZWE](#CD000053-bbs2-0027){ref-type="ref-list"}MethodsRCT\
Diagnostics: urine sample collection; three midday urine samples (10.00 to 14.00), filtration (13 mm nytrl filter), staining with Lugol\
Follow‐up at 1, 3 and 6 monthsParticipantsSchool children aged ten to 15 years, mixed infection with *S. haematobium* and *S. mansoni*\
Number of participants randomized: 373\
Inclusion: mixed *S. haematobium* and *S. mansoni* infection\
Exclusion: not reportedInterventions1. Praziquantel 10 mg/kg single dose\
2. Praziquantel 20 mg/kg single dose\
3. Praziquantel 30 mg/kg single dose\
4. Praziquantel 40 mg/kg single dose\
4. Control: NilOutcomesParasitological cure\
Egg countNotesLocation: Zimbabwe\
Setting rural, primary school\
Endemicity: seasonal transmission\
Date: not reported\
Funding: Rockefeller Foundation (financial support)\
Authors\' conclusion: Doses of 20 to 40 mg praziquantel may be equally effective in *S. haematobium* infection***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly assigned.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesLow riskSingle blind manner \"only the principal investigator knew which children had been assigned to which treatment group.\"Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up unclear, as only means and percentages of cure are reported.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence for other source of bias.[Tchuente 2004 CMR](#CD000053-bbs2-0028){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of two urine samples on two consecutive days in 50 mL plastic screw cap vials, processing in field laboratory, agitation of urine (from dispersal of eggs) filtration of 10 mL (Nucleopore filter), egg counts\
Length of follow‐up 3, 6 and 9 weeksParticipantsSchool children, age not reported\
Number of participants randomized: 592\
Inclusion: *S. haematobium* positive\
Exclusion: not reportedInterventions1. Praziquantel 40 mg/kg single dose\
2. Praziquantel 40 mg/kg two single doses, dose interval three weeks\
3. Praziquantel 40 mg/kg three single doses, dose interval three weeksOutcomesCure rates\
Egg counts, egg reduction rates\
ProteinuriaNotesLocation: Cameroon, Loum\
Setting: urban, schools\
Date: April to June 2002\
Endemicity: endemic all year, prevalence amongst school children 41.8%, trial carried out during high transmission period\
Funding: European Commission INCO‐DC (ICA‐4‐CT‐2001‐10079)\
Authors\' conclusion: No significant differences between the three dosing regimens, persistent high cure rates with a single dose of Praziquantel. Findings suggest efficacy of praziquantel against immature schistosoma stages.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskAssigned to random groups.Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskNo use of placebo mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesHigh riskHigh loss to follow‐up of 13% at six weeks, very high loss to follow‐up of 58.6% at nine weeks (change in schools schedules).Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias.[van den Biggelaar 02 GAB](#CD000053-bbs2-0029){ref-type="ref-list"}MethodsRCT\
Diagnostics: collection of urine samples on three different days, filtration of 10 mL urine, nucleopore pore size 13 µm), staining with ninhydrin, eggs count\
Follow‐up at two and three years, length of follow‐up three yearsParticipantsSchool children aged five to 14 years\
Participants randomized: 135\
Inclusion: positive for *S. haematobium* eggs\
Exclusion: not reportedInterventionsPraziquantel 40 mg/kg single dose\
Praziquantel 40 mg/kg in repeated doses, dose interval three months, over two yearsOutcomesCure rates, failure rates\
Egg counts\
MicrohaematuriaNotesLocation: Gaboon, near Lambarene\
Setting: rural, village schools\
Endemicity: high\
Funding: not reported\
Dates: not reported\
Authors\' conclusion: relate to immunologic outcomes also measured by this trial, but not of interest for this review***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskAllocated randomly.Allocation concealment (selection bias)High risk\"The allocation of children to the treatment group was open.\"Blinding of participants and personnel (performance bias)   All outcomesUnclear riskUse of placebo (given every three months) not mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesHigh riskHigh loss to follow‐up (not balanced, reasons not given):\
at 24 months 8%, 23%, 44% in different treatment groups;\
at 36 months 40%, 64%, 77%.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskNo evidence of other bias.[Wilkins 1987 GMB](#CD000053-bbs2-0030){ref-type="ref-list"}MethodsRCT\
Diagnostics:\
Follow‐up at two to three monthsParticipantsResidents aged two to 19 years, median age 9.5 years\
Participants randomized: not reportedInterventions1. Praziquantel 10 mg/kg\
2. Praziquantel 20 mg/kg\
3. Praziquantel 40 mg/kg\
4. Metrifonate 10 mg/kg\
5. Praziquantel 10 mg/kg and metrifonate 10 mg/kgOutcomesEgg counts\
Side effectsNotesLocation: Gambia Upper River Division, Nyanamari\
Setting: rural\
Endemicity: seasonal, trial conducted during season of low transmission\
Dates: not reported\
Funding: not reported\
Authors\' conclusion: Mass treatment of intensely infected groups should be based on the standard dose of praziquantel, with metrifonate as second choice.\
Note: only one of the two trials reported in this publication, the Nyanamari trial, fulfilled the inclusion criteria.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Subjects\...were stratified into four age groups and within each age stratum were ordered by intensity of egg counts. They were then placed sequentially into groups of five. Computer generated random sets of the numbers one to five were used to allocated on subject in each group of five to each of the five regimens used.\"Allocation concealment (selection bias)Unclear riskNot mentioned.Blinding of participants and personnel (performance bias)   All outcomesUnclear riskPlacebo and blinding not mentioned.Blinding of outcome assessment (detection bias)   All outcomesUnclear riskNot mentioned.Incomplete outcome data (attrition bias)   All outcomesUnclear riskLoss to follow‐up unclear, as cure rates are reported as percentages.Selective reporting (reporting bias)Low riskNo evidence of selective reporting.Other biasLow riskBaseline characteristics not reported.

Characteristics of excluded studies \[ordered by study ID\] {#CD000053-sec2-0025}
===========================================================

StudyReason for exclusion[Aryeetey 1999](#CD000053-bbs2-0031){ref-type="ref-list"}Study of health education and community participation.[Ayoya 2007](#CD000053-bbs2-0032){ref-type="ref-list"}No comparison group (treatment groups receive praziquantel with or without iron supplements and multivitamins).[Bausch 1995](#CD000053-bbs2-0033){ref-type="ref-list"}Not a RCT.[Beasley 1999](#CD000053-bbs2-0034){ref-type="ref-list"}This study compares a combination of praziquantel and albendazole with placebo. This outcome is not of interest for this review.[Bejon 2008](#CD000053-bbs2-0035){ref-type="ref-list"}Study of gastrointestinal helminths, not urinary schistosomiasis.[Bhargava 2003](#CD000053-bbs2-0036){ref-type="ref-list"}This study does not report baseline criteria for control group, as the control group was not screened at baseline.[Boulanger 2007](#CD000053-bbs2-0037){ref-type="ref-list"}No comparison group (both groups receive artesunate).[Burchard 1984](#CD000053-bbs2-0038){ref-type="ref-list"}This study compares praziquantel 2 x 30 mg/kg to oltipraz, which is obsolete. Details of this trial can be seen in earlier versions of this review.[Clarke 1969](#CD000053-bbs2-0039){ref-type="ref-list"}Not a RCT.[Clarke 1973](#CD000053-bbs2-0040){ref-type="ref-list"}Not a RCT, allotted to groups, \"for practical reasons, the infected children in the two senior grades were set aside for treatment with i.m. hycanthone\".[Creasey 1986](#CD000053-bbs2-0041){ref-type="ref-list"}This study compares different doses of praziquantel (8 mg/kg, 15 mg/kg and 20 mg/kg) combined with oxaminique in patients with *S. haematobium* and *S. mansoni* co‐infections. A comparison of the praziquantel dosages used is not of interest for this review.[Danso‐Appiah 2009](#CD000053-bbs2-0042){ref-type="ref-list"}Systematic review.[Davis 1966](#CD000053-bbs2-0043){ref-type="ref-list"}This study evaluates different doses of ambilhar which is now obsolete. Details of this trial can be seen in earlier versions of this review.[Davis 1979](#CD000053-bbs2-0044){ref-type="ref-list"}Outcomes are not reported per treatment group, only for the total number of participants randomized.[De Clercq 2002](#CD000053-bbs2-0045){ref-type="ref-list"}Not a RCT, \"systematically allocated\".[Druilhe 1981](#CD000053-bbs2-0046){ref-type="ref-list"}Not a RCT.[el Hawey 1990](#CD000053-bbs2-0047){ref-type="ref-list"}No comparison group.[el Tayeb 1988](#CD000053-bbs2-0048){ref-type="ref-list"}This study compares praziquantel 2 x 20 mg/kg to oltipraz 2 x 15 mg/kg, which is now obsolete. Details of this trial can be seen in earlier versions of this review.[el‐Zayadi 1985](#CD000053-bbs2-0049){ref-type="ref-list"}No outcome of interest reported.[Erikstrup 2008](#CD000053-bbs2-0050){ref-type="ref-list"}This is a study of HIV and *S. haematobium* or *S. mansoni* co‐infection, no outcomes of interest for this review are reported.[Fontanilles 1964](#CD000053-bbs2-0051){ref-type="ref-list"}Conference speech.[Forsyth 1964](#CD000053-bbs2-0052){ref-type="ref-list"}Not a RCT. \"At three of the schools, every sixth injected child received \"curative\" treatment\...\"[Garba 2001](#CD000053-bbs2-0053){ref-type="ref-list"}Study of health education.[Garba 2004](#CD000053-bbs2-0054){ref-type="ref-list"}This study evaluates mass treatment with praziquantel without comparison group.[Hammad 1997](#CD000053-bbs2-0055){ref-type="ref-list"}This cross‐sectional study evaluates the diagnosis of urinary schistosomiasis by reagent strip and parasitological methods.[Jewsbury 1977](#CD000053-bbs2-0056){ref-type="ref-list"}No comparison group (sequence of treatment, then prophylaxis within one group).[Jinabhai 2001](#CD000053-bbs2-0057){ref-type="ref-list"}This study compares a combination of praziquantel and albendazole with placebo. This outcome is not of interest for this review.[Jordan 1966](#CD000053-bbs2-0058){ref-type="ref-list"}Quasi‐RCT. \"children were allocated to Groups 1‐4 corresponding to different regimens of treatment, in rotation down the list (pre‐treatment results in descending order), thus ensuring four groups matched for egg output.\"[Kardaman 1983](#CD000053-bbs2-0059){ref-type="ref-list"}No comparison group.[Kern 1984](#CD000053-bbs2-0060){ref-type="ref-list"}Study of intestinal manifestations of schistosomiasis, very low number for *S. haematobium* positive patients, outcome data not reported separately.[King 1989](#CD000053-bbs2-0061){ref-type="ref-list"}Review article.[King 1992](#CD000053-bbs2-0062){ref-type="ref-list"}Data reported in other publications.[Kurz 1986](#CD000053-bbs2-0063){ref-type="ref-list"}This study evaluates metrifonate in hookworm infections.[Latham 1983](#CD000053-bbs2-0064){ref-type="ref-list"}No comparison group.[Lucas 1969](#CD000053-bbs2-0065){ref-type="ref-list"}This study reports ultrasound findings in patients with urinary schistosomiasis after treatment with Niridazole to a untreated control. Niridazole is now obsolete.[Mwanakasale 2009](#CD000053-bbs2-0066){ref-type="ref-list"}Study of iron supplementation in *S. haematobium* treatment with no outcomes of interest for this review.[N\'Goran 2003](#CD000053-bbs2-0067){ref-type="ref-list"}Study of *S. haematobium* prevention.[Nagaty 1962](#CD000053-bbs2-0068){ref-type="ref-list"}This trial studies the therapy of drug side effects in urinary schistosomiasis treatment.[Odongo‐Aginya 1996](#CD000053-bbs2-0069){ref-type="ref-list"}Not a RCT, study of *S. mansoni.*[Olsen 2007](#CD000053-bbs2-0070){ref-type="ref-list"}Review article.[Pitchford 1978](#CD000053-bbs2-0071){ref-type="ref-list"}No comparison group.[Podgore 1994](#CD000053-bbs2-0072){ref-type="ref-list"}Study of *S. haematobium* prevention.[Rabarijaona 2001](#CD000053-bbs2-0073){ref-type="ref-list"}Epidemiological survey.[Rey 1984](#CD000053-bbs2-0074){ref-type="ref-list"}This study compares oltipraz 30 mg/kg to a combination of metrifonate 10 mg/kg and niridazole 25 mg/kg. Niridazole and oltipraz are now obsolete.[Rugemalila 1984](#CD000053-bbs2-0075){ref-type="ref-list"}Study of *S. mansoni*.[Schutte 1983](#CD000053-bbs2-0076){ref-type="ref-list"}No comparison group.[Sellin 1986](#CD000053-bbs2-0077){ref-type="ref-list"}This study compares metrifonate 10 mg/kg to oltipraz 30 mg/kg, which is now obsolete.[Sissoko 2009 MLI](#CD000053-bbs2-0078){ref-type="ref-list"}This study compared praziquantel to a combination of artesunate with sulfamethoxypyrazine pyrimethamine; it is therefore not possible to attribute observed effects to artesunate alone.[Snyman 1997](#CD000053-bbs2-0079){ref-type="ref-list"}Study of calcitriol as experimental antischistosomal treatment.[Snyman 1998](#CD000053-bbs2-0080){ref-type="ref-list"}Study of levimasole as experimental antischistosomal treatment.[Squires 2000](#CD000053-bbs2-0081){ref-type="ref-list"}Review article.[Stephenson 1985](#CD000053-bbs2-0082){ref-type="ref-list"}No comparison group (compares children of moderate and severe infection intensity with uninfected children, using the same treatment regimen for infected children).[Taylor 2001](#CD000053-bbs2-0083){ref-type="ref-list"}This study compares a combination of praziquantel and albendazole with placebo. This outcome is not of interest for this review, whereas a comparison the combination of praziquantel and albendazole versus praziquantel would be of interest.[Teesdale 1980](#CD000053-bbs2-0084){ref-type="ref-list"}Not a RCT.[Thigpen 2011](#CD000053-bbs2-0085){ref-type="ref-list"}Not a RCT.[Urbani 1997](#CD000053-bbs2-0086){ref-type="ref-list"}Epidemiological survey.[Utzinger 2001](#CD000053-bbs2-0087){ref-type="ref-list"}Review article.[van Lieshout 1994](#CD000053-bbs2-0088){ref-type="ref-list"}Study of *S. mansoni*.[Wilkins 1987 Simoto trial](#CD000053-bbs2-0089){ref-type="ref-list"}Not a RCT, alternate allocation.[Wolfe 1967](#CD000053-bbs2-0090){ref-type="ref-list"}Not a RCT.[Xiao 2002](#CD000053-bbs2-0091){ref-type="ref-list"}Review article.[Zwingenberger 1990](#CD000053-bbs2-0092){ref-type="ref-list"}Case study.

While inclusion criteria of the first protocol included all RCTs which studied antischistosomal drugs, we decided to change the protocol. We excluded trials which evaluated obsolete drugs as ambilhar, oltipraz and niridazole. We also excluded studies which compared a combination of praziquantel and albendazole to placebo only, as this comparison is not of interest for this review. We included trials evaluating metronidazole.

We did not contact researchers or organizations looking for unpublished studies, as stated in the protocol. We did not report parasitological outcomes at three months as primary outcomes.

The older version of this review concluded that both metrifonate and praziquantel were effective in treating urinary schistosomiasis, even if metrifonate had operational disadvantages. As implications for further research, evaluation of different metrifonate doses and regimens and of evaluation of artemisinin drugs and of combination therapy is recommended.

While we agree with these conclusions, the data on egg reduction allow some further recommendations. We have newly included three trials evaluating artemisinin drugs, and one recent trial using mefloquine, and present this new evidence here.

Additional analysis carried out in this edition of the review, which was not in the previous edition ([Danso‐Appiah 2008](#CD000053-bbs2-0118){ref-type="ref-list"}), is the presentation of egg reduction rates in summary tables.

VK developed the protocol with input from PG and DS. VK and FZ assessed eligibility and extracted the data. We resolved any disagreements through discussion with DS and PG. VK entered the data and drafted the manuscript with input from DS, PG and PO. DS, PG and PO assisted in interpretation of the results and revisions of the text.
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